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ABSTRACT 
   I 
ABSTRACT 
Mesenchymal stromal cells (MSC) enhance growth and protect leukaemic cells from 
drug-induced toxicity in the bone marrow microenvironment (BMM), however, these 
interactions are not fully understood and less is known about the impact of leukaemic 
cells on supportive MSC. The nucleoside-analogue, cytarabine (ara-C), has for 
several decades been the mainstay of chemotherapy regimens for acute myeloid 
leukaemia (AML), despite poor efficacy. Despite research efforts, chemoresistance 
mechanisms are heterogeneous between patients or remain unknown. Additionally, 
DNA damage following chemotherapy treatment can persist in patient bone marrow 
(BM)-MSC. This genotoxicity hinders functionality and may be implicated in long-term 
complications including hematopoietic failure and secondary malignancies. This 
study aimed to further elucidate the mechanisms by which BM stromal cells interact 
with leukaemic cells, leading to changes in chemosensitivity and implicated in poor 
response/relapse in leukaemia.  
This study utilised an in vitro trans-well co-culture model for assessment of leukaemic-
stromal interactions, both with the leukaemic cell lines HL-60 and K562, combine with 
the BM stromal cell line HS-5 or primary patient MSC. Protection of leukaemic cells 
by stromal cells from ara-C cytotoxicity in this study confirmed evidence in the 
literature, both by unidirectional and bidirectional interactions. Altered ara-C 
genotoxicity by leukaemic-stromal crosstalk was shown for the first time in this work; 
stromal cells were sensitised to genotoxicity, while leukaemic cells were themselves 
protected in co-culture. Expression of hENT1 was not altered by co-culture, however 
bidirectional interactions did cause differential cytokine secretion, with macrophage 
migration-inhibitory factor (MIF) secretion decreased in co-culture. Separation of cells 
uncovered opposing MIF secretion profiles with high (HL-60) and low (K562) ara-C 
sensitive cells, but this was not correlated to chemosensitivity when MIF was 
enhanced or inhibited. 
Overall, this thesis contributes evidence that the BMM is remodelled to benefit 
haematological malignancies, with evidence of altered cytokine secretion and drug 
handling by leukaemic-stromal interactions. Chemoresistance involves a network of 
interlinking mechanisms which are compounded by patient heterogeneity. This study 
shows for the first time that leukaemic-stromal interactions alter ara-C genotoxicity 
and provides a basis for future research to fully understand how cells in the BMM can 
be targeted. This could potentially improve patient outcomes and reduce the long-
term complications of current therapies in AML.
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Chapter 1 - INTRODUCTION 
1.1  BACKGROUND 
1.1.1  The Bone Marrow Microenvironment 
An intricate molecular and cellular network exists within the bone marrow (BM), 
termed the BM microenvironment (BMM) or BM niche (Kumar et al., 2018; Tikhonova 
et al., 2019). The BMM is ultimately responsible for the maintenance of 
haematopoiesis and bone homeostasis in healthy individuals, and home to an 
abundance of cell populations which function to this end (Calvi and Link, 2015). 
Together with haematopoietic stem and/or progenitor cells (HSPC), constituting 0.01–
3% of BM mononuclear cells (MNC; Pang et al., 2011), there reside cells including 
osteoprogenitors, osteocytes, chondrocytes and adipocytes for bone modelling, 
neuronal and glial cells for nervous system function, and fibroblasts, endothelial cells 
and mesenchymal stromal cells (MSC) for protective stromal support (Krause and 
Scadden, 2015). These MSC (constituting just 0.001–0.01%; Crippa and Bernardo, 
2018), fibroblasts and endothelial cells not only provide a supportive infrastructure, 
but secrete cytokines, growth factors and adhesion proteins facilitating HSPC fate, 
differentiation and migration (Tabe and Konopleva, 2015; Crippa and Bernardo, 
2018). Non-cellular elements, such as hypoxia, mechanical force and the extracellular 
matrix (Verma and Krause, 2017), also influence characteristic cellular functions 
within the BMM – as well as cells at distant sites (Agas et al., 2015). 
 
1.1.2  Functional Composition of Bone Marrow Niches 
The dynamically regulated processes of haematopoiesis and homeostasis involve 
multiple cell types in the BM, inhabiting the haematopoietic niche (Wei and Frenette, 
2018). Haematopoiesis is responsible for balancing the production and proportions of 
billions of mature blood cells each day (Anthony and Link, 2014), facilitating transport 
of oxygen, tissue remodelling and adequate immunity (Tikhonova et al., 2019). BM of 
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the pelvis, cranium, sternum and vertebrae are the major sites for haematopoiesis in 
adults (Agas et al., 2015) and are uniquely adapted to provide an ideal 
microenvironment to support HSPC to differentiate, self-renew and maintain 
adequate cell reserves (Ciciarello et al., 2019). The high demands for blood and 
immune cell production are met by the vast aptitude of HSPC to proliferate and 
differentiate into functional mature cells, of either myeloid or lymphoid lineages, and 
for these cells to mobilise and migrate to other organs (Wei and Frenette, 2018). 
In addition to the broader haematopoietic niche, cells within the BM reside within two 
distinct niches. The endosteal niche is responsible for the maintenance of stem cell 
quiescence by HSC-osteoblast binding and adhesion (Wilson and Trumpp, 2006; 
Tabe and Konopleva, 2014) and the vascular niche promotes proliferation through 
supply of oxygen, nutrients and growth factors (Tabe and Konopleva, 2014; Eltoukhy 
et al., 2018). In the endosteal niche, osteoblasts lining the bone surface provide niche 
support by contact with some HSPC (Sugiyama and Nagasawa, 2012; Ciciarello et 
al., 2019). However, HSPC predominantly localise near MSC and endothelial cells 
(Sugiyama and Nagasawa, 2012; Ghazanfari and Behravan, 2017); approximately 
85% localise close to the sinusoid endothelium in the vascular BM (Wilson and 
Trumpp, 2006; Xie et al., 2009; Ciciarello et al., 2019). 
Another key feature of the BMM is that regions are known to be hypoxic (Nombela-
Arrieta and Silberstein, 2014; Méndez-Ferrer et al., 2020). Deeper perisinusoidal 
areas are shown to be less hypoxic than the endosteal niche however – often 
perfused with Nestin+ (an intermediate filament protein associated with neural stem 
cells and MSC (Xie et al., 2015)) small arteries – due to these differences in oxygen 
tension (Spencer et al., 2014). HSC have been shown to localise near Nestin+ cells 
in the BM, of which MSC have been classified (Méndez-Ferrer et al., 2010). The 
hypoxic states of the BMM have been shown to be maintained by hypoxia-inducible 
factor (HIF)1α, and linked to pro-malignant chemokine signalling (Abdul-Aziz et al., 
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2018). The hypoxic environment of the endosteal niche allows for maintenance of 
HSC quiescence, while oxygen is more readily available to proliferating cells in the 
vascular niche (Suda et al., 2011). 
 
1.1.3  Mesenchymal Stromal Cells 
MSC are major cellular constituents of the BMM, deriving skeletal tissues, such as 
perivascular cells, osteocytes, adipocytes, chondrocytes and endothelial cells (Crippa 
and Bernardo, 2018). Mesenchymal stem cell-like populations were first identified for 
their ability to readily adhere to plastic culture surfaces and were easily distinguished 
from HSC due to their fibroblastic morphology (Friedenstein et al., 1970; Ciciarello et 
al., 2019). They were able to form colonies, and so were termed colony-forming unit-
fibroblasts (CFU-F), and had potential for multilineage differentiation (Friedenstein et 
al., 1970). MSC are present in several bodily compartments at varying levels, 
including BM, adipose tissue, cord and peripheral blood (PB), among others (Wexler 
et al., 2003); this study will refer to MSC which originate in the BM. BM-MSC are 
known for their ability to support haematopoiesis (Saleh et al., 2015) and are not a 
pluripotent population, but instead possess certain multipotent plasticity; their 
stemness remains an ongoing debate (Agas et al., 2015) as it is not homogeneous 
throughout MSC populations (Horwitz et al., 2005).  
MSC are known to secrete soluble factors within the BMM, including growth factors, 
cytokines and interleukins (IL) which function as haematopoiesis regulatory signals 
(Ghazanfari and Behravan, 2017; Ciciarello et al., 2019). Some such cytokines are 
known to favour HSC quiescence or self-renewal, for example stem cell factor (SCF), 
CXCL12 (also called stromal cell-derived factor 1) and transforming growth factor 
(TGF)-β (Ghazanfari and Behravan, 2017). One of the most studied interactions is 
between the G-coupled chemokine HSC receptor CXCR4 and the stromal ligand 
CXCL12 (Nagasawa, 2015; Yazdani et al., 2020). This axis has been identified as 
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essential for the maintenance of HSC quiescence, HSC pool and homing to the BM, 
as most HSC are found to contact stromal cells expressing high levels of CXCL12 
(Sugiyama et al., 2006). Granulocyte macrophage colony-stimulating factor (GM-
CSF) and granulocyte colony-stimulating factor (G-CSF) are implicated in the 
maturation and mobilisation of HSC (Tay et al., 2017; Ciciarello et al., 2019). 
Interleukins are also produced, including  IL- 1, IL-6, IL-7, IL-8, 1L-11, IL-12, IL-14, 
IL-15 (Dazzi et al., 2006; Ciciarello et al., 2019), with functions in pro/anti-
inflammatory pathways, autophagy, stemness and migration, among others (Eltoukhy 
et al., 2018). Additionally, deregulation of such factors has been implicated in tumour 
development (Nipp and Rao, 2015). The MSC secretome plays an important role in 
influencing the crosstalk between cells and surrounding tissues to mediate a 
biological function (Kupcova Skalnikova, 2013; Eltoukhy et al., 2018), so much so that 
it has potential for cell-free therapy (Kumar et al., 2019). Factors of this secretome 
exist within complex signalling networks, adding challenge to experimentation in the 
influence of cellular interactions, hence the need for further research in this area. 
 
1.1.3.1  In vitro confirmation of mesenchymal stromal cells 
Mechanisms controlling MSC differentiation and self-renewal are dictated by complex 
signalling factors, which define MSC into distinct trajectories of maturation (Wolock et 
al., 2019). The gold standard for identification of MSC remains assessment of their 
multipotent capacity to differentiation into osteocytes, adipocytes and chondrocytes 
(Dominici et al., 2006). MSC differentiation in vitro is induced by culture with inducing 
supplements, noted by morphological change and cellular staining (Dominici et al., 
2006; Vater et al., 2011; Baghaei et al., 2017). 
Differentiation of MSC is known to be altered in a number of environments (Sobacchi 
et al., 2017; Sisakhtnezhad et al., 2017). One such factor is time in in vitro culture, 
with a study finding that osteogenesis, but not adipogenesis, was significantly 
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compromised at passage 8 as compared to passage 4 (Yang et al., 2018). 
Additionally, aging influences MSC differentiation, correlating with impaired 
chondrogenesis, reduced proliferation and ultimately senescence (Beane et al., 
2014). MSC differentiation is also altered in disease states, such as haematological 
malignancy (HM), with significant implications for the dynamics of the BMM. For 
example, MSC osteogenic potential was decreased by co-culture with an acute 
lymphoblastic leukaemia (ALL) cell line (Bonilla et al., 2019). MSC derived from 
patients with acute myeloid leukaemia (AML) had increased adipogenic potential 
compared to MSC from healthy donors (Azadniv et al., 2020); with changes in MSC 
differentiation in AML contributing to malignant progression (Battula et al., 2017). 
Immunophenotyping also plays an important role clinically, for example for 
haematological disease diagnosis and monitoring of minimal/measurable residual 
disease (MRD) in leukaemia (Schuurhuis et al., 2018; Voso et al., 2019). MSC 
express specific genes and surface molecules which can be measured to assess the 
purity of isolation. These include expression of cluster of differentiation (CD) markers 
CD73, CD90 and CD105, alongside low or negative expression of CD11b, CD19, 
CD34, CD45 and HLA-DR, as minimal requirements outlined in international 
guidelines, alongside differentiation and plastic adherence, for confirmation of MSC 
purity (Dominici et al., 2006). Immunophenotype is dynamic in that cell expression 
changes in different cellular states (Sisakhtnezhad et al., 2017). Yang et al. (2018) 
found that passage 8 MSC had significantly lower CD146 expression than at passage 
4. Additionally, states such as HM change the phenotype of MSC, with decreased 
expression of CD44 and CD49a (leading to enhanced clonal haematopoiesis), and 
increased expression of CD271 (an MSC marker) in patients with myelodysplastic 
syndrome (MDS) (Fracchiolla et al., 2017). It is evident then that states of HM are 
able to alter MSC in the BMM, with potential consequences for their functionality. 
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1.1.4  Haematological Malignancies in the Bone Marrow Niche 
It is perhaps unsurprising that the BMM is permissive of the progression and 
protection of HM in its ideal environment (Tripodo et al., 2011; Krause and Scadden, 
2015). MSC in the BM are often described to have Yin and Yang properties, referring 
to their inherent abilities to support haematopoiesis (e.g. following allogeneic stem 
cell transplantation (SCT)) in contrast to their advantage to malignant cells (Ciciarello 
et al., 2019). Studies have revealed abnormal BM niche properties in HM (Batsivari 
et al., 2020), including leukaemia (Civini et al., 2013; Kim et al., 2015; Passaro et al., 
2017), multiple myeloma (Ribatti and Vacca, 2018; Ria and Vacca, 2020) and 
lymphoma (Cao et al., 2014; Sircar et al., 2020). BM investigations are at the forefront 
of haematological disorder diagnosis; due to the nature of these diseases originating 
from transformation of HSPC in the BM (Taylor et al, 2017; Döhner et al., 2017). 
Like other cancers, those of the haematopoietic system feature the hallmarks of 
cancer, including: genome instability; inflammation; unchecked proliferation; inhibited 
growth suppression; invasion/metastasis; apoptosis resistance; angiogenesis; 
aberrant cell metabolism; and immune detection evasion (Hanahan and Weinberg, 
2011; Wang et al., 2017). HMs are traditionally described to include four broad 
categories: myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma and leukaemia 
(Smith et al., 2011). Myeloma, for example, is a clonal B-cell malignancy, 
characterised by the destructive proliferation of aberrant plasma cells in the BM, bone 
lesions and renal disease (Fairfield et al., 2016). The BMM has been implicated in the 
development of this disease (Ghobrial et al., 2018), with IL-6 production by BM 
stromal cells shown to contribute to chemoresistance in vitro (Cheung and Van Ness, 
2001). Non-Hodgkin lymphoma, accounting for ~ 95% of lymphoma cases (Park et 
al., 2016), alternatively develops by clonal proliferation of mature lymphocytes 
originating in the BM, which circulate in the PB and lymphatics and populate 
throughout the body (Lee et al., 2016; Sircar et al., 2020). BM involvement is also 
recognised at later stages of Hodgkin lymphoma, with the BMM implicated in poorer 
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prognosis and therapeutic outcomes (Sircar et al., 2020). Drug resistance in 
lymphoma has been attributed to protection by the tumour microenvironment, both by 
adhesion of MSC-lymphoma interactions and MSC soluble factors; lymphoma 
protection is in part through NF-ĸB-mediated apoptosis avoidance (Lwin et al., 2007). 
MDS and myeloproliferative neoplasms (MPN), such as essential thrombocythemia, 
myelofibrosis, and polycythemia vera, are chronic disorders of blood cell production 
also classified as HMs (Medyouf, 2017). The BM niche is also implicated in their 
pathogenesis, which can lead onto more aggressive disorders, such as leukaemia 
(Medyouf, 2017). The prognosis of this secondary leukaemia is significantly poorer 
than primary leukaemia (Szotkowski et al., 2010), perhaps correlating existing stromal 
dysfunction in MDS/MPN disorders to leukaemogenesis (Raaijmakers et al., 2010). 
In general, second to non-Hodgkin lymphoma (CRUK, 2020c), leukaemia is a 
common HM, whose name is used as an umbrella term for four main classes 
(Shephard et al., 2016). Broad classification is based on the rapidity of progression 
and the initiating cell myeloid or lymphoid lineage (Shephard et al., 2016). 
Breakthroughs have been made in the pathogenesis and targeted treatment of 
chronic leukaemias, which on the most part are successfully managed long-term with 
tyrosine kinase inhibitors (Greaves, 2016). In contrast, acute leukaemias are 
aggressive and complex forms of the disease, thus requiring rapid diagnosis and 
treatment for patient survival (Sekeres et al., 2009; Ibrahimi, 2018). Research 
attention in this area has hence increased drastically over recent years (Greaves, 
2016; NIH, 2019) – and is additionally the focus of this thesis. 
 
1.1.5  Clinical Presentation of Acute Leukaemia 
Leukaemia encompasses many complex haematological disorders, for which 
biological and clinical heterogeneity present great difficulties in treatment and with 
diverse clinical outcomes (Patel et al., 2012). Acute leukaemias are typically 
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characterised by the accumulation of dysfunctional, immature leukocytes (blasts) in 
both the BM and PB (Arber et al., 2016). Blast burden of ≥ 20% (leukocytosis) is 
diagnostic of acute leukaemia, however this can reach 80–90% in active disease 
(Döhner et al., 2010; Arber et al., 2016). These blasts fail to undergo normal 
differentiation, exhibit growth that lacks control and are less sensitive to apoptosis 
(Konopleva et al., 2002; Singh et al., 2018), overcoming the homeostatic balance 
seen in health. They therefore form a blockage in lymphoid or myeloid differentiation, 
with profound effects on haematological balance (Zhou et al., 2016). Clinical 
manifestations reflect the accumulation of malignant cells and BM failure, notably 
presenting as recurring infection due to immunodeficiency, anaemia and 
thrombocytopaenia; as insufficient numbers of mature blood cells develop from their 
HSC or more differentiated progenitors; depending on the point of developmental 
blockage (Grove and Vassiliou, 2014). When left untreated, death is likely to ensue 
within weeks or months in acute disease due to rapid progression (De Kouchkovsky 
and Abdul-Hay, 2016; Percival and Estey, 2017), therefore prompt diagnosis and 
treatment induction is essential. As patients often present with non-specific 
symptoms, it is important that a full blood count and blood film are investigated and 
patients referred to haematology as soon as possible in order for appropriate 
treatment to be initiated (Sekeres et al., 2009; Ibrahimi, 2018). 
 
1.1.5.1  Incidence of leukaemia 
The incidence of leukaemia is increasing annually in the UK, with an average of 
10,084 new cases reported between 2015–2017 (CRUK, 2020d) – a 9% increase in 
the past decade (CRUK, 2020d). Even though cases of leukaemia are becoming 
more frequent, the proportion of leukaemia deaths conversely has decreased by 7% 
in a decade, with 4,688 deaths per year in 2015–2017 (CRUK, 2020d); highlighting 
the impact of improved diagnostic and disease management strategies. Around one 
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third are of the AML subtype (3,152 cases annually; CRUK, 2020b), primarily a 
disease of adults in later life, with a median age of 68 years at diagnosis (Short et al., 
2018), and with high incidence of comorbidities (Smith et al., 2011; CRUK, 2020b). 
ALL on the other hand has high incidence in children under 4 years, with a second 
peak in later life (Smith et al., 2011; CRUK, 2020a). AML is in itself therefore a 
comparatively rare disease, which adds challenge to research in this area using 
primary patient material. 
 
1.1.6  Aetiology of AML 
The majority of cases of presenting AML occur de novo in previously healthy 
individuals (Østgrd et al., 2010; Grove and Vassiliou, 2014). AML can also arise as a 
consequence of exposure to cytotoxic and genotoxic agents, such as alkylating 
agents or radiation (therapy-related; De Kouchkovsky and Abdul-Hay, 2016) or 
develop secondary to preceding clonal haematopoietic disorders, such as MDS or 
MPN (Deschler and Lübbert, 2006; Figure 1.1). The mutations that lead to 
leukaemogenesis select for the expansion of several leukaemic clones (Ding et al., 
2012), deriving from small populations of malignant cells with the ability to self-renew, 
termed leukaemic stem cells (LSC; Grove and Vassiliou, 2014). 
Many chromosomal translocations, deletions and inversions are well characterised 
and known to result in chimeric genes and protein products which affect the 
maturation of myeloid precursor cells (Fiegl, 2016). For example t(8;21) in core 
binding factor (CBF) AML results in RUNX1-RUNX1T1 gene fusion, while t(15;17) in 
acute promyelocytic leukaemia (APML; M3) results in PML-RARA gene fusion 
hybrids (Lo-Coco and Hasan, 2014; De Kouchkovsky and Abdul-Hay, 2016). These 
chromosomal alterations play a large part in the accurate and differential diagnosis of 
AML through mandatory molecular and cytometric assessments. 
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Figure 1.1. Pathogenesis of myeloid leukaemia disorders. Genetic mutations, as 
caused by transforming events, initiate clonal haematological disorders. 
Haematopoietic stem and/or progenitor cells (HSC/HSPC) develop abnormal 
maturation, proliferation and apoptosis, and accumulate in the BM in disorders such 
as myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) or chronic 
myeloid leukaemia (CML). Further transformation of MDS/CML can develop to blast 
crisis in AML. Correct management of the disorders can lead to stable or treated 
disease by myeloablative, non-myeloablative or paliative therapy, or patients 
succumb to disease effects. Based on diagram credited to Cornell University and 
eClinpath (2013) (CC BY-NC-SA 4.0). 
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1.1.7  Diagnostic Strategies for AML 
Diagnosis of AML relies upon clinical presentation, disease morphology, 
immunophenotype and cytogenetics for an appropriate treatment course to be 
initiated (Dombret and Gardin, 2016a; Döhner et al., 2017). This clinical pathway is 
summarised in Figure 1.2. Due to the complex presentation of AML, and symptoms 
that are often synonymous with many disorders, a multifaceted approach must be 
taken to rapidly distinguish AML from other haematological disorders (Angelescu et 
al., 2012). Morphological assessment of blood and BM smears often marks the first 
step towards diagnosis of any haematological disorder (Döhner et al., 2010). PB and 
BM aspirates are taken at the point of suspected neoplasm, with morphological 
diagnosis often assumed by presence of ≥ 20% blasts, with the exception of t(8;21), 
t(15;17), t(16;16) and inv(16) for example (Vardiman et al., 2002; Döhner et al., 2010). 
Myeloid blast origin is often confirmed by myeloperoxidase activity, or the presence 
of Auer rods in APML, t(8;21) AML or acute myelomonocytic leukaemia for example 
(De Kouchkovsky and Abdul-Hay, 2016).  
Lineage involvement is determined by flow cytometric immunophenotyping, 
assessing the expression of cytoplasmic and surface antigens, for example CD 
markers, or those that signify the level of maturation (the early blast marker CD34 
and myelocyte–neutrophil marker CD11b for example) (Haferlach and Schmidts, 
2020). Immunophenotype cannot be used alone to diagnose AML, as disease 
heterogeneity causes subgroups of cells to not follow normal trends. For example 
t(8;21) AML cells often express the lymphoid markers CD19, CD7 and CD56 (Döhner 
et al., 2010). Instead, these analyses help to build a clearer picture of cell profiles, in 
conjunction with other tests. This holds clinical value for identification of complex cell 
aberrations, including cross-lineage antigens (CD19+ AML), under (HLA-DR– AML) or 
over (CD34++ AML) expression of typical markers (Haferlach and Schmidts, 2020). 
Additionally, confirmatory thresholds are not truly diagnostic; generally ≥ 20% marker  
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expression is considered positive in most cases (Arber et al., 2016), while CD34, CD3 
and CD117 are accepted at ≥ 10% (Döhner et al., 2010). 
Somatic mutations are present in over 97% of AML cases (Patel et al., 2012). The 
pathogenesis of AML still depends on how somatic mutations interact with different 
chromosomal rearrangements (De Kouchkovsky and Abdul-Hay, 2016). A suspected 
diagnosis can be confirmed via cytogenetics, with critical importance for guiding 
therapeutic strategies (Taylor et al., 2017). Of these techniques, gene arrangements 
are determined by fluorescence in situ hybridisation by probing specific chromosomal 
loci (Haferlach and Schmidts, 2020), such as RUNX1-RUNX1T1 or CBFB-MYH11 
(Döhner et al., 2017). Additionally, molecular genetics approaches are routinely 
undertaken on PB/BM for mutation detection (Döhner et al., 2010). Of around 30 
genes identified to have prognostic value, those with the most clinical importance are 
FLT3, NPM1, TP53, DNMT3A, TET2 and IDH1/2 genes (Tabe and Konopleva, 2015; 
Ladikou et al., 2020). The diagnostic workflow of AML subtypes is particularly 
complex, mirroring the intricate heterogeneous display of the disease in patients. In 
many cases, the mutation profile is specific to the individual, thus exceptions to the 
workflow are frequent. This highlights the challenges present in the diagnosis and 
treatment of AML and therefore the importance of a multifaceted approach. 
Classification of the disease is ever improving, for better prognostic stratification, 
MRD monitoring and therefore disease management for the individual. 
 
1.1.8  Classification of AML 
Leukaemias are classified according to the nature of the initiating cells as determined 
by cytological assessment of morphology and genetic signatures. The use of genetic 
markers for delineation of leukaemia subtype has been invaluable both diagnostically 
and prognostically (Taylor et al., 2017). The main systems used to classify leukaemia 
are the French-American-British (FAB) system from the 1970s (Bennett et al., 1985), 
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immunophenotypic criteria in the 1990s (Catovsky et al., 1991) and most recently the 
World Health Organisation (WHO) classification, introduced in 2001 (Arber et al., 
2016). FAB classification is based on the initiating cell and level of maturation, while 
WHO classification also takes into account the chromosomal abnormalities, which act 
as prognostic risk factors; arguably more clinically valuable than the initiating cell 
alone (Haferlach and Schmidts, 2020). These classification systems for AML are 
summarised in Table 1.1 and Table 1.2. The rapid and reliable classification of AML 
is incredibly important in determining the correct induction treatment approach for 
patients (Döhner et al., 2017). Since AML is such an aggressive and rapidly 
progressing disease, receiving efficacious treatments as soon as possible following 
diagnosis drastically improves survival outcomes for patients (Sekeres et al., 2009; 
Ibrahimi, 2018). 
The classification of AML is incredibly important in determining the correct treatment 
strategy and understanding the prognostic risk for patients (Greaves, 2016). The age 
of onset and 5-year survival vary substantially between subtypes (Gupta et al., 2019). 
APML is an excellent example of where selecting the most appropriate treatment can 
have outstanding impact on outcome. This disease, typically presenting in younger 
patients (median age of 30–40 years; Arber et al., 2003; Zhu et al., 2016), has shown 
preferential 5-year survival rates in contrast to abysmal outcomes in other groups, 
such as 20.8% in M0 AML (Arber et al., 2003) and 28.7% for all subtypes combined 
(NIH, 2020). Survival has increased from ~ 30% to > 90% following implementation 
of all-trans retinoic acid (ATRA)/arsenic trioxide (ATO) based therapies, with 
chemotherapy consolidation, in APML (Zhu et al., 2016; Platzbecker et al., 2017). 
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FAB 
SUBTYPE1 
DOMINANT 
MORPHOLOGY1 
INCIDENCE (%)2 COMMENTS3 
M0 Undifferentiated 6 
Myeloperoxidase 
negative 
M1 
Myeloblastic with minimal 
maturation 
16.3 
Some granulocyte 
differentiation 
M2 Myeloblastic with maturation 24.3 
+/- t(8;21) AML-ETO 
fusion 
M3 Promyelocytic 7.3 
t(15;17) PML-RAR or 
other RAR 
translocation 
M4 Myelomonocytic 11.6  
M4EOS 
Myelomonocytic with BM 
eosinophilia 
11 
Insertion of 
chromosome 16 
involving CBF, 
forming heterodimer 
with AML1 
M5 Monocytic 4  
M6 Erythroleukaemic 2.3  
M7 Megakaryoblastic 2  
RAEBT 
Refractory anaemic in 
transformation 
8  
OTHER  7 
GATA mutation 
associated with 
Down’s syndrome 
1 Bennett et al. (1985), 2 Arber et al. (2003), 3 Kulsoom et al. (2017). CBF; core binding factor, 
FAB; French-American-British. 
Table 1.1. FAB classification and incidence of AML. 
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WHO SUBTYPE GENETIC ABNORMALITIES 
PROGNOSTIC 
RISK 
AML WITH 
RECURRENT 
GENETIC 
ABNORMALITIES 
AML with t(8:21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11 
APML with PML-RARA 
AML with t(9;11)(p21.3;q23.3); MLLT3-KMT2A 
ML with t(6;9)(p23;q34.1); DEK-NUP214 
AML with inv(3)(q21.3q26.2) or 
t(3;3)(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); 
RBM15-MKL1 
AML with BCR-ABL1 (provisional entity) 
AML with mutated NPM1 
AML with bi-allelic mutations of CEBPA 
AML with mutated RUNX1 (provisional entity) 
Favourable 
Favourable 
 
Favourable 
Intermediate 
Adverse 
Adverse 
 
 
 
 
Favourable 
Favourable 
Adverse 
AML WITH MDS-
RELATED 
CHANGES AND 
THERAPY-
RELATED 
MYELOID 
NEOPLASMS 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Acute erythroid leukaemia 
Pure erythroid leukaemia 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
 
MYELOID 
SARCOMA OR 
PROLIFERATIONS 
RELATED TO 
DOWN’S 
SYNDROME 
Transient abnormal myelopoiesis 
ML associated with Down’s syndrome 
 
Arber et al. (2016), De Kouchkovsy and Abdul-Hay (2016). 
Table 1.2. World Health Organisation (WHO) classification and prognostic risk 
of AML. 
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1.1.9  AML Treatment Strategies and Outcomes 
1.1.9.1  Chemotherapy regimens 
Despite significant leaps in understanding the pathogenesis of AML over recent 
years, the general therapeutic approach has not considerably changed for several 
decades (Yates et al., 1973; Lichtman, 2013; Döhner et al., 2017; Short et al., 2020). 
The standard treatment for AML, besides a few cases (Wang and Chen, 2008), 
typically constitutes standard-dose infusions of the nucleoside analogue cytarabine 
(ara-C) at 100–200 mg/m2, in combination with an anthracycline, such as 
daunorubicin (DNR) at 60 mg/m2, idarubicin or mitoxantrone as induction treatment. 
This induction is typically administered in a ‘7 + 3 regimen’, which consists of 7 days 
of this standard-dose ara-C in combination with the anthracycline on days 1–3 (Yates 
et al., 1973; Momparler, 2013; Döhner et al., 2017) (Figure 1.2). The first goal is to 
induce a complete remission – defined as BM blasts of < 5% at day 28 after treatment 
commencement (Maurillo et al., 2013; Percival and Estey, 2017), and sufficient 
neutrophil and platelet counts (Percival and Estey, 2017). BM assessments are 
performed at this time to measure treatment response (Percival and Estey, 2017), 
and additional induction cycles, consolidation cycles or an allogeneic SCT may be 
given (Figure 1.2; Dombret and Gardin, 2016; Döhner et al., 2017). 
The main changes made to the regimen style over the years have related to 
intensification or combination therapy, however, attempts to improve post-remission 
treatments have largely failed to improve outcomes (Lancet et al., 2018; Short et al., 
2018). Single-agent therapies are not curative in AML due to its polyclonality, while 
combination regimens can pose significant toxicity to patients (Lichtman, 2013; Short 
et al., 2020). Patients are initially considered for their suitability for intensive induction 
chemotherapy, where administration is avoided in patients with poor performance 
status at cycle 1, significant comorbidities or adverse cytogenetics (Döhner et al., 
2017). This does not, however, exclude patients by increasing age, as fit older 
patients may also benefit from intensive therapy (Nipp and Rao, 2015; Ossenkoppele 
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and Löwenberg, 2015). This recent shift from age bracket to fitness is highlighted by 
the inclusion of older patients in the ongoing AML19 clinical trial, designed for patients 
aged 18–60 years; this inclusion was not seen for the previous AML17 trial (ISRCTN, 
2020b). Treatment for AML is now often undertaken with a risk-stratified approach, 
where patients with intermediate or adverse-risk disease are referred for an 
allogeneic SCT due to a high relapse risk when chemotherapy treated alone (Short 
et al., 2020); while favourable-risk patients continue with intensive consolidation 
(Short et al., 2020). However, a risk-stratified treatment approach is curative in only 
15% of patients > 60 years of age, in comparison to 35–45% in patients < 60 years; 
due to treatment-related mortality from poor tolerance (Döhner et al., 2017; Short et 
al., 2020). Considering that AML has a median age of 68 years (Short et al., 2018), 
balancing tolerance with efficacy is an ongoing challenge in its management.  
Dose escalation has been a complex challenge in treatment optimisation, particularly 
with a risk of tumour lysis syndrome and cardiotoxicity from ara-C and DNR (Seftel et 
al., 2002). Ara-C and DNR can be administered as high-dose induction treatment, 
typically > 1,000 mg/m2 ara-C (Percival and Estey, 2017) and > 90 mg/m2 DNR 
(Burnett et al., 2016). A UK study found no difference between the overall survival of 
patients receiving ‘7 + 3’ with 90 or 60 mg/m2 DNR, except for patients with FLT3-ITD 
AML, who had improved survival of 20% with the higher DNR dose (Burnett et al., 
2016). This again highlights the need for rapid diagnostics in AML, as therapy 
modifications which are likely to benefit some populations of patients (in this case, 
those with FLT3-ITD mutations), can be initiated earlier in their treatment protocol. 
One study found that Ara-C at 1,500 mg/m2 was as effective as 3,000 mg/m2 (Burnett 
et al., 2013), used as consolidation therapy, once complete remission is observed 
post-induction (Percival and Estey, 2017). Another study, comparing induction and 
consolidation, found that intermediate-risk patients treated with high-dose 
consolidation ara-C had lower relapse rates and greater disease-free survival than 
those treated with high-dose induction ara-C, while adverse-risk patients did not see 
CHAPTER 1 - INTRODUCTION 
   19 
such benefit (Schwarer et al., 2018). High-dose ara-C has, however, been found to 
serve no significant benefit for 5-year survival or remission as compared to standard-
dose in one cohort of patients, but with higher toxicity and hospitalisation (Löwenberg 
et al., 2011). 
Treatment for frailer patients has included low-dose ara-C or hypomethylating agents, 
which inhibit DNA methyltransferases, including azacitidine or decitabine (Short et al, 
2018; Short et al., 2020). Outcomes using low-dose Ara-C have, however, been 
suboptimal for the majority of older patients, especially when many also have complex 
cytogenetics associated with poor-risk (Short et al., 2018). Improved overall survival 
has been seen in older patients treated with standard of care azacitidine by 4.8 
months (Dombret et al., 2015) or decitabine by 2.7 months (Kantarjian et al., 2012) 
as compared to low-dose ara-C (6.4/5.0 months in respective studies). However, the 
outcomes for these patients clearly remain poor. 
Another strategy for improved treatment is the novel packaging of agents for greater 
drug delivery (Winer and Stone, 2019). CPX-351 is a liposomal formulation of ara-C 
and DNR, which has shown promise of improved remission, survival and safety 
against standard induction in secondary AML patients > 60 years (Lancet et al., 2018; 
Mayer et al., 2019). CPX-351 does not require transport into cells by the human 
equilibrative nucleoside transporter (hENT)1 (Anderson et al., 2018) – a limiting factor 
for ara-C cellular entry and cytotoxicity (Macanas-Pirard et al., 2017a). 
Clinical trials are constantly ongoing in efforts to improve treatment efficacy, many of 
which feature current drugs in different combinations and doses (Döhner et al., 2017). 
The LI-1 trial is an example of innovative trial design to allow rapid testing of more 
arms than conventional trials (ISRCTN, 2020a). The main developments for new 
drugs for AML have included mutation-specific therapies, targets of the apoptotic 
pathway and immune therapies (Short et al., 2020). These include midostaurin for 
FLT3, venetoclax for NPM1 and the monoclonal antibody gemtuzumab ozogamicin 
CHAPTER 1 – INTRODUCTION 
20 
for CD33 (Short et al., 2020), however resistance to novel agents remains a challenge 
in AML treatment (Short et al., 2020). APML for example is a clinically and biologically 
distinct form of AML (Short et al., 2020). It remains one of the only subtypes where 
drastic improvements have been made to survival outcomes, with response of 100% 
and complete remission of 97% in one study (Platzbecker et al., 2017), and so serves 
as a role model for future therapy developments (Short et al., 2020). 
 
1.1.9.2  Allogeneic stem cell transplantation 
The most curative measure for AML is an allogeneic SCT, though graft failure remains 
a significant complication (Olsson et al., 2015). Referral to consolidative SCT is 
informed by genetic risk stratification and MRD status (Percival and Estey, 2017; 
Schuurhuis et al., 2018). Unfortunately, without further treatment, AML often recurs; 
even if CR has been reached (Döhner et al., 2017). The discovery of a graft-versus-
leukaemia effect by donor cells allowed for reduced intensitiy conditioning and non-
myeloablative regimens to be used for allo-SCT (Loke et al., 2020), which extended 
its use to older and co-morbid patients by superseding myeloablative conditioning, 
such as high-dose combination chemotherapy and total body irradiation with high 
toxicity (Gyurkocza and Sandmaier, 2014). That being said, low-dose chemotherapy 
has its own toxicity issues, in that reduced intensity conditioning regimens have been 
associated with increased secondary malignancies in later life of surviving patients 
(Shimoni et al., 2013; Ringdén et al., 2014; Delage et al., 2015); an indication of 
increased persisting genotoxicity in the BM (Fordham et al., 2015; May et al., 2018). 
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1.1.9.3  Treatment outcomes 
Chemotherapy drugs are often limited by targeting only actively dividing cells, where 
in leukaemia, a small subpopulation (1/million blasts; Shiozawa et al., 2008) reside 
as quiescent LSC (Bakker et al., 2016), where chemotherapy fails to eradicate the 
primary leukaemic clone (Ho and Wagner, 2006; Ding et al., 2012). The presence of 
LSC at high levels at diagnosis have been correlated with adverse outcome in AML 
(Farge, 2017). The greatest challenge in the treatment of leukaemia is subsequent 
drug-resistant disease. Despite ongoing developments in the management of AML, 
survival outcomes remain suboptimal (CRUK, 2020b). Induction regimens containing 
ara-C have minimally changed for several decades (Kern et al>, 1998; Dombret and 
Gardin, 2016a), highlighting the challenges of novel therapies. Survival of AML 
patients is very poor, with 90% of older patients and 60% of younger patients dying 
from their disease (Burnett, 2013; Shafat et al., 2017). Treatment regimens are still 
heavily reliant on ara-C (Short et al., 2018), with approximately 30–50% of patients 
treated for AML failing to show continued response due to MRD (Lamba et al., 2011; 
Anderson et al., 2014). This chemoresistance is subject to intra-tumour 
heterogeneity, including epigenetics, mutations and chemoprotection by harbour of 
LSC in the BMM (Meads et al., 2008; Shafat et al., 2017). The protection of leukaemic 
cells by MSC in the BM is well recognised in leukaemogenesis (Fathi et al., 2019; 
Ladikou et al., 2020) which will be detailed further in this thesis. 
 
1.1.10  Ara-C Mechanism of Action 
The mainstay of AML therapies, ara-C – cytarabine/cytosine arabinoside – is a 
pyrimidine analogue prodrug that is activated within dividing cells (Figure 1.3). Due to 
low levels of passive diffusion across cell membranes with standard-dose, the drug 
relies on membrane transporters for cellular entry (Kong et al., 2004). 
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Figure 1.3. Ara-C mechanism of action. Ara-C enters leukaemic cells by the human 
equilibrative nucleoside transporter 1 (hENT1; Sundaram et al., 2001; Kong et al., 
2004) before triphosphorylation by deoxycytidine kinase (dCK), deoxycytidine 
monophosphate kinase (dCMPK) and nucleoside diphosphate kinase (NDK) to active 
ara-CTP (Emadi and Karp, 2012). Integration into replicating DNA causes damage 
and subsequent apoptosis (Kern et al., 1998; Galmarini et al., 2001). 
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Cellular uptake of exogenous nucleosides, control of extracellular adenosine 
concentration and regulation of neurotransmission processes are functions of hENT 
membrane transporters (Sundaram et al., 2001). They are also therefore important 
for entry of ara-C, which is a nucleoside analogue (Kong et al., 2004). Specifically, 
hENT1 is responsible for 80% of ara-C uptake (Sundaram et al., 2001), and though 
ubiquitously expressed, is found primarily on cell plasma membranes (Kong et al., 
2004). 
Upon entry by hENT1, ara-C is activated through a sequence of phosphorylation 
steps; by deoxycytidine kinase (dCK; rate-limiting in ara-C activation),  deoxycytidine 
monophosphate kinase (dCMPK) and nucleoside diphosphate kinase (NDK) to ara-
CTP (triphosphate) (Emadi and Karp, 2012). Cytotoxicity of ara-CTP is proportional 
to its incorporation into DNA (Kufe et al., 1980), where it causes cell death by inhibition 
of polymerase, DNA fragmentation and subsequent chain termination (Galmarini et 
al., 2001; Kern et al., 1998). It does so in competition with cytidine, with its action 
specific to the S-phase of the cell cycle, therefore most affecting cells which require 
DNA replication for mitosis (Galmarini et al., 2001). 
 
1.1.11  Ara-C DNA Damage Response 
Drugs that target DNA metabolism, such as ara-C, result in DNA adducts, strand 
breaks or stalled DNA replication forks (Woods and Turchi, 2013). Double-strand 
breaks (DSB) are primarily generated by ara-C (Rechkoblit et al., 2019) and are the 
most deleterious form of DNA damage, often resulting in p53-mediated cell death if 
not adequately repaired (Hosoya and Miyagawa, 2014). With repair, cells can survive 
with little adversity, however, incomplete repair can result in genomic instability and 
contribute to future cancer development (Hosoya and Miyagawa, 2014). Single-
strand breaks (SSB) additionally result during the repair of DSB or stalled replication 
forks (Ma et al., 2017). 
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The DNA damage response (DDR) is a coordinated cascade of protein signals which 
induce cell death, DNA repair, or cell cycle arrest, in order to maintain genomic 
stability (Ciccia and Elledge, 2010; Hosoya and Miyagawa, 2014). Cell fate is largely 
determined by the extent of DNA damage, balancing this DNA repair/senescence with 
apoptosis (Liebl and Hofmann, 2019). DDR defects are implicated in 
leukaemogenesis as the persistence of DNA lesions promote the accumulation of 
additional mutations (Delia et al., 2017). Ara-C has been established as a base 
substitution mutagen, as mismatch repair-deficient cells have higher mutation 
frequency than those proficient in this repair (Fordham et al., 2015; Rechkoblit et al., 
2019). This is partly due to error-prone replication of ara-C adducted bases by DNA 
polymerase (Rechkoblit et al., 2019). 
One identified mechanism of chemoresistance is an increased DDR (Ma et al., 2017). 
Anti-metabolites activate the Ataxia–telangiectasia and Rad3 (ATR) related pathway 
(Woods and Turchi, 2013), which is a key regulator of the DDR (Ma et al., 2017). ATR 
is activated in response to single-stranded DNA structures, formed during repair of 
DSB or stalled replication forks (Sørensen and Syljuåsen, 2012). The ATR/Chk1 
checkpoint pathway plays a critical role in monitoring chromosomal replication and S-
phase DNA repair, such as homologous recombination (Dai et al., 2013) – the DNA 
repair pathway associated with ara-C (Woods and Turchi, 2013). As most tumour 
cells have defective DDR processes, including reliance on S and G2 checkpoints for 
survival, inhibition of defective ATR signalling has been investigated as a means to 
enhance current DNA damaging chemotherapeutics such as Ara-C (Woods and 
Turchi, 2013; Ma et al., 2017; Delia et al., 2017). The small molecule ATR VE82 was 
able to sensitise cells to gemcitabine, suggesting that ATR inhibition could be an 
effective treatment option in leukaemia (Woods and Turchi, 2013). One study found 
synergistic effects of ara-C with ATR-selective inhibitors, impeding proliferation, 
increasing apoptosis and removing ara-C-induced S and G2 cell cycle arrest in both 
AML cell lines and primary patient cells (Ma et al., 2017). 
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Ara-C inhibits the gap-filling step of excision repair, resulting in SSBs at these sites, 
which in turn induce chromosome breaks and formation of micronuclei at the next 
cellular division in surviving cells (Fenech et al., 1994; Brüsehafer et al., 2014). 
Additionally, ara-C metabolism by cells results in DNA fragmentation and apoptosis 
from this DNA damage (Bullock et al., 1996; Lorenzo et al., 2013). Ara-C is known to 
inhibit DNA repair and rejoining of DNA strand breaks induced by other agents 
(Güerci et al., 2009), relevant when considering that most regimens for AML treatment 
involve a combination of chemotherapeutics (Short et al., 2018). Both micronuclei 
formation and DNA fragmentation are recognised gold-standard analyses of 
genotoxicity in mammalian cells (Azqueta et al., 2011; OECD, 2014, 2016). 
 
1.1.12  Challenges of Ara-C Chemoresistance 
Up to half of patients treated for AML do not show continued response to ara-C 
(Lamba et al., 2011; Anderson et al., 2014) manifesting as either primary resistance, 
where the patient does not respond well to induction therapy, or acquired resistance, 
where an initial sensitive response gradually decreases over time (Zhang et al., 
2019). Chemoresistance development is a common cause of treatment failure, with 
patient mortality and morbidity linked to adverse drug effects (Lamba et al., 2011). 
Drug resistance can arise by a number of mechanisms specific to the agent, including 
aberrant signalling pathways, protein/enzyme secretion, gene alterations and 
microRNA changes (Zhang et al., 2019). For example, DNA polymerase and 
topoisomerases are enzymes implicated in reduced sensitivity to ara-C (Galmarini et 
al., 2002; Lamba et al., 2011). Moreover, resistant AML clones are able to adapt 
energy metabolism towards a mitochondrial oxidative phosphorylation profile in 
response to ara-C treatment (Farge, 2017). Additionally, the leukaemic niche and 
drug efflux have been implicated in chemoresistance, but understanding of these 
processes is incomplete (Farge, 2017). 
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A number of ara-C resistance mechanisms have been identified. For example, 
decreased intracellular ara-CTP by removal of surface hENT1 (Jin et al., 2009; 
Macanas-Pirard et al., 2017a), decreased dCK protein function (Cai et al., 2008; Levin 
et al., 2019), directional hypoxia and associated HIF1 expression (Degwert et al., 
2016; Valsecchi et al., 2016) and immunosurveillance evasion (Bakker et al., 2016). 
Macanas-Pirard et al. (2012) showed leukaemic cells to have increased ara-C 
resistance in mice by decreasing murine ENT1 transporter by 50% when exposed to 
BM-MSC factors, subsequently finding that these factors repress the transporter both 
short- and long-term (Macanas-Pirard et al., 2017a). More research is required to 
further elucidate the precise mechanisms of drug resistance in leukaemia and how 
cells interact to achieve continued disease. 
One of the greatest challenges in understanding chemoresistance, and therefore 
improving treatment outcomes, is patient heterogeneity (Kreso and Dick, 2014; 
Farge, 2017). This heterogeneity, along with the time to gain a full cytogenetic and 
molecular diagnosis for AML, absolutely restrict the efficacy of current therapies 
(Horibata et al., 2019). Horibata et al. (2019) showed distinct expression profiles by 
transcriptomic analysis of refractory (treatment resistant) AML patients, correlating 
four distinct patient signatures to overall survival. Though these techniques cannot 
yet be widely utilised due to cost and research restraints, they show the importance 
of a personalised therapy approach for AML patients due to such heterogeneity. 
 
1.1.13  Drug-Efficacy Screening 
Diagnosis of AML is based upon disease morphology, immunophenotype and 
cytogenetics before a treatment course is recommended (Döhner et al., 2010; 
Dombret and Gardin, 2016; Döhner et al., 2017), yet no drug-efficacy screening is 
currently performed, leaving groups of patients who do not respond well long-term 
having undergone unnecessary toxicity and a delay in delivery of effective therapy 
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(Alloush et al., 2010). A recent study used flow cytometry-based drug testing for AML 
chemosensitivity, with promising predictive results (Lin et al., 2020). On the back of 
the AML16 trial, flow-cytometric analysis also showed that high PB CD34+/CD38low 
blast frequency at diagnosis was associated was poor chemoresistance prognosis 
(Khan et al., 2015). Another study also showed improved treatment efficacy by 
chemosensitivity screening of 215 compounds to guide clinical decision-making 
(Swords et al., 2018). Testing was performed for up to 72 hours in both studies 
(Swords et al., 2018; Lin et al., 2020) however, holding the issue of delayed treatment 
initiation. 
As an alternative strategy, a bacterial bioluminescent biosensor was developed at 
UWE Bristol tor the rapid evaluation (within a working day) of leukaemic cell ara-C 
sensitivity (Anderson et al., 2014); with potential for use as a pre-treatment prognostic 
tool (Alloush et al., 2010). The assay has been previously optimised and verified in 
cell lines and patient blast samples (Anderson et al., 2014). Influences of the BM are 
neither well defined nor easily represented in vitro in the screening timeframe. This is 
hypothesised to be a contributing factor for the discrepancy between results of 10% 
of patient samples and corresponding clinical outcome, though this is also likely due 
to the presence of normal haematopoietic material in patient samples (E. Anderson, 
personal communication, 2016). The development of an in vitro model for leukaemic-
stromal interactions may further support the biosensor, providing an indication of BM 
influence in patient chemosensitivity not concordant with clinical outcome. 
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1.1.14  Effects of the Bone Marrow Microenvironment in 
Leukaemia Chemosensitivity 
1.1.14.1  Leukaemia-stroma; seed and soil 
Common to both LSC and healthy HSC is their dependency on the BM to survive 
(Dhami et al., 2016). Disease maintenance by the microenvironment is a recognised 
contributor in many cancer types; a relationship described by Stephen Paget between 
malignancy (seed) and microenvironment (soil) (Paget, 1889). As previously 
described (section 1.1.2), the BM niche is responsible for the maintenance of 
haematopoiesis in health and home to numerous cells, which provide both a 
supportive infrastructure, secreting cytokines, growth factors and adhesion proteins 
(Tabe and Konopleva, 2015). Leukaemic cells are difficult to grow ex vivo, and the 
disease does not propagate anywhere else in the body (with exception of myeloid 
sarcoma; Arber et al., 2016) – highlighting their dependence on the BMM (Krause 
and Scadden, 2015). In the early stages of AML development, HSC accumulate 
mutations transforming them into LSC, with support from signals provided by this 
microenvironment (Ladikou et al., 2020). LSC also share with HSC the properties of 
self-renewal, differentiation and lineage commitment pathways and are reliant on 
molecular mechanisms of the BM to perpetuate disease (Shiozawa et al., 2008). Just 
some of these known leukaemia-stroma interactions are depicted in Figure 1.4. 
 
1.1.14.2  Effects of the BMM on leukaemic cell progression and survival 
Studies investigating cell interactions utilise in vitro co-culture models, including 
conditioned media (CM; medium from one growing cell type transferred to another, 
containing the primary cells secretome), direct cell contact, indirect cell contact via 
porous trans-well inserts or 3D constructs (Nishida-Aoki and Gujral, 2019). However, 
due to the complexity of the BMM, there is no such ‘perfect’ in vitro model which adds 
challenge to research in the leukaemic microenvironment (Dhami et al., 2016).  
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Figure 1.4. Leukaemia-stroma interactions. Leukaemic and stromal cells are 
known to interact by direct contact (blue) and soluble factors (orange). These include 
VCAM-1-VLA-4 through NF-ĸB (Jacamo et al., 2014), CD44 through PI3K/Akt (Chen 
et al., 2016), CXCL12-CXCR4 (Yazdani et al., 2020) and a number of other signalling 
cytokines, for example IL-6, IL-8, SCF, IL-17, CD40, CCL2 and TGF-β1 (Plander et 
al., 2011; Civini et al., 2013; Huang et al., 2015; Ghazanfari and Behravan, 2017). 
MIF and PKCβ signalling have also been implicated in this crosstalk (Abdul-Aziz et 
al., 2017), with MIF also linked to HIF1α expression in hypoxia (Abdul-Aziz et al., 
2018). Ara-C enters the cell via the nucleoside transporter, hENT1, where it is 
triphosphorylated to active Ara-CTP for DNA damage to occur. Stromal cells have 
been shown to reduce hENT1 on leukaemic cells (Macanas-Pirard et al., 2017a). 
These provide just some of the known leukaemia-stroma interactions. 
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Extensive evidence using such models show that BM interactions promote long-term 
leukaemic survival (Garrido et al., 2001; Moshaver et al., 2008); leukaemic cells 
cultured with a stromal cell type are less likely to undergo spontaneous or drug-
induced apoptosis. Both direct cell contact and BM soluble factors protect leukaemic 
cells (Garrido et al., 2001; Moshaver et al., 2008). However, Garrido et al. (2001) 
found that AML cells were maximally protected from apoptosis when in direct contact 
with HS-5 (human stromal cell line) monolayers, in comparison to separation by trans-
well inserts or mono-cultures. Moshaver et al. (2008) compared four AML cell lines’ 
survival with HS-5 influence, concluding a significant increase in viable leukaemic 
cells in co-culture – both with indirect contact using inserts and direct contact. 
Additionally, Long et al. (2015) showed chemoprotection of AML cell lines by stroma, 
identifying genetic involvement. HS-5 and HS-27A (human stromal/epithelial cell line) 
protected NB-4 (AML M3; t(15;17) PML-RARA) and THP-1 (AML M5) cells from 
etoposide, mitoxantrone and ara-C. Interestingly, following trans-well co-culture, 
stromal cells provided little protection from apoptosis from etoposide/ara-C, but still 
protected from mitoxantrone (Long et al., 2015). This highlights the reliance on 
physical cell contact in response to some, but not all, drug classes. 
Konopleva et al. (2002) also showed reduced apoptosis of AML cells grown on MS-5 
(murine stromal cells), with an additional finding of significantly increased Bcl-2 and 
Bcl-XL (that block lymphocyte apoptosis). U937 (AML M5), KG1a (APML M3) and 
primary AML blasts also showed reduced apoptosis by Bcl-2 and Bcl-XL when 
allowed to adhere to healthy primary MSC, correlated with upregulation of c-Myc and 
deregulation of apoptotic markers, such as caspase-2 and PARP cleavage  (Xia et 
al>, 2015a). Therefore, contact with MSC protects leukaemic cells from apoptosis, in 
part through Bcl and c-Myc signalling. 
The HSC receptor CXCR4 is an important marker in leukaemogenesis, as high 
expression has been associated with poorer prognosis (Spoo et al., 2007; Du et al., 
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2019; Yazdani et al., 2020). For example, CXCR4 was higher in AML-M4/5 and those 
with FLT3-ITD mutant AML (Du et al., 2019); subtypes associated with poorer 
prognosis (Haferlach and Schmidts, 2020). Interactions of CXCR4 and its stromal 
ligand CXCL12 are well represented in the literature, with therapeutic efforts towards 
interfering this pathway (Yazdani et al., 2020). G-CSF inhibits CXCR4 signalling and 
overcomes stromal-mediated chemoresistance in HL-60 (AML M2) cultured with HS-
5 cells (Sheng et al., 2016). Li et al. (2015) also attempted to improve chemotherapy 
efficacy in AML by interfering with CXCR4/CXCL12 binding using synthetic peptides, 
resulting in prolonged lifespan in mice. Another study showed that inhibition of 
CXCR4 removes kinase inhibitor and ara-C chemoresistance (Zeng et al., 2009) and 
reduces migration and development (Zhang et al., 2017) of AML cells with stromal 
influence. AML cells therefore use the CXCR4/CXCL12 axis to exploit the safety of 
the BMM, with promoted survival and chemotherapy protection (Ladikou et al., 2020). 
Chen et al. (2015) found that NB-4 cells (AML M3/t(15;17)) that adhered to HS-5 or 
primary MSC, developed resistance to the anti-CD44 antibody A3D8. CD44 is a 
glycoprotein known to be involved in the maintenance of quiescence, niche homing 
and apoptosis resistance (Krause and Scadden, 2015). Pre-treatment with a PI3K/Akt 
inhibitor restored sensitivity, therefore suggesting PI3K/Akt signalling pathway 
activation as a chemoresistance mechanism (Chen et al., 2016; Pillinger et al., 2016).  
Conversely, some studies show MSC to have the opposite effect on leukaemia growth 
(Lee et al., 2019). Proliferation and apoptosis in K562 cells was reduced in co-culture 
with MSC from AML patients, with a G0/G1 phase shift in K562 (Wei et al., 2009). 
Another study also found reduced proliferation of leukaemic cell lines (U937, HL-60 
and multidrug-resistant HL-60) when in direct contact or insert co-culture with BM 
stromal cells, also with reduced S-phase and increased G1 (Liang et al., 2008). 
Contention of results in the literature due to heterogeneity or inadequate modelling 
are yet to be determined. 
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1.1.14.3  Effects of the BMM on leukaemic cell signalling 
The molecular signals from the BMM have been shown to affect leukaemic cells’ 
response to chemotherapy (Tabe and Konopleva, 2015; Zhou et al., 2016; Wang and 
Zhong, 2018; Ciciarello et al., 2019). Physiologically, these cells interact with one 
another both in proximity by direct contact and adhesion, and by distant signalling 
interactions. Cells which are not in direct contact use molecular signalling, including 
facilitation by soluble factors. Like other processes, AML cells are heterogeneous for 
both their responsiveness to cytokine signals and release of such cytokines (Bruserud 
et al., 2007). AML blasts are found to have increased proliferation by IL-3, GM-CSF 
and SCF for example, in some subsets of patients but not others (Bruserud et al., 
2007). Brenner et al. (2017) also showed that co-culture of normal MSC and AML 
cells in a trans-well model promoted AML growth and had anti-apoptotic effects, 
though the particular cytokines implicated varied between patients. These effects 
were not correlated with cytogenetic/molecular disease classification (Brenner et al., 
2017), however, highlighting again the multitude of heterogeneous profiles. Despite 
promising targeted therapies in clinical trials, for example FLT3 inhibitors (Gallogly 
and Lazarus, 2016) and monoclonal antibodies such as Gemtuzumab (Rowe and 
Lowenberg, 2013), the continued incidence of relapse highlights the collaboration of 
a myriad of pathways. 
AML cells co-cultured with human MSC had significantly higher proliferation when 
compared to co-culture with murine MS-5 or liquid culture (Schelker et al., 2018), 
highlighting the required communication in human biology between cells from the 
same species. CXCL12 and TGF-β1 modulated both proliferation and 
chemosensitivity, where inhibition of TGF-β1 increased proliferation and 
chemoprotection, while inhibition of CXCR4 reduced AML proliferation (Schelker et 
al., 2018). Work by Abdul-Aziz et al. (2017) showed that AML blasts co-cultured 
directly with BM-MSC from AML patients were supported in vitro, with increased 
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proliferation and survival, in addition to increased pro-inflammatory protein kinase C 
(PKC)β-mediated IL-8 expression in co-cultures with both direct and indirect contact.  
Many other studies have found soluble factors to have greater protective effects. 
Gordon et al. (2014) concluded that the cytokines G-CSF, IL-6 and SCF in HS-5 
conditioned media protected AML cells from drug-induced apoptosis. CM significantly 
reduced drug-induced apoptosis of K562 (AML M1) leukaemic cells in another study, 
demonstrating soluble factor-mediated resistance (Li et al., 2015). Civini et al. (2013) 
investigated global gene expression, concluding that co-cultures separated by inserts 
had upregulated pro-inflammatory genes and over-expressed canonical pathways for 
IL-17, CD40 and NF-ĸB signalling. Similar effects were found with direct co-cultures, 
where the most significant changes were seen in pathways involved in glucocorticoid 
receptor, IL-17 and acute phase response signalling. As these changes did not 
require direct contact, it is likely due to soluble factors released by cells.  
Because the BMM is adapted for leukaemic survival, it is the primary site for MRD, 
with LSC causing relapse and mediating drug resistance (Ladikou et al., 2020). Better 
understanding of leukaemia in the BMM is needed, given the clear dependency of 
AML cells on the BMM. It is hoped that studies in this area can aid the development 
of therapies to improve the poor outcomes of patients with AML. As leukaemia 
processes clearly involve a myriad of pathways, and with extensive patient 
heterogeneity, it is likely that drugs co-targeting several pathways will always be 
needed (Ladikou et al., 2020). 
Contact and secretome interactions are shown to have a parallel role in promoting 
malignant cell survival (Garrido et al., 2001; Moshaver et al., 2008; Civini et al., 2013; 
Gordon et al., 2014; Brenner et al., 2017), however, the elucidation of their individual 
roles is inconsistent among the literature. This highlights the extent of niche 
heterogeneity and validates the need for further research in larger cell populations. It 
also highlights the changeability of these cellular interactions in vitro. Many questions 
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are still raised here, for example, is it known which cell type initiates the interaction, 
and what effect do diseased cells have on the BM itself? This study aimed to elucidate 
how the stroma does in fact protect leukaemic cells, particularly examining genotoxic 
interactions, as these are particularly lacking, with most interaction studies to date 
focusing at the cellular level. To do so, it will be important to study the changes made 
to the stroma due to the influence of disease itself. 
 
1.1.15  Effects of Leukaemia in the Bone Marrow 
Microenvironment 
1.1.15.1  Leukaemia-stroma; yin and yang 
“Yin and Yang” is proposed as a more fitting analogy for leukaemia-stroma 
interactions than “seed and soil”, due to the dynamic relationship between leukaemic 
cells and the BMM (Zhou et al., 2016). MSC are ideally engineered for the support of 
HSC and other cells in BM niches, are essential for successful SCT and preventing 
graft-versus-host disease (Ciciarello et al., 2019), and hence can also be exploited 
by malignancy (Korn and Mendez-Ferrer, 2017). HSC transformed into malignant 
cells exhibit altered gene, adhesion and soluble factor expression/secretion (section 
1.1.14), and these signals have been shown to alter the BMM to perpetuate disease 
(Meads et al., 2008; Civini et al., 2013; Evans et al., 2015). This is also because 
leukaemic and stromal cells exhibit bidirectional effects (Korn and Mendez-Ferrer, 
2017), and so it is unsurprising that signalling within the niche is not limited to stromal 
cells. Much of the research in HM has shone a light on the malignant cells themselves, 
with leaps in understanding the pathogenesis of these cells over recent years (Fiegl, 
2016; DiNardo and Lachowiez, 2019). The effects on the BMM are now widely 
recognised, with some of the main interactions summarised in Figure 1.4, however 
there is still much to be learned about how stromal cells are themselves affected by 
malignant invasion, and how chemotherapy affects their ability to continue to 
adequately once the disease is under control. 
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1.1.15.2  Stromal damage by chemotherapy 
The BM stroma is known to be damaged by chemotherapy (Kemp et al., 2010; May 
et al., 2012, 2018), with clinical impact as MSC following SCT remain of host origin 
(Rieger et al., 2005; Wang et al., 2005). Stromal damage has only been seen to repair 
in children < five years of age (Galotto et al., 1999), though despite this lack of repair 
in adults, the drug doses administered to patients still allow for support of leukaemic 
cells; an ability that reduces with increasing chemotherapy dose (Moshaver et al., 
2008; Kemp et al., 2010), with clinical importance for dose escalation studies (section 
1.1.9.1). Morphological changes to MSC post-chemotherapy exposure, for example 
cyclophosphamide and melphalan (Kemp et al., 2011) and altered expression of 
CD44 (Kemp et al., 2010) have been observed. MSC morphology is also significantly 
altered following chemotherapy treatment, with decreases in both cell number and 
fibroblastic appearance after exposure to activated cyclophosphamide, dacarbazine, 
and vincristine (May et al., 2012). Patients treated with chemotherapy and 
radiotherapy had cytogenetic changes in BM-MSC, and in some cases increased 
cytogenetic aberrations in healthy HSC as well (Yeh et al., 2012). 
Additionally, our research group has shown that both HS-5 and cord blood MNC 
(partially MSC constituted) show significant genotoxic damage following 
cyclophosphamide treatment in appropriate models, which persists with cessation of 
therapy (May et al., 2018). Another study found that BM-MSC and CFU-F number 
reduced for up to one year post-SCT, which involved high-dose ara-C consolidation 
and busulfan/cyclophosphamide-based myeloblation (Shipounova et al., 2017). CFU-
F/MSC function was however retained, but gene expression was inhibited, including 
the proliferation genes platelet-derived growth factor and fibroblast growth factor 2 
(Shipounova et al., 2017). MSC derived from patients previously treated with 
chemotherapy for a HM displayed persisting genotoxic damage at one, seven and 17 
years post-treatment, as compared to matched untreated patients (May et al., 2018). 
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1.1.15.3  Bone marrow remodelling in leukaemia 
Chemotherapy treatment of MSC also affects their protection of AML cells (Moshaver 
et al., 2008; Somaiah et al., 2018). HS-5 pre-treated with ara-C lost their ability to 
protect HL-60 cells from spontaneous apoptosis, however, treatment of both cell 
types in co-culture resulted in increased HL-60 viability with stromal co-culture 
compared to without (Moshaver et al., 2008). Kemp et al. (2010) showed that 
diseased MSC pre-treated with high-dose chemotherapy became damaged, with 
decreased capacity to expand, whilst retaining the ability to support haematopoietic 
progenitors. Another study also found that treatment with ara-C, DNR and vincristine 
impaired MSC differentiation, proliferation and cell surface expression – though 
partially reversible post-treatment – with increased IL6, FGF2 and TNFα expression 
(Somaiah et al., 2018). Interestingly, MSC pre-treated with these drugs had reduced 
capacity to protect HL-60 cells from drug-induced apoptosis (Somaiah et al., 2018). 
Outside of our research group there is a distinct lack of published literature examining 
effects of chemotherapy on the BM stroma at a genotoxic level, however, one study 
did investigate the genotoxic effects of cisplatin on BM-MSC following co-culture with 
cancer cell lines (El-Badawy et al., 2017). BM-MSC co-cultured using trans-well 
inserts with MCF7 (breast) and Hela (cervical) malignant cell lines were shown to 
form sphere-like chemoresistant cells, termed ‘cancer-induced stem cells’ in this 
study. These cancer-induced stem cells showed significantly reduced cisplatin 
genotoxicity, as determined by the alkaline comet assay, as compared to cells 
cultured alone (El-Badawy et al., 2017). 
Previous research into chemoresistance mechanisms have focussed on BM 
protection of leukaemic cells, though evidently leukaemia-stroma interactions are a 
bidirectional occurrence (Krause and Scadden, 2015). Civini et al. (2013) found that 
leukaemic cells also induced a pro-inflammatory IL-17 profile in BM-MSC, 
independent of direct cell contact. Similarly, chronic lymphoblastic leukaemia cells 
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induced the expression of IL-6, IL-8 and CD40 inflammatory cytokines and adhesion 
molecules such as ICAM-1 on MSC, while simultaneously increasing expression of 
adhesion molecule ligands on their own surface (Plander et al., 2011). Jacamo et al., 
(2014) also showed VCAM-1 and VLA-4 to play a role in NF-ĸB activation in 
leukaemia-stroma, which promoted chemoresistance. IL-8 has been linked to an 
increase in MSC migration and number in AML (Kumar et al., 2018). Abdul-Aziz et al. 
(2017) showed that ex vivo AML CM caused differential cytokine secretion by BM-
MSC, including synergistic expression of the pro-inflammatory cytokines IL-8 and 
macrophage migration inhibitory factor (MIF), shown to be regulated by PKCβ 
signalling processes. Though the surface antigen and gene profile did not differ 
between BM-MSC in AML and healthy participants, Huang et al. (2015) showed 
reduced CCL-2 secretion, a migration regulatory cytokine, from AML-MSC. Chandran 
et al. (2015) demonstrated that MSC from AML patients attenuated normal 
haematopoiesis compared to healthy MSC, leaving leukaemic cells at an advantage 
within the niche due to reduced spatial competition.  
These studies demonstrate that the presence of leukaemic cells in the BMM induce 
changes favourable to their survival, by increasing adhesion, expression profiles and 
reducing niche competition from normal HSC/HSPC. There is a shortage of post-
treatment co-culture data, still studies in untreated cells are critical to understanding 
disease mechanisms. Nonetheless, they are not indicative of drug resistance 
mechanisms – the greatest challenge in treatment currently. 
Despite this lack of post-treatment assessment, the crosstalk between AML cells and 
BM-MSC is known to alter global gene expression in MSC, in most part of genes 
downstream of NF-ĸB, CCL/CXCL chemokine and Toll-like receptor signalling 
(Reikvam et al., 2015). Additionally, AML cells have been shown to adapt the BM 
niche by secretion of exosomes, supporting disease growth in detriment to normal 
haematopoiesis (Kumar et al., 2018). AML exosomes induced DKK1 (inhibitor of Wnt 
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signalling; Zhu et al., 2009) expression by BM stromal cells, which suppresses 
haematopoiesis and osteogenesis, and downregulated the haematopoiesis 
supporting factors CXCL12, SCF and insulin-like growth factor 1 in stromal cells 
(Kumar et al., 2018). 
Leukaemic cells induced transcriptional changes to MSC, including in CXCL12 and 
JAG1 expression (Kim et al., 2015). These aberrations were highly heterogeneous 
between AML patients, concordant with heterogeneous clinical outcomes, therefore 
with potential for future prognostic assessment (Kim et al., 2015). A study by Frisch 
et al. (2012) found pro-inflammatory CCL-3 expressed by AML cells to inhibit 
osteogenesis by MSC in murine models of the BMM. Geyh et al. (2016) also found 
diminished osteogenesis capacity and proliferation of MSC in AML CM. This was also 
associated with alterations of SCF and JAG1, with reduced support of HSPC in vitro 
(Geyh et al., 2016). 
This gives an indication of how malignant cells can induce remodelling of the BMM to 
enhance their survival, however, there is a lack of studies in the literature examining 
leukaemia-mediated chemosensitivity of stromal cells. Despite the evident 
bidirectional interactions of leukaemic and BM stromal cells, there are few studies 
that investigate these directional effects simultaneously. Hence, there is a need for 
more work investigating both the effects of co-culture and treatment on leukaemic 
cells and stromal cells, guiding the scope of this thesis. Unsurprisingly, the role of 
MSC and the supportive niche has recently become an emerging topic of interest for 
explaining chemoresistance, in efforts to answer the many questions still outstanding 
in leukaemia pathogenesis, including: are changes in BMM secondary to malignancy 
or part causative; is direct cell-contact required for therapy resistance; what are the 
main mediators of the crosstalk; and how can these changes be inhibited?  
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1.2  RESEARCH AIMS 
The intended outcome of this project was to better elucidate the mechanisms by 
which the BM stroma interacts with leukaemic cells, leading to changes in 
chemosensitivity and implicated in poor response/relapse in leukaemia. This work 
hypothesised that the interaction between leukaemic and BM stromal cells causes 
changes to the phenotypic profile and behaviour of cells, which proves preferential to 
the disease microenvironment, and that the BM is remodelled in haematological 
malignancies, leading to changes in cytokine secretion and the handling of 
chemotherapeutic drugs by cells. The following main research aims and related 
research questions were developed: 
1. Assess the altered chemosensitivity mediated by leukaemia-stromal interactions 
in cell line co-cultures (chapter 3) 
i. Are leukaemic cells chemoprotected by stromal cells unidirectionally? 
ii. Are stromal cells sensitised to chemotherapy-induced genotoxicity by 
leukaemic cells, while leukaemic cells themselves are protected by stromal 
cells? 
iii. Are stromal cells also chemosensitised to cytotoxic effects by leukaemic cells, 
while leukaemic cells themselves are chemoprotected by stromal cells? 
2. Further assess altered chemosensitivity mediated by leukaemia-stromal 
interactions in co-cultures using primary patient MSC (chapter 4) 
i. How do patient characteristics, including age, gender and disease state, affect 
the behaviour of BM-MSC? 
ii. Are primary MSC sensitised to chemotherapy-induced genotoxicity by 
leukaemic cells, while leukaemic cells themselves being protected by primary 
MSC? 
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iii. Are primary MSC also chemosensitised to cytotoxicity by leukaemic cells, 
while leukaemic cells themselves chemoprotected by primary MSC? 
iv. Is altered chemosensitivity in leukaemia-stroma co-cultures using primary 
MSC equivalent to cell line-mediated effects? 
3. Identify changes in protein expression mediated by leukaemia-stromal 
interactions in co-culture as mechanisms of altered chemosensitivity (chapter 5) 
i. Is hENT1 differentially expressed by leukaemic and stromal cells following co-
culture and ara-C treatment? 
ii. Does leukaemic-stromal co-culture in the utilised model result in the 
differential secretion of cytokines? 
iii. Are differentially expressed cytokines responsible for altered chemosensitivity 
in leukaemic and stromal cells? 
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Chapter 2 - MATERIALS AND METHODS 
Unless otherwise specified, reagents were sourced from Sigma-Aldrich (Dorset, UK). 
 
2.1  CELL CULTURE 
2.1.1  Leukaemic Cell Lines 
The leukaemic cell lines, HL-60 and K562 (LGC Standards [ATCC], Teddington, UK), 
were maintained in 75 cm2 vented culture flasks in the recommended Roswell Park 
Memorial Institute (RPMI) 1640 complete media (supplemented with 10% [v/v] foetal 
bovine serum [FBS] and 2 mM L-glutamine), as confirmed by preliminary media 
suitability experiments. HL-60 cells were resuscitated from cryopreserved stocks in 
Iscove’s Modified Dulbecco’s media (IMDM; Life Technologies, Paisley, UK), 
supplemented with 20% FBS and 2 mM L-glutamine, as per the manufacturer’s 
recommendations, then transferred to complete RPMI for all future conditions. Cells 
were incubated at 37°C in a 5% CO2/95% humidity atmosphere, sub-cultured every 
2–3 days by centrifugation (300 xg for 5 minutes) and seeded at 3 x105/mL. 
 
2.1.2  Stromal Cell Line 
The human stromal cell line, HS-5 (LGC Standards [ATCC], Teddington), was 
maintained by demi-depletion in high glucose (HG; 4,500 mg/L) Dulbecco’s Modified 
Eagle’s Medium (DMEM) complete media (supplemented with 10% FBS and 2 mM 
L-glutamine). Confluent cells were detached (0.05% trypsin/0.02% 
ethylenediaminetetraacetic acid [EDTA] in phosphate buffered saline [PBS]; TE) and 
incubated in the same conditions as leukaemic cell lines (section 2.1.1). In co-culture 
experiments, RPMI media was instead used as determined by preliminary media 
suitability experiments (see Figure 3.2). 
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2.1.3  Bone Marrow Aspiration 
BM aspirate samples were obtained from patients attending the Haematology 
Outpatient Department of the Royal United Hospitals NHS Foundation Trust, Bath, 
following informed consent and local ethics approval (18/NI/0036). Patients were 
undergoing routine investigations for the diagnosis or monitoring of a haematological 
disease. BM aspiration was performed by clinical professionals from the iliac crest, 
and collected into lithium heparin sample tubes, prior to transportation to UWE Bristol. 
 
2.1.4  Isolation of Mononuclear Cells from Bone Marrow 
MNC fraction was isolated by density gradient centrifugation. Samples were diluted 
1:1 with low glucose (LG; 1,000 mg/L)-DMEM before gentle layering onto an equal 
volume of Histopaque-1077 (d = 1.077g/mL) in a 50 mL sterile tube. Cells were 
centrifuged (600 xg for 20 minutes) without brakes. The MNC fraction was harvested 
and washed in MSC media, comprising LG-DMEM supplemented with 10% FBS for 
optimal MSC growth (STEMCELL Technologies, Cambridge, UK). Residual 
erythrocytes were removed by resuspension in red cell lysis (150 mM NH4Cl, 100 
mM NaHCO3 and 1.3 mM EDTA) for 10 minutes and followed by a final wash in MSC 
complete media. 
 
2.1.5  Isolation of Mesenchymal Stromal Cells 
MSC isolation is achieved on the basis of plastic adherence and can be confirmed by 
immunophenotype and differentiation capacity (Dominici et al., 2006). BM-MNC were 
seeded at a density of 1 x107/mL per 25 cm2 flask in 5 mL MSC media. Cultures were 
incubated in standard conditions and maintained by demi-depletion at day 3 and 
weekly thereafter to remove non-adherent haematopoietic cells and replenish 
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nutrients. Images were also taken weekly or at passage end by inverted phase-
contrast microscopy (Nikon Eclipse TE300) with Image-Pro Plus software (Meyer 
Instruments). When 70% confluency was reached, cells were trypsinised (as of 2.1.2) 
and washed twice in LG-DMEM, then reseeded at 1 x105/25 cm2 flask, defined as 
passage (P)1 and allowed to reach confluency. Cells were cryopreserved (LG-
DMEM, 25% MSC-FBS, 10% DMSO) at the end of P1 for synchrony of co-culture 
experiments. Cells were resuscitated in media containing 20% FBS and cultured in 
the same manner for further passages, until co-culture, immunophenotyping and 
differentiation experiments at P4. BM cultures which did not successfully expand were 
harvested for genotoxicity assessment by alkaline comet assay (section 2.5.2). 
 
2.2  CYTOTOXICITY ASSESSMENT 
2.2.1  Membrane Integrity 
Trypan blue (TB) is a dye that requires loss of membrane integrity to enter cells. A 
blue stained cell therefore correlates with a cell that has lost membrane control and 
infers non-viability. 
To assess cytotoxicity, cells were suspended 1:1 with 0.4% TB prior to manual 
counting using a haemocytometer. Viable/non-viable cell counts were evaluated 
based on the cells ability to exclude the dye and the cytoplasm remain clear. 
 
2.2.2  Metabolic Activity 
2.2.2.1  Alamar blue 
Alamar blue (AB; resazurin) is a fluorescent dye used as a metabolic indicator of 
cytotoxicity; a reduction reaction following electron exchange facilitates a colour shift 
from non-fluorescent blue to fluorescent pink (Rampersad, 2012). 
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Prior to cell viability assessment, the assay was optimised for each cell type to reflect 
the most appropriate cell density and incubation time. Cells were serially diluted in 
appropriate culture media and 100 µL plated in triplicate into a 96-well plate. AB 
reagent (0.0036 mg/mL stock) was added before incubation at 37ºC with 5% CO2. 
Fluorescence was measured using a microplate reader (Tecan Infinite F200 Pro, 
Tecan, Reading, UK) at hourly intervals from 1–6 hours, at 535 nm(ex)/590 nm(em), to 
deduce the linear range of cell density, then at 24 hours to reflect full reduction (see 
Appendix). 
To measure cell viability, AB was added to the relevant well (10% of well volume) and 
fluorescence read after the appropriate incubation period. Percentage AB reduction 
was calculated based upon the positive control, created by autoclaving of AB reagent 
stock, which causes full reduction. A negative control of media and AB without cells 
was included, as well as blank media for background fluorescence. 
 
2.2.2.2  CellTiter-Glo 
Intracellular ATP production was determined by the CellTiter-Glo® (CTG) 
Luminescent Cell Viability Assay (Promega, Southampton, UK). Upon mixing the 
CTG reagent with suspended cells, cells are lysed and intracellular ATP catalyses 
production of a luminescent signal; conversion of luciferin to oxyluciferin proportional 
to viable cell number and therefore indicative of metabolic activity (Promega, 2020). 
To assess intracellular ATP/metabolic activity, cells were cultured and treated with 
ara-C, prior to addition of 100 µL of suspended cells, or media only control, to a black 
micro-titre 96-well plate (Greiner Bio One Ltd., Stonehouse, UK). CTG reagent (100 
µL) was added and cell lysis induced by mixing for 2 minutes on an orbital shaker. 
The plate was incubated for 10 minutes at room temperature to stabilise the signal, 
then luminescence recorded using a microplate reader (Tecan Infinite F200 Pro). 
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2.2.3  Culture Dynamics 
2.2.3.1  Cell Growth and Adherence 
Prior to co-culture modelling, the dynamics of leukaemic and stromal cultures were 
established. This was to ensure all cells were in optimal conditions for a successful 
model before chemosensitivity assessments could take place. 
HL-60, K562 and HL-60 cells were seeded at 1 x105/mL into 24-well plates in 
complete RPMI media and incubated in standard conditions. Cells were counted 
manually by TB exclusion at appropriate time points to determine growth. For 
adherence, HS-5 were seeded at 3 x105/mL into 24-well plates in complete HG-
DMEM for up to 36 hours. Percentage adherence was calculated from the ratio of 
suspended and trypsinised adherent cells, determined by manual counting of 
membrane viable cells with TB. Representative wells were imaged by inverted phase-
contrast microscopy (Nikon Eclipse TE300). Metabolic activity of cells cultured in 
three culture media formulae was determined by AB reduction. Briefly, HL-60, K562 
and HS-5 cells were seeded at 5 x105/mL into 96-well plates in the appropriate media 
and incubated for up to 72 hours. AB reagent was added 4 hours prior AB reduction 
as of 2.2.2.1. 
 
2.2.3.2  Ara-C Treatment 
For cell viability with increasing dose, cells were treated with ara-C at 0.1–100 µM, 
relevant to the clinical standard dose of 100–200 mg/m2 (Kadia et al., 2015). Cells 
were exposed for 1–72 hours for cytotoxicity assays and 1 hour for biosensor and 
genotoxicity assays, as indicated. Conversion from in vivo to in vitro ara-C dose was 
based on the average person weighing 70 kg, equivalent to 50 L total body volume 
and a surface area of 1.79 m2 (Sacco et al., 2010). Therefore, the relevant in vivo 
dose ranged from 14.7–29.4 µM. 
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2.3  CO-CULTURE MODELS 
2.3.1  Conditioned Media 
Supernatant was collected after conditioning by adherent HS-5 cells in log phase of 
growth. Cells were seeded into 75 cm2 culture flasks at 3 x105/mL in 20 mL of 
complete HG-DMEM media, before incubation in standard conditions for 24 hours. 
Media was then replaced with complete RPMI media and incubated for a further 24 
hours. The supernatant was harvested and centrifuged at 2000 xg for 10 minutes to 
remove any potential detached cells and debris. To further ensure cells were 
removed, CM was passed through a 0.2 µm filter and aliquots stored at −20°C, 
thawing only once before use. 
For CM experiments, HL-60/K562 were seeded at a minimum of 3 x105/mL into 6-
well culture plates and suspended in complete RPMI media with or without CM 
(Figure 2.1). For each independent experiment, CM was pooled before administration 
to ensure uniform conditions. Plates were incubated for 24 hours prior to treatment 
with 25 µM ara-C for 1–72 hours. Cells treated for use in the biosensor assay were 
instead seeded into 25 cm2 culture flasks to ensure retrieval of > 2 x106 cells as a 
requirement of the assay (Anderson et al., 2014). 
 
2.3.2  Co-Culture Inserts 
HS-5 (3 x105/mL) were seeded into 6-well (3.8 cm) culture plates in 3 mL of complete 
HG-DMEM and allowed to adhere for 24 hours. Media was then replaced with 
complete RPMI media and HL-60/K562 (3 x105/mL) were seeded in 3 mL into 0.4 µm 
pore hanging trans-well inserts (Millipore (UK) Ltd., Watford, UK) above the stromal 
layer (Figure 2.1). Cells were co-cultured for 24 hours prior to treatment and 
assessment. 
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Figure 2.1. Co-culture models using conditioned media or trans-well inserts. 
Media was conditioned by stromal cells and this media, containing the stromal 
secretome, was used in experiments involving leukaemic cells. Alternatively, stromal 
cells were allowed to adhere to culture plate wells prior to co-culture with leukaemic 
cells suspended above in porous trans-well culture inserts. With such, leukaemic-
stromal interactions could take place bidirectionally without direct cell contact. 
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Experiments involving primary MSC were performed in the same way, except for MSC 
seeding at 5 x104 and HL-60 at 1 x105 and complete media containing FBS validated 
for MSC growth. For protein secretion studies (cytokine array and ELISA), all wells 
contained a final volume of 6 mL, as opposed to maintaining cells/mL as defined 
above. 
 
2.4  BACTERIAL BIOLUMINESCENT BIOSENSOR 
2.4.1  Bacterial Strain and Culture Conditions 
A previously engineered strain of Escherichia coli (E. coli) was used as the biosensor. 
To create the bioluminescent properties of E. coli HA1, a vector carrying the 
luxCDABE operon from Photorhabdus luminescens was inserted by bacterial 
transformation (Kovach et al., 1995; Billard and DuBow, 1998; Alloush et al., 2010). 
The HA1 plasmid vector carries resistance genes, for kanamycin and ampicillin, to 
enable isolation from bacterial strains not expressing lux. Tetracycline is also used to 
maintain the transposon directed cytidine deaminase-knockout on the chromosome. 
The main features of HA1 as a bioluminescent biosensor are that it is cytidine 
deaminase-deficient (will not inactivate ara-CTP), expresses dCK (can phosphorylate 
ara-C) and requires pyrimidine (of which ara-C is an analogue). 
Cultures were maintained on nutrient agar plates or complete RPMI media, both 
containing kanamycin, ampicillin and tetracycline (10, 50 and 10 µg/mL respectively). 
Plates were imaged following 16–18 hours incubation using an electron multiplying 
charge-coupled device low-light digital camera (Andor Technology iXonEM+ 897; 
Figure 2.2). To ensure consistency of fresh cultures, a glycerol stock from a single 
bioluminescent colony was also created in Luria-Bertani broth (25% glycerol), where 
an individual aliquot was inoculated into the overnight culture. 
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Figure 2.2. Single colonies of bioluminescent E. coli HA1. E. coli HA1 was streak 
plated onto nutrient agar and images acquired by electron multiplying charge-coupled 
device imaging. Light image with luminescent overlay; purple-orange (false colour) 
represents low–high light. 
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2.4.2  Lysate Preparation 
Cells were resuspended in a minimum 1 mL clear RPMI (no supplementation/phenol 
red) at 2 x106/mL. Cells were treated with 25 µM ara-C in standard culture conditions 
for 1 hour. Following treatment, cells were harvested by centrifugation as previously 
described and washed in clear RPMI at double the original volume before final 
suspension in the original volume of clear RPMI. EDTA (1.75 mM) and saponin (1%) 
were added before vortex mixing for 30 seconds to facilitate cell lysis and centrifuged 
at 2000 xg for 10 minutes to remove cell debris. Lysate supernatants were either used 
immediately or stored at −20°C for future use. 
 
2.4.3  Biosensor Assay 
Prior to the assay, the HA1 biosensor was incubated at 37°C overnight in antibiotic- 
supplemented complete RPMI media, shaking at 175 rpm for 16–18 hours. Following 
microcentrifugation at 13,000 rpm for 1 minute and resuspension in clear RPMI, 
optical density (OD) was adjusted to 1.0 absorbance units at 600 nm (Helios Alpha 
UV-vis spectrophotometer), prior to incubation at 37°C with shaking for 30 minutes. 
Immediately prior to the assay, all reagents and samples were held at 37°C to ensure 
no delay in biosensor metabolism. The biosensor was mixed with Isopropyl β-D-1-
thiogalactopyranoside (IPTG; 1 mM), +/− alkaline phosphatase (ALP; bovine 
intestinal mucosa; 0.5 units/reaction), and 100 µL total plated with appropriate cell 
lysate into wells of a black half-area micro-titre 96-well plate (Greiner Bio One Ltd., 
Stonehouse, UK) and mixed gently. Bioluminescence, relative light units (RLU), by 
biosensor conversion of ara-CTP (Figure 2.3) was monitored using a Tecan Infinite 
200 Pro microplate reader every 15 minutes for a total of 15 hours to ensure the peak 
value for each curve was measured. 
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Figure 2.3. Schematic of the biosensor assay. Ara-C enters the dividing cell where 
it is triphosphorylated to active ara-CTP (Emadi and Karp. 2012), which causes DNA 
damage by integration (Kern et al., 1998; Galmarini et al., 2001). Ara-CTP within cell 
lysates is converted back to ara-C using alkaline phosphatase (ALP), which allows 
the bacterial biosensor (E. coli HA1) to amplify bioluminescence (Alloush et al. 2010). 
The difference in light production (+/− ALP) indicates level of ara-C metabolism in 
cells (Alloush et al. 2010). 
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2.4.3.1  Ara-CTP Standard Curve 
Alongside cell lysates a standard curve of ara-CTP was produced to allow for ara-
CTP quantification (indication of cellular ara-C metabolism). An initial stock of ara-
CTP in water was diluted in clear RPMI for a calibration curve ranging from 0–0.5 µM 
ara-CTP and plated in a similar manner to cell lysate. Peak RLU of each sample curve 
was interpolated to determine the peak ara-CTP generation of treated cells. 
 
2.4.3.2  Data Analysis for Sensitivity Index 
The chemosensitivity marker of the cells was denoted as sensitivity index (SI; 
Anderson et al., 2013), calculated by comparison of peak bioluminescence between 
plus and minus AP samples in treated and untreated groups. Each sample was 
measured in triplicate per independent experiment from lysate. 
Sensitivity index (SI) = [(
+ ALP RLU
- ALP RLU
) 25 µM - (
+ ALP RLU
- ALP RLU
) 0 µM]  X 100 
 
2.5  GENOTOXICITY ASSESSMENT 
2.5.1  Micronucleus Assay 
The micronucleus (MN) assay is often used in conjunction with the comet assay as 
part of a battery of genotoxicity tests on new compounds, to determine the level of 
DNA damage in interphase cells. MN are often formed as a result of fragments of 
chromosome which fail to migrate during anaphase (Azqueta et al., 2011; OECD, 
2014, 2016). 
HL-60, K562 and HS-5, or HL-60 and patient MSC, were co-cultured and treated with 
25 µM ara-C or untreated for 1 hour. Following treatment, cells were reseeded into 
co-culture plates and returned to culture for 1.5–2 cell divisions (48–72h). Cells were 
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then washed and resuspended in 150 µL PBS and 50,000 cells loaded into 
ShandonTM CytofunnelTM (Life Technologies, UK) mounted to polished (100% 
ethanol) glass slides by CytospinTM 4 centrifugation (Life Technologies, UK) at 1,000 
rpm for 10 minutes with high acceleration. Mounted cells were fixed using 100% 
methanol for 8 minutes, washed in phosphate buffer (pH 6.4–6.5; 0.66% KH2PO4 and 
0.33% Na2HPO4) and air dried. For staining, slides were dipped briefly in phosphate 
buffer before exposure to 0.12 mg/mL Acridine Orange for exactly 45 seconds, then 
finally washed in phosphate buffer for 15 and then 10 minutes. Slides were scored by 
addition of 20 µL phosphate buffer and a coverslip, and imaged by fluorescence 
microscopy (Nikon Eclipse 80i) under triple band-pass filter. Example images with 
nuclear abnormalities are shown in Figure 2.4.A. 
 
2.5.1.1  RICC and Population Doubling 
In line with OECD guidelines (OECD, 2014) for the testing of chemicals at the time 
the work was undertaken, cytotoxicity and proliferation was measured to assure 
sufficient cells had undergone division in control and treated cultures. (Lorge et al., 
2008) recommended using relative population doubling (PD) or relative increase in 
cell count (RICC) calculations in lieu of standard cytotoxicity values as this can 
underestimate cytotoxicity and produce false negative genotoxicity results. 
PD = 
final population
initial population
 
RICC = [
(final population - initial population)25 µM
(final population - initial population)0 µM
]  X 100 
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Figure 2.4. Damaged cell examples detected by micronucleus and comet assay. 
Following appropriate culture and treatment, cells (HL-60 as per this example) are 
mounted for micronucleus (MN) (A) or comet (B) assays. For MN, images are 
manually scored to include the indicated (arrow) nuclear abnormalities. Green = DNA, 
orange = cytoplasm. For comet, damaged DNA (H2O2 example) forming a ‘comet’ is 
scored by Comet Assay IV software. 
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2.5.2  Alkaline Comet Assay 
The alkaline comet assay is a method for detection of DNA damage in individual cells, 
specifically single/double strand breaks, alkali-labile sites and crosslinking (Güerci et 
al., 2009). The DNA is allowed to unwind under alkaline conditions and fragments 
migrate through the gel under electrophoresis. Fluorescence of resultant ‘comets’ is 
determined by fluorescence microscopy, giving insight into the head/tail length and 
proportion, as well as signal intensity (DNA damage). 
HL-60, K562 and HS-5, or HL-60 and patient MSC, were co-cultured and treated with 
25 µM ara-C or untreated for 1 hour prior to washing in PBS. Cells (5 x104) were 
mounted onto Gelbond® Film (Lonza, Slough, UK) in 0.5% low-melt agarose (held at 
37°C). As a positive control, gels were treated with 50 µM H2O2 for 5 minutes. Gels 
were exposed to lysis solution (2.5 M NaCl, 100 mM EDTA disodium salt, 10 mM Tris, 
1% Triton X-100 and 10% dimethyl sulfoxide [DMSO]) for > 30 minutes until 
electrophoresis. Gels were exposed to electrophoresis buffer (pH 13; 1 mM EDTA 
and 300 mM NaOH) for 20 minutes to unwind the DNA, electrophoresed for 20 
minutes (25 V, 300 mA) and then washed three times in neutralisation buffer (pH 7.5; 
0.4 M Tris). 
Immediately prior to scoring, 20 µg/mL propidium iodide was added to stain, and cells 
imaged by fluorescence microscopy (Nikon Eclipse 80i) under red filter and scored 
using Comet Assay IV software (Perceptive Instruments Ltd., Bury St. Edmunds, UK). 
Example images for untreated and H2O2 treated cells are shown in Figure 2.4.B. 
 
 CHAPTER 2 – MATERIALS AND METHODS 
56 
2.6  FLOW CYTOMETRY ANALYSES 
2.6.1  Flow Cytometry 
For MSC immunophenotyping, a NovoCyte® 3000 analyser and NovoExpress® 
software (ACEA Biosciences Inc., San Diego, California, USA) at the University of 
Bristol was utilised. All other flow cytometric analyses were performed using a BD 
AccuriTM C6 analyser and Accuri™ C6 software (Becton Dickinson (BD), Oxford, UK) 
at UWE Bristol. Sufficient cells were analysed to yield 10,000 live cell events following 
exclusion of cell debris, doublets and dead cells through appropriate gates. Gating of 
cells was performed by creation of forward scatter (FSC) and side scatter (SSC) plots 
with polygonal gating positioned around the main population of events, and 
fluorescence intensity (FL) was visualised by histogram or dot plots. Performance of 
the BD instrument over time was tracked by CV% of the highest peak of Spherotech 
8-Peak and 6-Peak validation beads (BD, Oxford, UK). MSC immunophenotyping 
data was analysed by FlowJo software (v10.6.2; Becton Dickinson Ltd, Oxford, UK). 
 
2.6.2  Cell Proliferation Assessment 
The carboxyfluorescein succinimidyl ester (CFSE) assay was used to determine cell 
proliferation. It is capable of doing so by staining intracellular amine structures with a 
fluorescent probe, where upon cellular division, each daughter cell carries half of the 
original fluorescence intensity (Quah and Parish, 2010). Proliferation by cell doubling 
can then be tracked as a decrease in fluorescence over subsequent days and 
compared between treatment groups (Figure 2.5). 
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Figure 2.5. Example histogram of CFSE indicating proliferation. Cells were 
stained with CFSE and the fluorescence intensity (FL1A) was analysed on the days 
following staining (D0–3). Cell generation (proliferation) is inferred from the halving of 
median CFSE FL1-A and number of times the fluorescence halved over a given time 
period. 
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2.6.2.1  CFSE Optimisation 
The appropriate CFSE concentration for each cell line was determined. Cells were 
stained with 0–10 µM CFSE (Abcam, Cambridge, UK) and fluorescence intensity (FL) 
measured on days 0–4. The dose at which the FL1 peak was entirely in scale on day 
(D)0 was chosen (HL-60, K562 and HS-5: 100 nM). 
 
2.6.2.2  CFSE Assay 
Cells (2 x106/group) were resuspended in 500 µL filtered PBS. CFSE concentrations 
were prepared at twice the desired final concentration, and 500 µL added to cell 
suspensions and incubated at 37°C for 15 minutes. Stained cells were quenched with 
500 µL filtered complete RPMI, spun at 300 xg for 5 mins and resuspended in 1 mL 
media; 750 µL transferred to a 12-well culture plate with 1 mL of complete RPMI and 
the remaining 250 µL resuspended in 1 mL PBS for flow cytometric analysis. 
 
2.6.3  MSC Immunophenotyping 
The immunophenotype of the MSC population was confirmed at the same passage 
as experiments (P4). Cells were stained with Zombie NIR™ viability dye (1/100; 50 
µL/1 x106 cells; BioLegend, London, UK) at room temperature and in the dark for 15 
minutes. Cells were washed in 1 mL 1% bovine serum albumin (BSA) before using 
the Human MSC Phenotyping Kit (Miltenyi Biotec Ltd., Woking, UK) according to 
manufacturer’s instructions.  
Briefly, cells were stained by addition of either 10 µL of MSC antibody cocktail (CD73-
APC, CD90-FITC, CD105-PE, CD14-PerCP, CD20-PerCP, CD34-PerCP and CD45-
PerCP) or 10 µL of isotype control cocktail in the dark at 4ºC for 10 minutes. Cells 
were washed in 1% BSA, resuspended in 300 µL of 1% paraformaldehyde and stored 
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at 4ºC for analysis by flow cytometry within 7 days. The gating strategy used for 
patient MSC immunophenotyping is shown in Figure 2.6. Multi-colour compensation 
applied based on fluorescence of single-stained cells. 
 
2.7  TRILINEAGE MSC DIFFERENTIATION 
Among the minimal requirements for confirmation of MSC populations, cells must 
have the capacity to differentiate into a number of lineages (Dominici et al., 2006). To 
assess the differentiation capacity of cultured MSC, isolated cells were induced using 
StemPro® Differentiation Kits (Thermo Fisher Scientific). 
 
2.7.1  Osteogenic Differentiation 
MSC (5 x103 cells/cm2) were seeded in 3.8 cm cell culture plates in MSC complete 
media. After 48 hours, Complete Osteogenesis Differentiation Media was added and 
cultures were maintained by complete media change every 3–4 days. Following 7–
14 days, cells were washed twice in PBS, fixed by addition of pre-cooled methanol 
for 5 minutes and washed in dH2O. Fixed cells were incubated with SIGMAFAST™ 
BCIP®/NBT substrate for 10 minutes and washed in dH2O. Cells were visualised by 
light microscopy and images captured for analysis, with blue/purple staining indicative 
of ALP production, an early marker of osteocyte development. 
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2.7.2  Chondrogenic Differentiation 
MSC (8 x105 cells) in a 5 µL droplet were seeded into the centre of a dry 3.8 cm cell 
culture plate well and incubated for 2 hours under high humidity. Complete 
Chondrogenesis Differentiation Media was added and cultures were maintained by 
complete media change every 2–3 days. Following 14 days, cells were washed in 
PBS, fixed in 4% paraformaldehyde at room temperature for 30 minutes, rinsed in 
PBS, and stained with 1% Alcian Blue solution (in 0.1 N HCl). Stained cells were 
rinsed three times in 0.1 N HCl and neutralised in dH2O before visualisation by light 
microscopy and images captured for analysis. Blue staining is indicative of 
polyanionic glycosaminoglycan chains of proteoglycan synthesis of chondrocytes. 
 
2.7.3  Adipogenic Differentiation 
MSC (1 x104 cells/cm2) were seeded in 3.8 cm cell culture plates in MSC complete 
media. After 48 hours, Complete Adipogenesis Differentiation Media was added and 
cultures were maintained by complete media change every 3-4 days. Following 14–
21 days, cells were washed in PBS, fixed in 4% paraformaldehyde at room 
temperature for 30 minutes and washed with dH2O. To stain cells, 0.1% Oil Red-O 
solution (in isopropanol) was incubated at room temperature for 15 minutes, followed 
by three washes in dH2O. Cells were visualised by light microscopy and images 
captured for analysis, with red staining indicative of the presence of neutral 
triglyceride and lipid formation by adipocytes. To elute the dye, 1 mL isopropanol was 
added to dry wells and incubated on a plate shaker for 15 minutes. Absorbance (540 
nm) was measured from 100 µL of differentiation or control well eluate. 
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2.8  WESTERN BLOTTING 
In order to ascertain changes to hENT1 expression in the leukaemic 
microenvironment, western blot was performed. 
 
2.8.1  Lysate Preparation 
Cells were harvested and resuspended in lysis buffer (10mM Tris-HCl, 0.4M NaCl, 
2mM EDTA, 1% sodium dodecyl sulphate (SDS), pH 8.2) before being passed 
through a 21-guage needle twenty times. Samples were incubated for 30 minutes at 
4ºC on a rotating incubator. Samples were centrifuged at 10,000 xg for 10 minutes at 
4ºC and total cell lysate supernatants stored at −80ºC. 
 
2.8.2  Subcellular Fractionation 
Subcellular fractionation was performed using the Thermo Scientific™ Subcellular 
Protein Fractionation Kit for Cultured Cells (Thermo Fisher Scientific, Waltham, USA). 
Following appropriate treatments, cells were harvested by centrifugation at 4ºC and 
500 xg for 5 minutes. Collected cells (3 x106) were washed twice in complete RPMI, 
followed by a wash in ice cold PBS (0.1 M Na3PO4, 0.15 M NaCl, pH 7.2). Halt™ 
Protease Inhibitor Cocktail (Thermo Scientific) was added to fraction/lysis buffers 
immediately before use. Ice cold Cytoplasmic Extraction Buffer (300 µL) was added 
to the cell pellet and incubated at 4ºC for 10 minutes on a gentle rotating mixer. 
Samples were centrifuged at 500 xg for 5 minutes and the supernatant transferred to 
a clean pre-chilled tube on ice (cytoplasmic fraction). Ice cold Membrane Extraction 
Buffer (300 µL) was added, tubes vortexed for 5 seconds on high and incubated for 
10 minutes as per cytoplasmic fraction. Centrifugation was performed at 3,000 xg for 
5 minutes and the supernatant collected (membrane fraction). Nuclear Extraction 
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Buffer (150 µL) was added, vortexed for 15 seconds and incubated for 30 minutes. 
Samples were centrifuged at 5,000 xg for 5 minutes and the supernatant collected 
(soluble nuclear fraction). Nuclear Extraction Buffer at room temperature was 
supplemented with 5 mM CaCl2 and 300 U micrococcal nuclease, and 150 µL added 
for 15 minutes. Samples were then vortexed for 15 seconds and supernatant 
collected on ice following centrifugation at 16,000 xg for 5 minutes (chromatin-bound 
nuclear fraction). Finally, Pellet Extraction Buffer (150 µL) was added and vortexed 
for 15 seconds and incubated at room temperature for 10 minutes. Samples were 
finally spun at 16,000 xg for 5 minutes and the supernatant collected on ice 
(cytoskeletal fraction). All fractions were stored at −80ºC for assessment of protein 
expression by western blotting. 
 
2.8.3  Protein Estimation 
Protein estimation was performed by the Bradford assay, whereby protein binding to 
Coomassie dye under acid conditions results in a colour change from brown to blue 
(ThermoFisher, 2020). Protein standards were prepared using 1 µg/µL BSA and 
diluted in deionised (d)H2O to final concentrations of 0.1–1.6 µg. Samples were 
diluted in dH2O and 5 µL of standard or sample added to micro-titre wells. The 
Bradford reagent stock (3.3 mg/mL Coomassie blue G dye in 2:1 phosphoric acid and 
ethanol) was prepared. Working dye was prepared (3% stock, 8% phosphoric acid, 
3.8% ethanol in dH2O) and 200 µL added to samples or standards and absorbance 
(595 nm) was measured. Sample protein quantification was determined by 
interpolation with the BSA standard curve.  
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2.8.4  SDS-PAGE 
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was performed to separate 
proteins by molecular weight. A 12% SDS-PAGE resolving gel was prepared (12% 
acrylamide, 1% SDS, 1% APS, 0.06% TEMED, 0.375 M Tris-HCl, pH 8.8) and layered 
with a 4% stacking gel (4% acrylamide, 0.8% SDS, 1% ammonium persulfate, 0.1% 
TEMED, 0.125 M Tris-HCl, pH 6.8). Sample lysate was mixed with loading buffer 
(20% glycerol, 4.6% SDS, 0.02% bromophenol blue, 130 mM Tris-HCl, pH 8; 25%) 
and β-mercaptoethanol at 5%. Samples were denatured at 95ºC for 10 minutes and 
20 µg loaded into wells of the cast gel. Samples were run alongside 5 µL of Spectra 
Multicolor Broad Range Protein Ladder (Thermo Scientific). The gel tank (Dual Mini 
Slab Kit, AE-6450; ATTO Technology, Amherst, New York) was filled with running 
buffer (25 mM Tris, 190 mM glycine, 0.1% SDS) and electrophoresis performed at 
100 V for 30 minutes to allow samples to pass through the stacking gels, and then at 
185 V for 75 minutes - or until the dye front had reached the end of the resolving gel. 
 
2.8.5  Wet Transfer 
Protein in the gel was transferred to Amersham™ Hybond™ 0.45 µm polyvinylidene 
difluoride (PVDF) blotting membrane (GE Healthcare; activated in 100% methanol for 
10 minutes). Transfer electrophoresis was performed overnight (20 hours) at 35 V in 
transfer buffer (20% methanol, 25 mM Tris, 190 mM glycine, 0.1% SDS, pH 8.3) using 
a Trans-Blot® Cell electrophoresis tank (Bio-Rad Laboratories, Watford, UK). All 
further membrane washes were performed in Tris-buffered saline with Tween (TBST; 
1% Tween, 200 mM Tris, 2 mM NaCl, pH 7.5) three times for 10 minutes. Membranes 
were washed in TBST and blocked for 2 hours in blocking buffer (5% non-fat milk 
powder in TBST). Membranes were incubated in primary antibody in blocking buffer 
overnight (20 hours), washed and incubated in secondary antibody in blocking buffer 
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for 1 hour. Membranes were then washed, placed on to clean acetate and 2 mL 
Immobilon® Forte Western horseradish peroxidase (HRP) substrate (Millipore) gently 
rocked over the membrane for 2 minutes. Protein bands were identified by 
chemiluminescent detection with a 2 minute exposure and the ladder detected by 
fluorescence at 600 and 700 channels for 30 seconds (LI-COR Odyssey). 
To reprobe for additional antibodies, the membranes were washed and stripped in 
0.5 M NaOH for 10 minutes. Membranes were washed, blocked for 2 hours and 
assessed for additional protein signals as previously described. 
To detect hENT1, the Anti-ENT1 Rabbit Polyclonal antibody (Abcam; 1/20,000) was 
used. Anti-β-actin Mouse Monoclonal (Sigma-Aldrich; A5441; 1/10,000) was used as 
a total protein loading control. Signal was detected using Goat Anti-Rabbit or Anti-
Mouse IgG HRP-linked secondary antibodies (Vector Laboratories Inc, California, 
US; 1/10,000). To confirm the purity of subcellular fractions, the following primary 
antibodies and dilutions were used: MEK1/2 Rabbit Monoclonal (cytoplasmic; 
1/10,000); AIF XP Rabbit Monoclonal (mitochondrial; 1/10,000); Histone H3 XP 
Rabbit Monoclonal (nuclear; 1/10,000) and Vimentin XP Rabbit Monoclonal 
(cytoskeleton; 1/10,000) (Cell Fractionation Antibody Sampler Kit, Cell Signaling 
Technology, Leiden, Netherlands); Na/K ATPase Rabbit Monoclonal (Abcam; 
membrane; 1/20,000).  
 
2.8.6  ENT1 Antibody Specificity 
To determine the specificity of the Anti-ENT1 antibody to detect ENT1 protein in 
samples, western blot was performed on pure ENT1 protein in addition to protein 
antibody blocking. 
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For antibody blocking, the ENT1 antibody was pre-incubated overnight with peptide 
(supplier) at a 5x weight excess (0.25:1.25 µg/mL in blocking buffer), in order to bind 
all available antibody. Western blot was performed as of section 2.8 on rENT1 (30 
ng) and HL-60 total cell lysates (5 µg), and membranes were incubated in the 
following: 
A – Primary antibody followed by secondary antibody 
B – Blocked antibody followed by secondary antibody 
C – Secondary antibody only 
A positive band for A and negative band for B and C would therefore indicate antibody 
specificity. 
 
2.9  DIFFERENTIAL CYTOKINE SECRETION 
2.9.1  Cytokine Array 
Cytokine secretion in the co-culture model was assessed in HL-60, K562 and HS-5 
cells by the Proteome Profiler Human Cytokine Array Kit B (R&D Systems). For 
supernatant collection, cells were cultured in the insert model before media collection; 
HS-5 (9 x105) were cultured for 24 hours to adhere. Media was replaced, with addition 
of HL-60 or K562 (9 x105) in inserts for co-culture wells; in a final volume of 6 mL 
complete RPMI. Cells were cultured for 24 hours, treated with 25 µM ara-C for 1 hour 
and supernatant centrifuged at 2,000 xg for 10 minutes, 0.2 µm filtered to remove 
potential residual cells/debris, aliquoted and stored immediately at −80°C. 
The cytokine array is a membrane-based sandwich immune-array. The array uses 
nitrocellulose membranes pre-spotted, in duplicate, with capture antibodies for 36 
cytokines (Figure 2.7). Membranes were blocked in Array Buffer 4 in a 4-well dish for 
1 hour, where the visible blue spots disappeared.  
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Figure 2.7. Schematic of the cytokine array. The membrane is coated with capture 
antibodies correlating to 36 pair spots, where the target analyte within the sample 
binds. The biotinylated detection antibody is conjugated to IRDye 800CW (R&D 
Systems) and the membrane imaged by fluorescence imaging (Li-Cor). The 
fluorescence intensity (green) is proportional to the amount of target analyte detected. 
Schematic created by the author (Gynn, L.) with some information from R&D Systems 
(2016). 
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Supernatants were thawed on ice and 1 mL diluted in 500 µL Array Buffer. Diluted 
samples were mixed with 15 µL biotinylated detection antibody cocktail and incubated 
for 1 hour. The supernatant/detection antibody mix was incubated with the 
appropriate membrane overnight on a rocking platform at 9°C, to allow any cytokines 
present to complex with the capture and detection antibodies. Membranes were 
washed three times for 10 minutes each in Wash Buffer to remove unbound material. 
The array kit was then adapted to allow for detection by a Li-Cor Odyssey Fc Imaging 
System (Li-Cor, Cambridge, UK). To achieve this, the HRP-conjugated Streptavidin 
in the kit was replaced with IRDye 800CW conjugated Streptavidin (Li-Cor). The 
stamped identification number on the membrane was previously removed, as the dye 
will fluoresce and interfere with detection; identification numbers were instead marked 
with pencil. For imaging, IRDye was diluted in Array Buffer 5 and 2 mL added to the 
4-well dishes. Arrays were incubated with the dye for 30 minutes on a rocking platform 
and washed. Images were collected by the Odyssey Fc Imager (Li-Cor) for both 700 
and 800 channels. The average pixel density signal from duplicate spots was 
determined for each cytokine using Image Studio™ Lite software (Li-Cor). Average 
background signal from negative control spots was subtracted from each cytokine 
spot. Relative intensity was calculated against the average signal from positive 
control/reference spots for each individual array. Corresponding cytokines were 
correlated with array spots with a provided template and signals of each cytokine 
compared between groups to determine relative differential production of cytokines. 
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2.9.2  Enzyme-Linked Immunosorbent Assay 
To confirm the array and quantify cytokine secretion, an enzyme-linked 
immunosorbent assay (ELISA) was utilised. The inflammatory cytokine, macrophage 
migration inhibitory factor (MIF), was further investigated due to differential 
expression in co-culture and involvement of both stromal and leukaemic cell secretion 
in the cytokine array. 
To confirm the array result, HL-60, K562 and HS-5 cells were co-cultured and 
supernatant collected as described in section 2.9.1, with the addition of an untreated 
control. To track cytokine secretion over time, cells were co-cultured and treated as 
above, then washed and reseeded into fresh media for 2, 4, 8, 16 and 24 hours post-
treatment. Supernatant was collected at each timepoint as previously described. To 
discriminate which cell type (leukaemic/stromal) was responsible for differential 
secretion, cells were co-cultured and treated as above, then washed, separated from 
inserts and reseeded into individual wells for 24 hours prior to supernatant collection. 
The Human MIF ELISA Kit (Invitrogen, UK) is a solid-phase sandwich ELISA used for 
the quantification of MIF protein. MIF capture antibodies are pre-coated to the 96 well 
plate, which bind to the MIF analyte within the sample. A biotinylated detection 
antibody is added, followed by a detection enzyme. A substrate is added to form a 
blue coloured product, and acidified to form a yellow coloured product. Absorbance 
is read, where colour is proportional to the quantity of bound analyte. Quantification 
is achieved by use of a standard curve. 
MIF ELISA was performed according to manufacturer’s instructions. All reagents and 
samples were equilibrated to room temperature before use. Standard or samples (100 
µL) were added to appropriate wells, covered and incubated at room temperature for 
2.5 hours with gentle shaking. To wash the wells, the standard and sample were 
discarded and each well filled with wash buffer using a squirt wash bottle. Liquid was 
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inverted vigorously between addition and washing repeated for a total of four washes. 
After the last wash, the plate was inverted and blotted against clean paper towels to 
remove any residual buffer. Biotinylated antibody (100 µL) was added and incubated 
for 1 hour prior to washing as described. HRP-conjugated streptavidin (100 µL) was 
added and incubated for 45 minutes prior to washing. The 3,3',5,5'-
Tetramethylbenzidine substrate was added and incubated in the dark for 30 minutes. 
Finally, 50 µL stop solution was added and absorbance measured within 30 minutes 
using a FLUOstar Omega micro-plate reader (BMG Labtech, Aylesbury, UK). 
Absorbance readings at 550 nm were subtracted from 450 nm readings to correct for 
optical imperfections in the plate. A standard curve from known standards provided 
in the kit was generated using mean absorbance obtained across duplicate wells. 
Sample MIF concentration was calculated by interpolation with the standard curve. 
 
2.10  MIF TREATMENT AND INHIBITION 
To investigate the effect of MIF on cellular response to treatment, cells were treated 
with defined concentrations of recombinant human MIF (rhMIF) protein or ISO-1, a 
MIF antagonist. 
For initial MIF inhibition toxicity assessments, HL-60, K562 and HS-5 cells were 
harvested and treated with ISO-1 (0.07–80 µM) in PBS for 5 minutes. Cells were 
washed twice in complete RPMI and seeded at 2 x105/mL in a final volume of 200 µL 
complete RPMI media, followed by standard incubation. Metabolism by AB reduction 
(see 2.2.2.1) was determined for 24 and 48 hours post-treatment with ISO-1. 
For further chemotoxicity assessments with MIF inhibition, cells were again pre-
treated with ISO-1 at 10 µM, or DMSO (vehicle control) for 5 minutes and washed 
twice in complete RPMI media. Cells were seeded into black micro-titer plates at 2 
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x105/mL in a final volume of 100 µL complete RPMI media, with or without 25 µM ara-
C and CTG assessments (see 2.2.2.2) performed following 48 hours of treatment. 
To investigate the baseline effects of rhMIF exposure, HL-60, K562 and HS-5 cells 
were harvested and washed in PBS for 5 minutes. Cells were washed twice in 
complete RPMI and seeded at 2 x105/mL in a final volume of 200 µL complete RPMI 
media containing rhMIF (0.5–400 ng/mL) and metabolism assessed by AB reduction 
at 24 and 48 hours. 
For further chemotoxicity assessments with rhMIF, cells were again washed in PBS 
for 5 minutes and twice more in complete RPMI media. Cells were seeded into black 
micro-titer plates at 2 x105/mL in a final volume of 100 µL complete RPMI media 
containing 100 ng/mL rhMIF, with or without 25 µM ara-C and CTG assessments 
performed following 48 hours of treatment.  
 
2.11  MIF PROTEIN INTERACTIONS 
To further explore the interactions of MIF with other proteins, the functional protein 
association network was investigated using the Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) database (https://string-db.org). Networks of 
MIF were searched for molecular action with an interaction score cut-off of 0.4 
(medium confidence). 
 
2.12  MIF CLINICAL EXPRESSION 
mRNA expression was correlated with clinical features to further understand the 
clinical importance of MIF. The cBioPortal database (http://www.cbioportal.org) was 
utilised to correlate the clinical attributes, cytogenetic code and cytogenetic risk, with 
MIF mRNA expression from 173 patients with AML.
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Chapter 3 - CHEMOSENSITIVITY MEDIATED BY LEUKAEMIC-
STROMAL INTERACTIONS IN CELL LINE CO-CULTURES 
3.1  INTRODUCTION 
It is widely accepted that the tumour microenvironment is implicated in the 
development, progression and relapse of a number of cancers (Balkwill et al., 2012; 
Quail and Joyce, 2013; Wang et al., 2017). Components of the microenvironment are 
known to aid tumourigenesis (Wang et al., 2017), however, the interactions that these 
cells have with malignant or transforming cells are not fully elucidated. MSC provide 
essential support to haematopoietic stem and progenitor cells in the BM, necessary 
for their proliferation, self-renewal and differentiation (Kfoury and Scadden, 2015) and 
disease pathology is significantly impacted by dysfunction in the BMM (Duarte et al., 
2018). This is especially of note when considering that a haematological malignancy 
arises from these HSC or progenitors in the BM, which are transformed into LSC 
capable of propagating the disease. 
Studies have shown that interactions between leukaemic cells and the BM stroma 
contribute to chemoresistance, by apoptosis avoidance (Konopleva et al., 2002), 
increased cell growth (Moshaver et al., 2008) and phenotypic expression (Civini et 
al., 2013). Due to the complex nature of leukaemic disease, and of the BMM itself, 
these mechanisms are not fully understood, warranting further investigation. 
Research to date has focused on the effects of the stroma on leukaemic cells, with 
less focus on how the BM stroma itself is impacted in disease. A dynamic relationship 
exists in the BMM, whereby malignant cells transform their environment in favour of 
disease progression and at the expense of healthy cells (Ghobrial et al., 2018; Crippa 
and Bernardo, 2018). Long-term chemotherapy-induced damage to the BM stroma 
has been documented in patients years following cessation of chemotherapeutic 
treatments (May et al., 2018; Batsivari et al., 2020), important as MSC survive 
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myeloablation in preparation for SCT (Rieger et al., 2005), leaving cells functionally 
inhibited (Kemp et al., 2011; Münz et al., 2018). Even with evidence of genotoxic 
damage in patients following chemotherapy, much research focus has regarded the 
cytotoxic effects of such therapies. The effect of the BMM on leukaemic cells’ 
sensitivity to genotoxicity is understudied, with no known studies investigating the 
effects of leukaemia-stroma co-culture on genotoxicity. This can have serious 
downstream impact on BM failure post-SCT (Crippa and Bernardo, 2018), relapse of 
disease in the BM, and also the incidence of secondary malignancies in surviving 
patients (Delage et al., 2015).  
 
3.1.1  Chapter Aims 
The aim of this chapter was therefore to evaluate altered chemosensitivity by 
leukaemic-stromal interactions in cell line co-cultures. This required the optimisation 
of an appropriate in vitro model of leukaemia-stroma for chemosensitivity testing, 
followed by the assessment of cytotoxicity and genotoxicity-based chemosensitivity, 
mediated by cellular interactions. 
 
3.2  RESEARCH QUESTIONS  
This chapter set out to answer the following research questions: 
1. Are leukaemic cells chemoprotected by stromal cells unidirectionally? 
2. Are stromal cells sensitised to chemotherapy-induced genotoxicity by leukaemic 
cells, while leukaemic cells themselves are protected by stromal cells? 
3. Are stromal cells also chemosensitised to cytotoxic effects by leukaemic cells, 
while leukaemic cells themselves are chemoprotected by stromal cells? 
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3.3  RESULTS 
3.3.1  Determination of Culture Dynamics for Co-Culture Models 
Prior to co-culture modelling, the dynamics of leukaemic and stromal cultures were 
established. This was to ensure all cells were in optimal conditions for a successful 
model, before chemosensitivity assessments could take place. 
 
3.3.1.1   HS-5 Adherence for 24 h and Culture between 12–72 h Are 
Appropriate For Co-Culture Experiments 
To determine cell line growth rates, the number of viable HL-60, K562 and HS-5 cells 
was assessed at 12-hour culture intervals (Figure 3.1). HL-60 cells had a shorter lag 
phase of < 12 hours than K562 and HS-5, both of which began exponential growth 
between 12–24 hours, and all showed steady exponential growth up to 72 hours. Cell 
doubling time was calculated between 36 and 72 hours, showing K562 with the 
greatest growth, doubling in 21.28 hours, followed by HL-60 with 36.67 hours. HS-5 
had a much longer doubling time of 50.02 hours than suspension leukaemic cells.  
The co-culture model requires a monolayer of stromal cells beneath suspended 
leukaemic cells, therefore HS-5 adherence was determined (Figure 3.1.D/E). By 12 
hours, > 75% of cells had adhered to the culture surface, with > 95% adherent by 14 
hours. After this point, adherence remained stable until the 24-hour timepoint, with a 
slight yet insignificant decrease at 36 hours (Figure 3.1.D). 
Culture of all cell types between 12 and 72 hours is therefore appropriate in culture 
experiments, and with HS-5 adherence achieved by 16 hours, initial culture of 24 
hours would thus be appropriate. 
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Figure 3.1. Cell growth of HL-60, K562 and HS-5 cell lines. Cells were seeded into 
standard culture plates in appropriate complete medium. Viable cells were counted 
by trypan blue exclusion following initial seeding at 1 x105 cells/mL. Displayed as 
mean viable cells (A–C) or HS-5 cell adherence (D) +/− SD with polynomial non-linear 
exponential fit (A–D) and phase-contrast microscope images representative (E) of cell 
adherence (D) (x10 objective). A–C; n = 2 in triplicate, D–E; n = 3 in triplicate. 
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3.3.1.2  RPMI Complete Media is the Most Appropriate for Co-Culture 
The ATCC recommended media differs between cells, therefore to define the most 
appropriate culture media for all of the cell types intended for use within a co-culture 
model, metabolism of each cell line was monitored for up to 72 hours in three media 
formulations (Figure 3.2). RPMI complete media was preferential to cell metabolism, 
as determined by the ability of cells to reduce the AB reagent, in all cell types and 
timepoints, except for at 72 hours in HL-60 due to high error. Despite trends in AB 
reduction between media formulations in each cell line tested, none of the 
relationships showed statistical significance (P > 0.05), however RPMI can be 
concluded as the most appropriate media for co-culture. 
 
3.3.1.3  Treatment of 25 µM Ara-C for ≤ 24 h is Appropriate for Co-Culture 
Experiments 
The response of HL-60, K562 and HS-5 cells to increasing ara-C dose was assessed 
24 and 72 hours post-treatment (Figure 3.3). At 24 hours, HL-60 showed a significant 
increase in viability with 0.1 µM (P = 0.0311), with significantly reduced viability (P < 
0.0001) shown with all other doses, 1–100 µM – with the greatest reduction of 44.15% 
with 25 µM (Figure 3.3.A). K562 and HS-5 viability however did not significantly 
change (P > 0.05) from that of the control (Figure 3.3.B/C). When treated for 72 hours, 
HL-60 viability was significantly reduced at all doses tested (P < 0.0001), showing ~ 
50% reduction with the lowest dose of 0.1 µM and minimum survival of just 6.54% at 
higher doses (Figure 3.3.A). K562 viability was consistently reduced by 40–50% 
across all doses at 72 hours (P < 0.001; Figure 3.3.B). Viability of HS-5 cells was not 
significantly reduced from untreated cells with 0.1 µM for 72 hours (P > 0.05), 
however, there was a 48.45% reduction with 1 µM which continued to decrease with 
increasing dose (P < 0.0001; Figure 3.3.C). Ara-C at 25 µM for a treatment time of ≤ 
24 hours therefore induced < 50% reduction in cell viability and was therefore 
considered for experiments with cytotoxicity limits, such as genotoxicity assessments. 
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Figure 3.2. Cell metabolism with culture media formulation. HL-60 (A), K562 (B) 
or HS-5 (C) cells were seeded in the appropriate complete medium and metabolism 
by alamar blue (AB) reduction was measured at 24, 48 and 72 h. AB reagent was 
added 4 h prior to each timepoint measurement. Data represent mean % AB reduction 
+ SD as of positive control. n = 2 in triplicate. 
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Figure 3.3. Cell viability with increasing dose of ara-C. HL-60 (A), K562 (B) and 
HS-5 (C) were cultured with ara-C (0–100 µM) and viability assessed by CellTiter-
Glo™ (CTG) at 24 and 72 h post-treatment. Viability was normalised to the untreated 
control (0 µM). Bars represent mean + SD. n = 3. Horizontal bars span the doses 
which are statistically significant from the control for that timepoint. * = P < 0.05; *** = 
P < 0.001; **** = P < 0.0001. 
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3.3.2  Effects of Stromal Conditioned Media on Leukaemic Cell 
Lines 
3.3.2.1  Stromal Conditioned Media Increases Leukaemic Cell Line 
Metabolism and Viability With or Without Ara-C Treatment 
Based on optimisation experiments, summarised in section 3.3.1, the developed 
model used complete RPMI conditioned by HS-5 for 24 hours, during exponential 
growth and optimal density, following 24 hours of culture to allow adherence. 
Conditioned media (CM) contains soluble factors secreted by HS-5. The AB reduction 
assay was used to assess leukaemic cell metabolic activity following CM exposure. 
Leukaemic cells were grown in standard media (0% CM) or media comprising HS-5 
CM at 25, 50, 75 and 100% for 24 hours to allow any effects to occur before treatment. 
HL-60 metabolism was significantly increased by 50% CM (P = 0.0487), 75% (P = 
0.0111) and 100% (P = 0.0086) when untreated (Figure 3.4.A). K562 metabolism was 
only significantly increased by 75% CM (P = 0.0381) as compared to 0% CM (data 
not shown). Greater stromal effects on HL-60 than K562 cells justified continued 
investigation.  
Treatment with ara-C for 24 hours reduced metabolism of HL-60 cells, which was 
significantly increased by HS-5 CM (P < 0.001) as compared to treated cells without 
CM (Figure 3.4.B). Untreated HL-60 viability was not significantly changed following 
exposure to 25–100% CM (P > 0.05; Figure 3.4.C), however, cells cultured in 25% 
HS-5 and then treated for 24 hours following CM exposure showed significantly 
increased viability (P = 0.0212; Figure 3.4.D). This CM dose was hence taken forward 
for further experiments over longer time periods (Figure 3.4.E–F). Untreated HL-60 
increased viability at 72 hours with 25% CM (P = 0.0004; Figure 3.4.E). Exposure to 
25% CM also improved HL-60 viability in ara-C treated cells at 24 (P = 0.0377), 48 
and 72 (P < 0.0001) hours (Figure 3.4.F). Together this data suggests that the stromal 
secretome provides a growth advantage in untreated cells, and can protect leukaemic 
cells from drug-induced toxicity. 
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Figure 3.4. Effects of HS-5 conditioned media on untreated and ara-C treated 
HL-60 leukaemic cell metabolism and viability. HL-60 cells were grown in 0–100% 
HS-5 CM for 24 h (A–D) or 0/25% HS-5 CM for 24, 48 and 72 h (E–F). Cells were 
additionally untreated (0 µM; A, C, E; blue bars) or treated with ara-C (0 µM; B, D, F; 
pink bars). Bars represent AB reduction (A–B), a measure of metabolism, or cell 
viability (C–F), normalised to the relevant untreated control, mean + SD. AB reduction 
was assessed 4 h following addition of the reagent and compared to positive control. 
Viability was assessed by manual counting with trypan blue. n = 3 in triplicate. 
Horizontal bars encompass multiple bars significant from the control. * = P < 0.05; ** 
= P < 0.005; **** = P < 0.0001. 
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3.3.2.2  Stromal Conditioned Media Does Not Alter Leukaemic Cell Ara-C 
Chemosensitivity by Ara-CTP Production or Sensitivity Index 
Altered chemosensitivity of ara-C by HS-5 CM was assessed in HL-60 cells using a 
bacterial bioluminescent biosensor assay (see Methods 2.4), which considers the 
cells ability to convert ara-C to the active ara-CTP form. Chemosensitivity in this 
assay is denoted by sensitivity index (SI), calculated based on peak bioluminescence 
in untreated and treated samples as the biosensor reverts any ara-CTP produced by 
cells back to ara-C (Methods 2.4.3). Treatment with 25 µM ara-C for 1 hour has 
previously been optimised for chemosensitivity assessments in this assay (Anderson 
et al., 2014), and was therefore used in this work.  
Initially, HL-60 cells treated with 25 µM ara-C for 1 hour in the absence of HS-5 CM 
had a SI% of 289.17 (Figure 3.5). Exposure to 12.5% and 25% CM reduced SI% by 
up to 56.17%, however, an increase was then followed from 25% to 50% CM (P > 
0.05; Figure 3.5) This trend was also noted for ara-CTP production, as measured by 
interpolation with an ara-CTP standard curve. HL-60 cells showed a trend of reduced 
chemosensitivity by both sensitivity index and ara-CTP parameters, however, without 
statistical significance (P > 0.05), with maximal protection/reduction in mean 
sensitivity observed at 25% HS-5 CM (P > 0.05). 
 
3.3.3  Effects of Co-Culture on Stromal and Leukaemic Cell Lines 
This work also set out to understand whether altered chemosensitivity has 
bidirectional effects in stromal and leukaemic cells. To follow on from work using CM, 
a co-culture model was optimised to allow for simultaneous cell-cell interactions 
(Figure 2.1). In this model, HS-5 are allowed to adhere for 24 hours prior to addition 
of leukaemic cells into trans-well inserts suspended above the stromal layer and in 
shared media for 24 hours (see Methods 2.3), after which point the effect of co-culture 
and treatment on stromal and leukaemic cell lines could be assessed.  
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Figure 3.5. Sensitivity index and ara-CTP production of ara-C treated HL-60 cells 
with HS-5 conditioned media. HL-60 cells were exposed to HS-5 conditioned media 
(0–50%) for 24 h and treated with ara-C for 1 h. Chemosensitivity was assessed with 
the biosensor assay and sensitivity index determined by comparison of untreated and 
treated cell bioluminescence. Ara-CTP production (above bars) was calculated by 
interpolation with a standard curve. Bars represent mean sensitivity index + SD (n = 
2–6 in triplicate). 
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3.3.3.1  Stromal Cells are Sensitised to Ara-C-Induced Genotoxicity By 
Leukaemic Cells, While Leukaemic Cells Are Themselves Protected 
One such parameter with clinical implications is altered genotoxicity, as it is 
associated with incidences of secondary malignancies and SCT failure due to 
functional inhibition in the BM (see 1.1.9.2). The micronucleus (MN) and comet 
assays were utilised for assessment of genotoxicity as per International guidelines 
(Vasquez, 2010). Leukaemic and stromal cells were co-cultured within the insert 
model for 24 hours prior to treatment with 25 µM for 1 hour, which was selected based 
on several factors: appropriate dose used in the biosensor assay, requirements of > 
50% viability in genotoxicity guidelines (OECD, 2014, 2016) and time interval of 
dosing with some patients receiving 1 hour ara-C infusions. 
The MN assay infers genotoxic damage by visualisation of abnormalities in dividing 
cells – for example micronuclei result when fragments of chromosome are not 
correctly incorporated into daughter nuclei. Additionally, apoptotic/necrotic, 
lobed/notched and multinucleated cells were visualised and manually scored, as 
demonstrated in Figure 2.4. MN analyses were performed on cells in the co-culture 
model after a 72 h recovery period post-treatment; in accordance with the OECD 
guidelines which recommend testing after 1.5–2 PD (OECD, 2014). Comet analyses 
were performed by a semi-automated scoring system (Comet Assay IV), whereby the 
dimensions and fluorescence intensity of single-cell DNA fragments are determined 
(Figure 2.4). 
The incidence of total abnormalities was significantly decreased in treated HL-60 
previously co-cultured with HS-5 (P = 0.0067; Figure 3.6.A). Around one third of these 
abnormalities were a consequence of MN formation, the predominant measure of 
genotoxicity. MN incidence, when considered alone, was also significantly decreased 
in treated and co-cultured HL-60 (P = 0.0007; Figure 3.6.B); a reduction of 4.70%.  
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Figure 3.6. Division abnormalities and MN incidence of HL-60 and HS-5 cells in 
co-culture following ara-C treatment. HL-60 (A/B) and HS-5 (C/D) cells were 
cultured alone or in co-culture using inserts for 24 h prior to treatment with 25 µM ara-
C for 1 h. The micronucleus (MN) assay was performed on cells after a further 1.5–2 
population doublings (48–72 h). Data represent HL-60/HS-5 abnormal cells: MN, 
apoptotic/necrotic, lobed/notched and multinucleated cells (A/C), or MN only (B/D) as 
percentage of total scored cells, mean + SD. A minimum of 2,000 cells were scored 
per group in four independent experiments. n = 4; n = 7 HS-5 alone. * = P < 0.05; ** 
= P <0.01; *** = P < 0.001. 
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Total abnormalities (P = 0.0033; Figure 3.7.A) and MN incidence (P = 0.003; Figure 
3.7.B) were also significantly decreased in treated K562 co-cultured with HS-5, with 
a reduction of 3.45%. No changes in total abnormalities (P > 0.05; Figure 3.6/Figure 
3.7.A) or MN incidence (P > 0.05; Figure 3.6/Figure 3.7.B) were noted in leukaemic 
cell lines in untreated co-cultures, nor within abnormalities other than MN (P > 0.05). 
Conversely, treated HS-5 cells showed a 2.7% increase in total abnormalities when 
co-cultured with HL-60 (P > 0.05; Figure 3.6.C), and a significant increase of 7.2% 
following co-culture with K562 (P = 0.0062; Figure 3.7.C). K562 co-cultured with HS-
5 caused an increase in HS-5 MN incidence following treatment 4.5% greater than 
that of HL-60 cells. MN incidence when considered alone was significantly increased 
in HS-5 cells previously treated and co-cultured with both HL-60 (P = 0.0214; Figure 
3.6.D), as well as with K562 (P = 0.0013; Figure 3.7.D). Likewise, total abnormalities, 
or other types of abnormality including MN incidence were not significantly altered by 
co-culture of HS-5 with HL-60/K562 when co-cultures were untreated (P > 0.05; 
Figure 3.6/Figure 3.7.A/C). The baseline levels of MN were lower in HL-60 cells 
(Figure 3.6.B) than in K562 (Figure 3.7.B) and HS-5 (Figure 3.6.D and Figure 3.7.D), 
therefore a more prominent increase in MN incidence is seen when these cells were 
treated. Equally, total abnormalities in untreated HL-60 (Figure 3.6.A) were also lower 
than in K562 (Figure 3.7.A) and HS-5 cells (Figure 3.6.C and Figure 3.7.C). Together 
this data suggests that stromal HS-5 protects HL-60 and K562 leukaemic cells, while 
leukaemic cells sensitise stromal cells to ara-C-induced MN formation, and therefore 
genotoxicity. The alkaline comet assay was used as a second genotoxicity method to 
confirm genotoxicity results obtained by MN incidence measurements, following 
OECD guidelines where possible (OECD, 2016). Genotoxicity is inferred by the 
degree of DNA fragmentation in the comet assay, whereby damaged and therefore 
fragmented DNA travels further during electrophoresis of a gel, producing a 
characteristic ‘tail’ distinct from the comet ‘head’. 
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Figure 3.7. Division abnormalities and MN incidence of K562 and HS-5 cells in 
co-culture following ara-C treatment. K562 (A/B) and HS-5 (C/D) cells were 
cultured alone or in co-culture using inserts for 24 h prior to treatment with 25 µM ara-
C for 1 h. The micronucleus (MN) assay was performed on cells after a further 1.5–2 
population doublings (48–72 h). Data represent K562/HS-5 abnormal cells: MN, 
apoptotic/necrotic, lobed/notched and multinucleated cells (A/C), or MN only (B/D) as 
percentage of total scored cells, mean + SD. A minimum of 2,000 cells were scored 
per group in three independent experiments. n = 3; n = 7 HS-5 alone. ** = P <0.01. 
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Treated HL-60 (P > 0.05; Figure 3.8.A) and K562 (P = 0.0208; Figure 3.8.C) were 
shown to have reduced % tail intensity when co-cultured with HS-5, suggesting less 
genotoxicity. A decrease in the median tail intensity of 2.24% in HL-60 and 1.92% in 
K562 was observed, although HL-60 had an overall greater level of DNA damage 
regardless of experimental group (Figure 3.8.A/B). 
A significant increase in tail intensity was also seen in untreated K562 following co-
culture with HS-5 (P = 0.0061; Figure 3.8.C), however, tail intensity did not 
significantly change in untreated HL-60 following co-culture (P > 0.05; Figure 3.8.A). 
HS-5 treated with ara-C had significantly higher tail intensity when co-cultured with 
either HL-60 (P = 0.0012; Figure 3.8.B) or K562 (P = 0.0001; Figure 3.8.D). This 
increase was again more evident in K562-HS-5 co-cultures, as HS-5 in HL-60 
experiments had an elevated tail intensity overall (Figure 3.8.B). Though a similar 
trend of increased tail intensity following co-culture existed in untreated HS-5, the 
increase was below the significance threshold (P > 0.05; Figure 3.8.B/D). 
International guidelines for the measurement of genotoxicity by the MN assay (OECD, 
2014) recommend that treated cells should be allowed to recover for a period 
equivalent to 1.5–2 population doublings (PD), to ensure that the majority of cells 
have undergone cell division (and are therefore able to accrue markers of 
genotoxicity). PD ranged from 1.64, in treated HS-5 previously co-cultured with K562, 
to 6.06 doublings in untreated HL-60 previously co-cultured with HS-5. The PD of 
6.06 had the greatest error of 3.9 SD (Table 3.1). Additionally, OECD guidelines state 
that measurements should be made to assure cells exhibit appropriate levels of 
cytotoxicity to reduce false positive and false negative genotoxicity results. 
In MN studies omitting the use of Cytochalasin B (CytoB) (as in this study), it is 
recommended that cytotoxicity is noted as the relative increase in cell count (RICC) 
(Lorge et al., 2008).  
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Figure 3.8. DNA damage of HL-60 or K562 and HS-5 cells following co-culture 
and ara-C treatment. HL-60 (A) or K562 (C) and HS-5 (B and D) cells were cultured 
alone or in co-culture using inserts for 24 h prior to treatment with 25 µM ara-C for 1 
h. The alkaline comet assay was performed on cells harvested immediately following 
treatment. Bars represent the 5–95 percentile with outliers, the median (line) and 
mean (cross). A minimum of 200 comets were scored per group. A/B; n = 4 
independent experiments, C/D; n = 3 independent experiments. * = P < 0.05; ** = P < 
0.01. 
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GROUP 
ARA-
C 
(µM) 
VIABILITY 
1H + 0H % 
(SD) 
VIABILITY 
1H + 1.5-2 
PD 
% (SD) 
RICC (SD) PD (SD) N 
MEAN 
SCORED 
FOR MN 
HL-60 
ALONE 
0 94.6 (1.8) 93.9 (2.8) 100 (0) 4.83 (4.3) 4 2,129 
25 92.0 (3.4) 43.5 (16.2) 47.0 (86.9) 2.10 (1.9) 4 1,121 
HL-60 CO-
CULTURE 
0 93.3 (3.3) 90.1 (13.6) 100 (0) 6.06 (3.9) 4 1,926 
25 91.9 (3.2) 56.3 (9.3) 27.0 (38.7) 2.25 (0.9) 4 1,587 
K562 
ALONE 
0 90.1 (4.3) 92.7 (3.1) 100 (0) 3.73 (2.0) 3 2,027 
25 90.9 (2.8) 75.0 (8.1) 66.3 (41.2) 2.12 (0.8) 3 2,039 
K562 CO-
CULTURE 
0 91.7 (4.2) 92.2 (6.1) 100 (0) 3.01 (0.4) 3 2,020 
25 93.3 (0.7) 82.5 (6.3) 49.3 (22.0) 1.77 (0.4) 3 1,946 
HS-5 
ALONE 
0 92.1 (3.5) 89.7 (2.9) 100 (0) 2.40 (1.5) 5 2,076 
25 89.0 (4.8) 78.1 (6.9) 71.3 (36.1) 1.77 (1.1) 6 2,065 
HS-5 CO-
CULTURE 
(HL-60) 
0 93.9 (2.4) 92.4 (1.3) 100 (0) 2.80 (1.7) 4 1,542 
25 89.9 (2.7) 77.5 (12.1) 50.5 (97.3) 1.90 (1.1) 4 2,136 
HS-5 CO-
CULTURE 
(K562) 
0 90.3 (4.8) 83.9 (7.4) 100 (0) 2.00 (0.9) 3 2,012 
25 90.7 (1.3) 80.1 (7.3) 71.0 (26.5) 1.64 (0.5) 3 1,751 
PD; population doubling, RICC; relative increase in cell count, SD; standard deviation. 
Table 3.1. Corresponding mean cytotoxicity of ara-C treatment for genotoxicity 
assays in HL-60, K562 and HS-5 co-cultures. 
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The RICC level > 50% is recommended, as higher cytotoxicity levels may increase 
false positive genotoxicity results. In this study, treated HL-60 cells alone and in co-
culture, as well as treated K562 cells in co-culture, showed RICC values below this 
threshold, of 47.0%, 27.0% and 49.3% respectively, though with high biological 
variance. All other samples were above acceptable thresholds for RICC (Table 3.1). 
In all samples (bar HL-60 alone), cell viability calculated by trypan blue counts were 
higher than that of RICC calculations (Table 3.1). 
 
3.3.3.2  Stromal Cells Are Chemosensitised to Ara-C Cytotoxic Effects by 
Leukaemic Cells, While Leukaemic Cells Are Not Significantly 
Chemoprotected 
Cytotoxicity was also investigated in cell lines following co-culture and treatment with 
ara-C, for comparison with CM results, to ensure validity of genotoxicity data, and to 
assess the bidirectional effects of co-culture on cytotoxicity. Ara-C induced a 
significant reduction in HL-60 viability after 1 hour (P = 0.0105; Figure 3.9.A), as well 
as HL-60 (P = 0.0413) and K562 (P < 0.0001) after 24 hours of treatment (Figure 
3.10). Co-culture with HS-5 showed a trend of increased HL-60 viability, both at 1 and 
24 hours when untreated and following treatment with ara-C (P > 0.05) (Figure 
3.9/Figure 3.10.A). K562 viability was minimally changed by co-culture or treatment 
at 1 hour, however, at 24 hours viability was significantly reduced following treatment 
(P < 0.0001), remaining significantly reduced from untreated cells despite a small 
increase in viability following HS-5 co-culture (Figure 3.10.C). 
HS-5 viability was not significantly impacted by 1 hour ara-C treatment (P > 0.05; 
Figure 3.9.B), however, treatment for 24 hours was significantly cytotoxic (P < 0.0001; 
Figure 3.10.B). Co-culture with both HL-60 (P = 0.0144; < 0.0001) and K562 (P = 
0.0002; < 0.0001) significantly reduced HS-5 viability at both 1 and 24 hours 
respectively (Figure 3.9/Figure 3.10.B/D), suggesting sensitisation of stromal cells by 
leukaemic cell influence.  
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Figure 3.9. ATP production of HL-60 or K562 and HS-5 cells following co-culture 
and ara-C treatment for 1 hour. HL-60 (A) or K562 (C) and HS-5 (B and D) cells 
were cultured alone or in co-culture using inserts for 24 h prior to treatment with 25 
µM ara-C for 1 h. ATP production, inferring cell viability, was determined by CellTiter-
Glo assay. Bars represent mean viability + SD. n = 3 * = P < 0.05; *** = P < 0.001. 
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Figure 3.10. Viability of HL-60 or K562 and HS-5 cells following co-culture and 
ara-C treatment for 24 hours. HL-60 (A) or K562 (C) and HS-5 (B and D) cells were 
cultured alone or in co-culture using inserts for 24 h prior to treatment with 25 µM ara-
C for 24 h. Cell viability was determined by trypan blue exclusion and manual 
counting. Bars represent mean viability + SD, normalised to untreated cells alone. n 
= 3; n = 6 HS-5 alone. * = P < 0.05; **** = P < 0.0001. 
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3.3.3.3  Leukaemic-Stromal Co-Culture Decreases Leukaemic Ara-CTP 
Production and Sensitivity But Not In Stromal Cells 
Altered chemosensitivity of ara-C was also assessed in both leukaemic and stromal 
cells, in order to evaluate the bidirectional effects of co-culture on drug efficacy. HL-
60 and K562 cells treated with ara-C for 1 hour in standard conditions had a similar 
SI% of 136.46 and 134.63% respectively (Figure 3.11). Co-culture with HS-5 for 24 
hours prior to and during the 1 hour ara-C treatment reduced SI% of HL-60 by 63.23% 
(P = 0.0027; Figure 3.11.A) and K562 cells by 23.66% (P > 0.05; Figure 3.11.B). 
Conversely, HS-5 stromal cells showed a lower mean SI% for ara-C in standard 
culture conditions than HL60 and K562 (Figure 3.11). Co-culture with HL-60 and K562 
cells increased SI% of HS-5 cells by 71.88% and 60.82% respectively (P > 0.05). The 
trends of reduced chemosensitivity in leukaemic cells and increased chemosensitivity 
in stromal cells following co-culture were also reflected in ara-CTP production, 
however, again without statistical significance (P > 0.05; Figure 3.11). 
 
3.3.3.4  Leukaemic-Stromal Co-Culture Does Not Affect Proliferation 
To investigate the bidirectional effect of co-culture on cell proliferation, cells were co-
cultured or cultured alone and treated with ara-C for 1 hour. Proliferation was tracked 
between 0–72 hours post-treatment by flow cytometric measurement of CFSE, and 
cell generation calculated (Figure 3.12). CFSE is a non-fluorescent dye which upon 
entry to viable cells, covalently binds to amine groups within the cell. With each cell 
division, daughter cells carry half of the original dye and therefore retain half of the 
CFSE fluorescence intensity of their parent cells (Methods 2.6.2); decreased 
fluorescence intensity therefore indicates increased proliferation. 
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Figure 3.11. Sensitivity index and ara-CTP production of ara-C treated HL-
60/K562 and HS-5 cells following co-culture. HS-5 were seeded into culture plates, 
incubated for 24 h prior to addition of HL-60 (A) or K562 (B) in co-culture inserts for 
24 h and treated with ara-C for 1 h. Chemosensitivity was assessed with the biosensor 
assay and sensitivity index determined by comparison of untreated and treated cell 
bioluminescence. Ara-CTP production (above bars) was calculated by interpolation 
with a standard curve. Bars represent mean sensitivity index + SD. n = 3 in triplicate. 
** = P < 0.01. 
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Treatment with ara-C reduced leukaemic cell proliferation, as measured in cell 
generations (P > 0.05; Figure 3.12). Reflecting previously observed chemosensitivity, 
proliferation of K562 was less affected than HL-60 by ara-C treatment. Both HL-60 
(Figure 3.12.A) and K562 (Figure 3.12.B) had small increases in proliferation following 
co-culture with HS-5 when treated (P > 0.05), but not in untreated cells (P > 0.05). No 
differences in proliferation were noted for HS-5 cells regardless of ara-C treatment or 
leukaemic cell co-culture condition (Figure 3.12.B/D). 
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Figure 3.12. Proliferation of HL-60 or K562 and HS-5 cells following co-culture 
and ara-C treatment. HL-60 or K562 and HS-5 cells were cultured alone or in co-
culture using inserts for 24 h prior to treatment with 25 µM ara-C for 1 h. Cells were 
stained with CFSE and proliferation monitored for three subsequent days. HL-60 (A) 
or K562 (C) following co-culture with HS-5, HS-5 following co-culture with HL-60 (B) 
or K562 (D). Bars show the number of cell generations at 24–72 h in co-culture 
conditions, mean + SD, with CFSE staining occurring at 24 h. n = 3 independent 
experiments; > 10,000 events in the final analysis. 
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3.4  DISCUSSION 
This chapter aimed to evaluate altered chemosensitivity by leukaemic-stromal 
interactions in cell line co-cultures (see 3.1.1), with the overall efforts of this thesis to 
identify potential mechanisms of such altered chemosensitivity (Intro 1.2), which may 
have survival implications for patients. When investigating the interactions between 
different cell types in vitro, several methods can be adopted (Nishida-Aoki and Gujral, 
2019). A number of considerations are necessary when determining the most suitable 
model, including the interactions to be investigated, retrieval for downstream assays 
and culture dynamics for cell types with varying requirements.  
This work had a focus on interactions between leukaemic and stromal cells without 
direct cell contact, with effects therefore resulting from cell secretions (da Cunha et 
al., 2019). To respond to the chapter research aim – are leukaemic cells 
chemoprotected by stromal cells unidirectionally? – stromal CM was utilised. The 
optimal conditions for co-culture models were first determined before 
chemosensitivity assessments could take place. For CM preparation, HS-5 were 
allowed to adhere for 24 hours in their recommended HG-DMEM, which was replaced 
with complete RPMI media for a further 24 hours for collection. This was to ensure 
that HS-5 were starting conditioning fully adhered, in log-phase of growth (Figure 3.1) 
and in media that would be suitable for all cells (Figure 3.2). Macanas-Pirard et al. 
(2017a) also collected HS-5 CM following 24 hours in supplemented RPMI, however, 
without prior growth for adherence. Another study alternatively conditioned media 
with HS-5 for 48–72 hours, with significant chemoprotection from c-KIT inhibitors in 
leukaemic cells even when constituting < 1% of the media (Gordon et al, 2014). The 
growth data presented in this work provide rationale for the culture dynamics selected 
(see 3.3.1), in addition to evidence that HS-5 consistently form feeder layers in vitro 
in 48–72 hours (Garrido et al., 2001) and that fibroblasts maximally secreted proteins 
at 48 hours and 95% confluency in another study (Paré et al., 2016). 
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An ara-C dose of 25 µM was selected based on calculated comparable standard dose 
(100–200 mg/m2; Methods 2.2.3.2) and < 50% cytotoxicity at 24 hours in all cell types 
(Figure 3.3) to suit experimental constraints. A diversity of ara-C doses are 
investigated in the literature, as justified within the scope of the project specifically; 
ranging from the equivalent of 50 nM to > 40 mM (Konopleva et al., 2002; Zeng et al., 
2009; Anderson et al., 2014; Long et al., 2015; Macanas-Pirard et al., 2017a). 
Reduced viability by ara-C (Figure 3.3) reflects the known sensitivity of HL-60 and 
K562 cells shown in other studies (Kanno et al., 2004; Anderson et al., 2013; Levin 
et al., 2019b); HL-60 being more sensitive than K562. No studies could be found 
quantifying ara-C cytotoxicity specifically in HS-5, despite a breadth of studies using 
these cells in co-culture experiments, which is surprising since stromal cells are also 
exposed to chemotherapy in vivo. However, viability of ~ 60% in BM-MSC treated 
with 10 µM ara-C for 48 hours (Somaiah et al., 2018) is in line with reported HS-5 
viability between 24–72 hours in this study (Figure 3.3.C). 
HS-5 CM was shown to reduce leukaemic cell line ara-C chemosensitivity, with 
chemoprotection significantly reduced in treated HL-60 cells, at 25–100% CM for 
metabolism and at 25% for cell viability (Figure 3.4.B–D). Macanas-Pirard et al. 
(2017) also showed protection of THP1 (AML M5) from ara-C cytotoxicity by HS-5 
(healthy stroma) diluted 1:1–1:1000 and BM-MSC from AML patients diluted 1:1–
1:100. A lower HS-5 CM dose of 12.5% was also investigated in this study, which 
showed reduced sensitivity index in 12.5–50% CM and ara-CTP production with 12.5 
and 25% (Figure 3.5). Maximal protection of HL-60 cells was again seen with 25% 
HS-5 CM. These trends were, however, not statistically significant (P > 0.05) due to 
high variation – a consideration of the biosensor assay using bioluminescent bacteria 
which are susceptible to culture variations as biological agents. Sheng et al. (2016) 
also confirmed HS-5 CM to protect HL-60 from spontaneous apoptosis and increase 
viability of untreated cells, which was significantly demonstrated in this study with 50–
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100% CM (Figure 3.4.A). This study sought to balance a CM dose which would induce 
an effect, with depletion of factors during conditioning and co-culture (Carroll et al., 
2014), however, future work could benefit from inclusion of lower CM doses for 
comparison with these other studies. On the other hand, investigations using 
undiluted BM-CM from AML patient samples were used to predict ara-C resistance, 
concluding that patients whose BM cells conferred ara-C chemoresistance in vitro 
had poorer overall survival clinically (Macanas-Pirard et al., 2017a). It could be argued 
that the effects of CM may be underestimated against control media since there will 
be depletion of nutrients by conditioning cells. 
CM is a valuable tool for assessment of cell-cell interactions, however, it only does 
so unidirectionally (Bogdanowicz and Lu, 2012); cells aren’t able to communicate in 
synchrony as they would in vivo. Consequently, the next phase of model development 
was with co-culture inserts, which allow for bidirectional interaction, but still with ease 
of cell collection for further analysis. Though 2D models are challenged in mimicking 
the heterogeneity of cell microenvironments (Dowling and Clynes, 2011), the 
identification of novel mechanisms from similar models in the literature (Moshaver et 
al., 2008; Gordon et al., 2014; Macanas-Pirard et al., 2017) give validity for use of 
such parameters. 
The complexity of co-culture models is continually improving, with development 
towards 3D models a focus in more recent years; though physiological relevance and 
experimental intricacy remain as ongoing challenges (Hamilton et al., 2012; 
Griessinger et al., 2014; Katt et al., 2016). Co-culture models in 2D are widely used 
to study cell-cell interactions (Bogdanowicz and Lu, 2012). A comprehensive study 
showed that an in vitro system using layered co-culture was able to replicate ara-C 
effects seen in vivo (Griessinger et al., 2014). The Dexter et al. (1977) co-culture 
model was one of the first for ex vivo leukaemic-microenvironment, whereby murine 
HSC were seeded onto BM stromal monolayers and maintained in culture longer than 
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previously possible. This method is, however, limited by the ability to separate cells 
in mixed monolayers for downstream assessments (Bogdanowicz and Lu, 2012); a 
contamination issue overcome within co-culture using trans-well inserts (Civini et al., 
2013; Katt et al., 2016; Renaud and Martinoli, 2016). 
This study optimised a co-culture model whereby HS-5 cells were cultured in 
recommended HG-DMEM for 24 hours, after which the media was replenished with 
RPMI media and leukaemic cells seeded into trans-well inserts suspended above the 
stromal layer, in shared media (see Methods 2.3). Cells were co-cultured for a further 
24 hours to allow any effects to occur, before concurrent treatment with ara-C. The 
stability of stromal cells was a priority variable in the model, especially with future use 
of primary MSC in mind, as malignant leukaemic cells are more robust (Mirabelli et 
al., 2019); though every effort was made to ensure health of all cells in the model by 
appropriate media and seeding densities that did not exhaust cells (Figure 3.1/Figure 
3.2). Similar cell line models have been utilised elsewhere (Civini et al., 2013; Long 
et al., 2015), however, Civini et al. (2013) investigated only untreated cells and Long 
et al. (2015) utilised NB-4, THP1 and primary AML cells. In this thesis, the leukaemic 
cell lines HL-60 and K562 were selected based on differences in their 
chemosensitivity (Anderson et al., 2013), while HS-5 was selected as a widely used 
BM niche cell line (Podszywalow-Bartnicka et al., 2018). 
As previously mentioned in section 3.3.3.1, the genotoxic effects of chemotherapy 
have clinical implications for patients, including functional damage of supportive MSC 
(Kemp et al., 2011), genomic instability (May et al., 2018), resulting BM failure and 
secondary malignancies (Delage et al., 2015). Based on this understanding and an 
apparent lack of genotoxicity studies in this area, this chapter sought to understand 
whether stromal cells are sensitised to chemotherapy-induced genotoxicity by 
leukaemic cells, while leukaemic cells themselves are protected by stroma (see 3.2). 
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This study utilised the MN and comet assays, commonly combined for genotoxicity 
assessments (Vasquez, 2010), following co-culture of HS-5 with HL-60 and K562 and 
treatment with ara-C for 1 hour. HS-5 significantly protected HL-60 and K562 
leukaemic cell lines from genotoxicity, as measured by total abnormalities and MN 
incidence in the MN assay (Figure 3.6/Figure 3.7.A/B). The greater protective effect 
of HS-5 previously co-cultured with HL-60 than with K562 reflects the sensitivity of 
these cells to ara-C as shown in this study and by Anderson et al. (2013). Conversely, 
HS-5 were sensitised to genotoxicity (MN incidence and total nuclear abnormalities) 
following treatment and co-culture (Figure 3.6/Figure 3.7.C/D). A greater effect was 
seen following co-culture with K562, the cell line with greater ara-C resistance. 
These findings were confirmed using the comet assay, where it was shown that tail 
intensity – inferring DNA fragmentation and therefore genotoxicity – was significantly 
reduced in ara-C treated leukaemic cells co-cultured with HS-5, and increased in HS-
5 co-cultured with leukaemic cells (Figure 3.8). 
Working within OECD guidelines for MN analysis in vitro, PD was calculated to assess 
adequate cell division following treatment with ara-C, in addition to calculation of 
cytotoxicity in the form of % viability and RICC (Table 3.1). Best efforts were made to 
adhere to these guidelines within this study. All experimental groups had a PD greater 
than 1.5 divisions (the minimum being 1.64 PD in this study; Table 3.1). Many of the 
cultures, however, were shown to have PD greater than the recommended 2 PD. For 
consistency, all cells were harvested 72 hours post-treatment, meaning that some 
groups had proliferated at a greater rate than others. This should be taken into 
consideration when interpreting this data, as cells which had undergone more 
divisions may have been able to repair genotoxicity, and so the potential for falsely 
reduced MN incidence is possible. That being said, false negatives are likely to be 
higher with too few divisions. The need for PD calculation is eradicated by the use of 
CytoB in MN experimental design as divided cells are fixed at the binucleate phase 
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of mitosis (Lorge et al., 2008), however due its highly toxic nature, the MN assay 
without CytoB was justified (OECD, 2014). In assays without CytoB, 2,000 cells must 
be scored for nuclear abnormalities including MN. In groups where this was not 
possible (Table 3.1), genotoxicity may be measured less accurately (OECD, 2014). 
To estimate cytotoxicity in treated cells, cell viability was calculated immediately 
following ara-C treatment and again following the recovery period (Table 3.1). Viability 
was reduced in treated cells following recovery as compared to immediately following 
treatment, as this allowed time for cells to accumulate toxicity and initiate 
apoptosis/necrosis. It has been documented that cell viability underestimates 
cytotoxicity in cells, and so calculations should be made based on the RICC between 
treated and untreated cells (Lorge et al., 2008). Guidelines suggest that cells should 
be used in studies only when RICC is > 50%, as excessive cytotoxicity can lead to 
falsely positive genotoxicity results, as shown by lower RICC than viability (Table 3.1). 
HL-60 cells were greatest affected by ara-C cytotoxicity, with reported RICC below 
the 50% threshold. Genotoxicity data using these cells should be interpreted with this 
in mind. In relation to the study design, ara-C dose concentration and time was 
justified by using a clinically relevant dose, and consistency across groups was 
maintained. It would therefore be useful for further studies to investigate these 
genotoxicity relationships with extended ara-C treatment at a lower dose. 
This work shows for the first time that interactions between leukaemic and stromal 
cells induce altered ara-C genotoxicity, with no known documented studies under 
these conditions. It would be of interest to investigate these interactions with greater 
physiological relevance, to answer whether this relationship extends from cell lines to 
primary patient cells. There is greater evidence in the literature of altered 
chemosensitivity in the form of cytotoxicity, perhaps with more research focus 
because of the clinical impacts of acute disease burden as opposed to long-term 
complications. Since survival of individuals with leukaemia is increasing due to 
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improved diagnosis and treatment, these long-term complications will become an 
ever more important consideration.  
Investigations into the cytotoxic effects of chemotherapy are therefore evidently 
crucial for improving disease outcomes, especially by understanding the mechanisms 
underpinning poor response in different subsets of patients. This work therefore 
aimed to determine whether, in this co-culture model, stromal cells are also 
chemosensitised to ara-C cytotoxic effects by leukaemic cells, while leukaemic cells 
are themselves chemoprotected (see 3.2). This was investigated by measurement of 
cell viability, ara-CTP production and proliferation (see sections 3.3.3.2–3.3.3.4). 
Treatment with ara-C for 1 hour significantly reduced HL-60, but not K562 or HS-5, 
viability (Figure 3.9), however, treatment for 24 hours significantly reduced the viability 
of all cell types (Figure 3.10). In accordance with genotoxicity results, and that of CM 
experiments, leukaemic cells co-cultured with HS-5 had improved viability, both when 
untreated and following ara-C treatment, in comparison to cells cultured 
independently. HS-5 stromal cells were significantly sensitised to ara-C following co-
culture with either of the leukaemic cell lines, following treatment for both 1 and 24 
hours (Figure 3.9/3.10). This was reflected by decreased ara-C sensitivity and ara-
CTP production in co-cultured leukaemic cells, and a converse increase in these 
parameters in HS-5 (Figure 3.11). Konopleva et al. (2002) demonstrated Bcl-2 related 
protection from ara-C-induced apoptosis in HL-60 and NB-4 cells by co-culture with 
murine stromal cells, both direct contact and using inserts, and stromal CM. Reduced 
apoptosis by direct culture of AML cells with HS-5 was also documented by Garrido 
et al. (2001) after both ara-C and DNR treatment. Moshaver et al. (2008) also showed 
that co-culture with HS-5 or primary BM stromal cells increased HL-60 and AML cell 
viability, both with inserts and in direct contact, however, indirect contact was less 
protective. This reflects findings in this study that indirect co-culture is more protective 
than CM, suggesting the closer the interaction, the greater the chemoprotection. 
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Interestingly, ara-C treated stromal cells (HS-5 and primary BM) retained their 
chemoprotective abilities when < 40 µM (Moshaver et al., 2008). This has relevance 
in the clinical setting, whereby MSC are not myeloablated prior to SCT, instead 
remaining of host-origin post-transplant (Rieger et al., 2005). Surviving yet damaged 
MSC preserved in the patients BMM (May et al., 2018) may therefore be able to 
support MRD and development of relapse, however, with functional damage 
preventing the support of healthy HSC (Kemp et al., 2011; Crippa and Bernardo, 
2018). 
Persistence of stromal cells in the BM post-SCT does suggest a level of intrinsic 
chemoresistance. A recent study concluded that BM-MSC are somewhat resistant to 
functional inhibition by antimetabolite drugs 5-fluorouracil and gemcitabine (Lopez 
Perez et al., 2019) (the same drug class as ara-C), with other studies on the contrary 
(Banfi et al., 2001; Zweegman et al., 2007; Batsivari et al., 2020). Here we show that 
when treated with a clinically relevant dose of ara-C (25 µM), HS-5 proliferation 
remains consistent; also being unchanged by co-culture with leukaemic cell lines 
(Figure 3.12). Perhaps this is reflective of inherent chemoresistance to cytotoxicity as 
well as reduced effects due to lower turnover (Banfi et al., 2001); 50 hours doubling 
time in HS-5 as opposed to 21 and 36 hours in K562 and HL-60 respectively (Figure 
3.1). HL-60 were again shown to be more sensitive than K562 to ara-C-induced 
cytotoxicity by reduced proliferation (Figure 3.12), reflective of other cytotoxicity 
parameters tested in this study (Figure 3.10/Figure 3.11) and in the literature 
(Anderson et al., 2013). Moshaver et al. (2008) also showed that HS-5 induce 
proliferation of HL-60 cells untreated and treated with 1 µM ara-C for 2 hours, with 
similar findings by (Abdul-Aziz et al., 2017) of increased proliferation and survival in 
direct and indirect co-cultures of AML cells with MSC from AML patients. A main 
question remaining in understanding the tumour microenvironment in haematological 
malignancies is which cell type is responsible for disease maintenance. One study 
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showed that healthy MSC adopted molecular properties similar to that of MDS-MSC 
when exposed to MDS cells (Medyouf et al., 2014) – a disease which often transforms 
to AML (Medyouf, 2017) – with another showing significant transcriptomic changes in 
MSC with interaction with myeloma cells (Garcia-Gomez et al., 2014). Taken together 
this could indicate that malignant cells drive disease-permissive reprogramming of 
the BMM, though this is not yet fully defined. 
It is still largely unknown how stromal cells from different patient groups will respond 
to treatment and co-culture with leukaemic cells, and how patient cells may 
differentially influence disease. Therefore, further work in this study will use primary 
patient MSC from different disease states with a leukaemic cell line to this end. 
The tumour microenvironment field is evidently challenged technically, though 
increased understanding of the complex BMM has undoubtedly improved the 
development of appropriate cell models and influenced therapy targets for AML 
(Hamilton et al., 2012; Dhami et al., 2016). Despite numerous studies evidencing the 
stromal protective effect on leukaemic cells, this was still important to investigate in 
this work to check the validity of the model and provide a baseline for further 
experiments to take place with known initial effects. Discrepancies between 
experimental findings between studies (Klopp et al., 2011) may reflect 
inadequate/inconsistent in vitro modelling in addition to the complex mechanisms 
involved in the leukaemic microenvironment (Katt et al., 2016). 
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3.5  CHAPTER SUMMARY 
The work in this chapter aimed to evaluate altered chemosensitivity to both 
genotoxicity and cytotoxicity by leukaemia-stromal interactions in cell line co-cultures. 
Leukaemic cell lines were found to be protected from ara-C toxicity by interactions 
with a bone marrow stromal cell line. This protection was shown to reduce cytotoxicity 
and increase metabolism in leukaemic cells using stromal CM, as well as to reduce 
genotoxicity, cytotoxicity, ara-C metabolite production and increase proliferation when 
indirectly co-cultured. Conversely, the stromal cell line was sensitised to the above 
mentioned effects, where toxic effects of ara-C in stromal cells were more pronounced 
when in communication with leukaemic cells. The altered genotoxicity seen in 
leukaemia-stromal cell line co-cultures following ara-C treatment have not been 
documented elsewhere, therefore, these results contribute new understanding of how 
malignant cells interact with their microenvironment. It is still unknown how these 
effects relate to primary patient MSC, and since the stromal cell line used was derived 
from a healthy donor, it would be useful to investigate whether the 
protective/sensitising effects seen in this chapter are also seen with primary MSC in 
different states of disease. Overall, this chapter presents further evidence for altered 
chemosensitivity by leukaemic-stromal interactions in cell lines, and provides a basis 
for continued work towards identification of their mechanisms with relevance to 
chemoresistance and poor outcomes in patients with AML.
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Chapter 4 - CHEMOSENSITIVITY MEDIATED BY LEUKAEMIC-
STROMAL INTERACTIONS IN CO-CULTURES USING PRIMARY 
PATIENT MSC 
4.1  INTRODUCTION 
The capacity for cell lines to accurately reflect the behaviour of primary patient cells 
is under constant question (Kennedy and Barabé, 2008; Dhami et al., 2016). 
Immortalised cell lines are a valuable resource for in vitro experiments, with generally 
higher proliferation and culture robustness (Mirabelli et al., 2019). They, however, 
lack the heterogeneity seen so readily in primary cells, particularly during disease 
states where aberrant gene expression and functionality has resulted from complex 
mutation profiles (Arber et al., 2016). When investigating the mechanisms 
underpinning a particular disease state, using primary cells in a form as closely linked 
to in vivo is therefore preferential. 
The results of chapter 3 in cell line co-cultures demonstrated that leukaemic cells are 
protected from ara-C-induced damage, with this work aiming to build on previous 
findings by use of primary BM-MSC from patients with a haematological malignancy 
(HM), in place of the stromal cell line HS-5, for greater physiological relevance. 
Malignant primary cells are notoriously problematic to culture in vitro, with poor 
baseline survival rates, limiting experiments involving further treatment (Jing et al., 
2010). For this reason, experiments in this chapter will be performed using primary 
BM-MSC and the leukaemic cell line HL-60, which showed the greatest 
chemosensitivity effects in chapter 3. 
The BMM is influenced by many external influences, including radiation, cytotoxic and 
genotoxic agents, as well as long-term DNA damage accumulation with aging (Kemp 
et al., 2010; Beane et al., 2014; Minieri et al., 2015; Si et al., 2018). Studies have 
shown that damage to BM cells effects their functionality (Kemp et al., 2011; Somaiah 
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et al., 2018; May et al., 2018), which is important to consider in MSC whose purpose, 
among others, is to support haematopoiesis (Ciciarello et al., 2019). 
Research in recent years has accelerated the understanding of the BMM and its 
interplay in HM (Tripodo et al., 2011; Krause and Scadden, 2015; Ciciarello et al., 
2019). Much of this research has focussed on the effects of the BMM on malignant 
cells, though there has been a shift to understand how the supportive BM is itself 
affected. There is an evident gap, however, in understanding the genotoxic 
consequences of HM therapies – gravely important as MSC with genotoxic damage 
undergo premature senescence (Minieri et al., 2015) and, unlike HSC which replace 
recipient cells, remain in the patient even following SCT (Rieger et al., 2005).  
 
4.1.1  Chapter Aims 
The findings in chapter 3 showed that leukaemic-stromal interactions affect the 
chemosensitivity of ara-C in in vitro co-cultures utilising cell lines. The aim of this 
chapter was to evaluate the involvement of mesenchyma in healthy and malignant 
BM; using patient MSC in place of the stromal cell line, HS-5. This study utilised 
patient BM aspirate samples for isolation of patient MSC in order to confirm the effects 
seen in leukaemic-stromal co-cultures using only cell lines (Chapter 3). Using MSC 
from patients diagnosed with different HMs will also allow for the investigation of any 
effects that BM disease itself has on the capacity of MSC to influence their 
microenvironment. 
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4.2  RESEARCH QUESTIONS 
This chapter set out to answer the following research questions: 
1. How do patient characteristics, including age, gender and disease state, affect 
the behaviour of BM-MSC? 
2. Are primary MSC sensitised to chemotherapy-induced genotoxicity by leukaemic 
cells, while leukaemic cells themselves being protected by primary MSC? 
3. Are primary MSC also chemosensitised to cytotoxicity by leukaemic cells, while 
leukaemic cells themselves chemoprotected by primary MSC? 
4. Is altered chemosensitivity in leukaemia-stroma co-cultures using primary MSC 
equivalent to cell line-mediated effects? 
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4.3  RESULTS 
4.3.1  Patient Characteristics 
A total of 31 patients were enrolled onto the study following assessment of the 
inclusion and exclusion criteria by the clinical team, providing 33 BM aspirate samples 
(one patient provided samples at three timepoints). Median patient age was 68 years, 
comprising 17 male and 14 female participants (see Appendix). Of the 33 samples 
provided, 10 were from previously chemotherapy-treated patients. Samples were 
grouped based on diagnosis in addition to treatment status. Of 10 samples from 
patients diagnosed with AML, six had received previous treatment. Samples from 
patients with other HMs were also processed for the study, where four of 21 were 
from those previously treated. Additionally, two samples were provided by 
participants who were found not to have malignant involvement of the BM, and had 
not received any previous chemotherapy. Not all samples could be used for co-culture 
experiments due to insufficient growth; the 22 BM cultures used in co-cultures are 
summarised in Table 4.1, with further characteristics in Table 4.2. 
CHARACTERISTIC N = 22 (%) 
AGE (YEARS)   
    MEDIAN (RANGE) 68 (36–90)  
GENDER   
    FEMALE:MALE 11:11 (50:50) 
TREATMENT   
    UNTREATED:TREATED 18:4 (82:12) 
DIAGNOSIS   
    AML (AT DIAGNOSIS) 3 13.6 
    AML (POST-TREATMENT) 2 9.1 
    OTHER HAEM. MALIGNANCY (AT DIAGNOSIS) 13 59.1 
    OTHER HAEM. MALIGNANCY (POST-TREATMENT) 2 9.1 
    NO HAEM. MALIGNANCY 2 9.1 
 
Table 4.1. Summarised patient characteristics from which BM samples were 
used for co-cultures. 
  CHAPTER 4 – MSC IN LEUKAEMIC-STROMAL CO-CULTURE 
   113 
  
AML 
UNTREATED 
AML TREATED 
OTHER 
MALIGNANCY 
UNTREATED 
OTHER 
MALIGNANCY 
TREATED 
NO BM 
INVOLVEMENT 
010 – AML 
(M69) 
011B – AML, 
myelodysplasia 
related changes 
(M36) 
001 – Essential 
thrombocythaemia 
(F73) 
009 – Small 
lymphocytic 
lymphoma (F62) 
005 – Infective 
endocarditis 
(non-malignant) 
(F78) 
011 – AML, 
myelodysplasia 
related changes 
(M36) 
011C –  AML, 
myelodysplasia 
related changes 
(M36) 
002 – Plasma cell 
myeloma (F67) 
024 – Follicular 
lymphoma 
(stage IV), 
MDS/MPN/ 
chronic anaemic 
BM (F73) 
031 – Immune 
thrombo-
cytopenic 
purpura (F57) 
025 – AML 
(M71) 
 003 – MDS-ring 
sideroblasts, 
single lineage 
dysplasia (M74) 
  
  004 – Ph+ CML 
(F68) 
  
  006 – 
Asymptomatic 
myeloma (F80) 
  
  007 – 
Myelofibrosis 
(M79) 
  
  012 – Plasma cell 
myeloma (M59) 
  
  016 – Plasma cell 
myeloma (F52) 
  
  018 – Plasma cell 
myeloma (F70) 
  
  019 – Leukaemic 
mantle cell 
lymphoma (F73) 
  
  020 – Essential 
thrombocythaemia 
(M56) 
  
  021 – Primary 
myelofibrosis 
accelerated phase 
(JAK2+) (M64) 
  
  023 - Refractory 
anaemia, ring 
sideroblasts, 
unilineage 
dysplasia (M90) 
  
Numbers refer to participant ID. M/F with number; gender and age. (n = 22) 
Table 4.2. Patient characteristics for BM samples used in co-cultures for each 
study group. 
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4.3.2  Study Feasibility 
This was a pilot study to investigate the interaction between BM-MSC and HSC in 
health and malignant disease. BM aspirates were sampled from patients following 
ethical approval and informed consent, before being sent to UWE for processing and 
culture to isolate MSC. Of 33 BM aspirate samples processed, 22 were successfully 
expanded in vitro (see Table 4.2), and were therefore utilised in co-culture 
experiments. The 11 samples which did not expand in vitro are summarised in Table 
4.3, and whilst insufficient numbers of cells for co-culture experiments, these were 
still utilised in some analyses, such as genotoxicity and cell survival (4.3.3). Two thirds 
of these samples that failed to expand in culture were from patients who had 
previously been treated with chemotherapy (see Appendix). Overall, six were from 
patients diagnosed with acute leukaemia or transforming MDS, four with myeloma 
and one with myelofibrosis; all diseases with significant BM involvement.  
AML 
UNTREATED 
AML TREATED 
OTHER 
MALIGNANCY 
UNTREATED 
OTHER 
MALIGNANCY 
TREATED 
NO BM 
INVOLVEMENT 
 008 – APML in 
remission (F68) 
014 – Plasma 
cell myeloma 
(F73) 
013 – IgG ĸ 
myeloma 
relapsing (M77) 
 
 017 – AML 2° to 
ALL (M56) 
015 – Plasma 
cell myeloma 
(F74) 
029 – Myeloma 
(IgG Kappa) 
(M67) 
 
 026 – AML 
(FLT3-ITD mut.) 
(M39) 
022 – JAK2+ 
myelofibrosis 
(F66) 
  
 027 – AML – 
FLT3 & NPM1 
wild type (M68) 
030 – MDS 
transforming to 
AML (complex 
karyotype 
including del 5q 
and del17) 
(M77) 
  
 028 – APML 
(M67) 
   
Numbers refer to participant ID. M/F with number; gender and age. 
Table 4.3. Patient characteristics for BM samples which did not expand in vitro 
for each study group. 
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4.3.3  Damage in Primary Bone Marrow Cells 
4.3.3.1  BM Cultures have Reduced Survival from Previously Treated 
Patients and Expand Slower from Older Patients 
Primary BM-MNC were isolated and cultured in order to expand pure populations of 
MSC (see 2.1.4–2.1.5). The survival of BM cells through each culture passage (P) 
was assessed and compared between samples from untreated and previously treated 
patients. Samples were ranked in a binary fashion at each passage end, whereby 0 
denoted censorship (cells were alive when measured) and 1 denoted an outcome 
occurrence (unsuccessful expansion). 
Cells from previously treated patients had significantly reduced survival, compared to 
cultures from patients at diagnosis by P4 (P = 0.0049; Figure 4.1.A). At P1, both 
untreated and treated groups had similarly high survival of > 90%, with a reduction to 
90.11% and 83.25% respectively by P2. This survival difference was further 
compounded at P3, where previously treated cells showed survival 20.03% lower 
than untreated. By P4, at which point co-culture, differentiation or immunophenotype 
experiments were performed, survival was estimated at just 23.31% in treated cells. 
Untreated cells had significantly superior survival of 62.85% (Figure 4.1.A). 
In patients with AML (Figure 4.1.B) and myeloma (Figure 4.1.C), P2 cells from 
untreated patients had increased survival as compared to their treated counterparts, 
by 6.19% and 11.10% respectively. At each subsequent passage, survival in 
previously treated patient cells continued to decrease compared to untreated cells. 
Though this was not a statistically significant difference (P > 0.05) in AML, a significant 
difference was evident in the myeloma group (P = 0.0395). By P4, unfortunately none 
of the samples from previously treated myeloma patients had survived (Figure 4.1.C). 
Population doublings (PD) were calculated in all cultures, where at P2–4 the number 
of cells was compared with the number seeded at the beginning of the passage 
(Figure 4.1.D).  
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Figure 4.1. Survival and expansion of primary BM cultures in vitro. Kaplan-Meier 
survival and population doubling (PD) was plotted for cultured BM cells from patients 
previously treated or untreated. Kaplan-Meier survival (%) for all groups (A), n = 23 
untreated, n = 10 treated; AML (B), n = 5 untreated, n = 6 treated; myeloma (C), n = 
7 untreated, n = 2 treated. Number of PD at each passage was calculated against the 
number of cells seeded at P1 for all groups (D), n = 18 untreated, n = 4 treated (P2), 
n = 3 treated (P3–4), n = 22 all cultures (P2), n = 21 all cultures (P3–4) (Mean +/− 
SD). Successfully expanded cells were used at P4 for MSC experiments. Doubling 
time correlated against patient age (P2) (E), n = 18 untreated, n = 3 treated. * = P < 
0.05; ** = P < 0.01. 
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Surviving cells expanded throughout each passage, with a similarly average 2.70 PD 
at P2. When considering all cultures, cells expanded a further 2.40 PD by P3 and 
1.97 PD by P4. Cultures from previously untreated patients followed a similar trend, 
with a 2.19 and 1.68 PD increase at P3 and P4 respectively. Cells from previously 
treated patients, however, had higher overall PD compared to untreated and all 
cultures at P3 (P > 0.05). By P4, previously treated cells showed increased expansion 
on untreated cells of 3.77 PD (P = 0.0246; Figure 4.1.D). Correlation between 
doubling time and patient age was calculated for BM cultures at P2, to take in 
consideration the speed of expansion. Figure 4.1.E shows that with increasing patient 
age, PD time increases. Cells from untreated patients generally showed an increased 
PD time compared to treated patients. These correlations did not, however, meet the 
significance threshold (P > 0.05), with weak regression (R2 = 0.1174 for all groups). 
 
4.3.3.2  Patient Gender, Treatment Group or Age Do Not Affect MNC Yield 
The number of viable MNC was correlated against sample and patient characteristics; 
the volume of BM aspirate, patient gender, treatment group and age (Figure 4.2). A 
weak positive correlation was seen between viable MNC count and BM volume 
(Figure 4.2.A). Viable MNC/mL of BM was compared for each of the study groups. 
Though not statistically significant (P > 0.05), there was a clear decrease in the mean 
number of MNC/mL in treated patients as compared to untreated patients (Figure 
4.2.B). In AML patients, viable isolated cells showed a decrease of 0.67 x107 MNC/mL 
of BM from untreated to treated patients. For all other HM diagnoses, a decrease of 
0.40 x107 MNC/mL was also seen. When considering all patients, those previously 
treated had a mean reduction of 0.33 x107 MNC/mL as compared to untreated 
patients. Patient age had no effect on the MNC/mL, with an R2 value of 0.0007 (Figure 
4.2.C). 
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Figure 4.2. Correlations of viable MNC with BM sample and patient 
characteristics. MNC were harvested from BM aspirate samples and a viable count 
determined. (A) Viable MNC number correlated against BM aspirate volume for all 
groups and each gender (female = triangle; male = square) with linear regression. (B) 
Viable MNC/mL for each study group as box and whisker with 95% confidence. (C) 
Viable MNC/mL correlated against patient age (years) with linear regression. n = 33. 
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4.3.3.3  Primary BM Cell Morphology is Heterogeneous 
Morphology of primary BM cultures was regularly assessed and images taken by 
inverted phase-contrast microscopy, every 7 days and once 70% confluency was 
reached. In primary cultures at P0, a variety of cell types could be seen. Figure 4.3.A 
shows that a primary culture of BM-MNC contained spindle fibroblast-like cells, 
polygonal cells, as well as suspension haematopoietic cells and debris. By day (D)14, 
adherent fibroblast-like cells had become confluent, and the number of 
haematopoietic cells was reduced, however with persisting debris (Figure 4.3.B). At 
each subsequent passage, the cells appeared to be striated, long and spindle-shaped 
with increasing uniformity (Figure 4.3.C–E). Though some cultures had successful 
growth, like this example, many showed slow growth and abnormal cell morphology, 
subsequently resulting in unsuccessful expansion (Figure 4.1).  
Heterogeneity in BM cell morphology was evident between patients; each behaved 
differently in culture. Figure 4.4 depicts this heterogeneity in six example patient 
cultures at the end of P1. Each patient’s cells exhibited distinct cell shape and 
arrangement. Large, flat, polygonal cells are clearly shown in the patients diagnosed 
with AML (Figure 4.4.A), MDS (Figure 4.4.E) and myeloma (Figure 4.4.F). Shorter 
phase-bright cells spindle-like cells could also be seen in the CML sample (Figure 
4.4.C), patient without BM involvement (Figure 4.4.D), MDS (Figure 4.4.E) and 
myeloma (Figure 4.4.F).  
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Figure 4.3. Morphology of BM cultures through each passage. BM MNC were 
initially seeded at 1 x107 (P0), with media replacement at D3. Cultures were fed every 
7 days thereafter and passaged when ~70% confluency was reached. Cultures were 
visualised by inverted phase-contrast microscopy and images taken at regular 
intervals. A) P0, D7; B) P0 end, D14; C) P1 end, D6; D) P2 end, D7 and E) P3 end, 
D6. These examples are from patient ID 011, a 36M untreated AML patient at 
diagnosis. x10 objective.
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Figure 4.4. Phase-contrast images of MSC from patients. BM-MNC were cultured 
to the end of P1 and imaged by inverted phase-contrast microscopy, x10 objective. 
Images depict heterogeneity in the morphology of cells from patients with different 
diagnoses from their BM investigation. Arrows show clear polygonal, spindle-like, 
small spherical and large round cells. Cells were sourced from patients diagnosed 
with the following (Diagnosis, sample ID): A) AML, 025; B) essential 
thrombocythaemia, 001; C) CML, 004; D) infective endocarditis, 005; E) MDS, 006; 
asymptomatic myeloma, 003. 
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4.3.3.4  Primary BM Cultures from Previously Treated Patients Have 
Increased Genotoxicity over Patients at Diagnosis 
The 11 BM samples which did not expand in vitro (Table 4.3) were harvested and 
assessed for genotoxicity by the alkaline comet assay (see 2.5.2). Primary cultures 
of BM-MNC from patients previously chemotherapy treated had significantly higher 
tail intensity than cells from untreated patients, i.e. at diagnosis (P = 0.0097; Figure 
4.5.A). Both untreated and previously treated patients’ cells had significantly higher 
comet tail intensity than the K562 negative control (P = 0.021 and < 0.0001 
respectively), as well as tail intensities falling much below that of the H2O2 positive 
control (P < 0.0001; Figure 4.5.A). 
Figure 4.5.B depicts example scored cellular DNA representative of each 
experimental group. The H2O2 positive control shows high levels of DNA damage, 
with the majority of the DNA intensity within the comet tail (orange line in the below 
histogram), producing the characteristic ‘comet’ shape. In contrast, the negative 
control cells show high comet intensity in the head of the comet (green line in the 
below histogram), with minimal DNA in the tail, therefore indicating minimal 
genotoxicity. In the untreated patient cells, small amounts of genotoxicity can be seen, 
which increases in treated patient cells. 
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Figure 4.5. Genotoxicity of primary BM cultures which did not expand in vitro. 
Primary BM MNC were cultured in standard conditions. Cultures which did not expand 
were harvested and genotoxicity assessed by the alkaline comet assay, alongside 
negative and positive (H2O2) K562 controls. Comet tail intensities were combined into 
untreated or previously treated patient groups. A) Box and whisker plot of tail intensity 
with 95% confidence. n = 6 untreated (1,208 cells); n = 5 treated (851 cells). ** = P < 
0.01. B) Examples of scored cells for each experimental group (Comet Assay IV 
software). Untreated; ID 027, Treated; ID 028. 
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4.3.4  Confirmation of MSC 
4.3.4.1  Primary BM-MSC were Confirmed by Tri-Lineage Differentiation 
Cultures were confirmed to have tri-lineage differentiation capacity under appropriate 
conditions for osteogenesis, chondrogenesis and adipogenesis, as per international 
guidelines (Dominici et al., 2006); on three representative samples to ensure the 
appropriateness of the MSC isolation method (see 2.7). Cells were morphologically 
examined, with images taken at regular intervals throughout differentiation, and 
confirmatively stained. All cells cultured in osteogenic conditions increased in number 
and became cuboidal in shape by D7 (Figure 4.6.C). Staining for ALP was observed 
in all three patient cultures, with a visual increase in staining in 011B, a 36 year-old 
male (M36) with AML post-cycle 1 of chemotherapy (Figure 4.7.B), as compared to 
staining in cells from samples 016 and 025 (Figure 4.7.D/F). 
Chondrocyte nodule development was observed in all patient cultures. Cells began 
to retract from the seeded area to form 3D nodules by 48 hours in 011B (Figure 4.8.C) 
and D9 in 016/025 (see Appendix). Chondrogenic staining by Alcian blue was 
observed in all cultures at D14 (Figure 4.9). The adherent cells growing in a 
monolayer on the surface of the culture plate were not stained, while the chondrocyte 
nodule stained blue. The nodule formed by 025 (AML; M71) was markedly larger than 
that of 011B (AML; M36) and 016 (myeloma; F52) (Figure 4.9). 
Adipocytes could be clearly visualised in culture prior to staining, with uniform 
spherical lipid formation within 7 days. Some lipid could be visualised at 48 hours with 
011B (Figure 4.10.B). Staining with Oil Red-O was confirmative of lipids. There was 
a decrease in adipocyte staining from 011B, 016 and 025 (Figure 4.11), a trend 
correlated to increasing patient age (36–71 years). Dye elution from stained cells was 
confirmative of this trend (Figure 4.12). The increase in adipocyte staining was 
significant in 011B as compared to 025 (P = 0.0223), and all patient cultures over the 
negative control (P < 0.05). 
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Figure 4.6. Development of osteocytes in a treated AML-MSC culture. 011B 
MSC cultures (passage 4) were seeded in osteogenic differentiation conditions for 
10 days. Cultures were visualised by inverted phase-contrast microscopy and 
images taken at hours 0 (A) and 48 (B) and days 7 (C) and 10 (D/E). A–D = x10, E 
= x20 objective. 
 CHAPTER 4 – MSC IN LEUKAEMIC-STROMAL CO-CULTURE 
126 
  
 
Figure 4.7. Osteogenic culture staining for alkaline phosphatase. MSC cultures 
(P4) were seeded in osteogenic differentiation conditions for 10 days. Cultures were 
visualised by inverted light microscopy and imaged prior to staining (A, C and E) and 
following staining with SIGMA FAST BCIP/NBT substrate (B, D and F) for detection 
of alkaline phosphatase (ALP). 
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Figure 4.8. Development of chondrocytes in a treated AML-MSC culture. 011B 
MSC cultures (passage 4) were seeded in chondrogenic differentiation conditions 
for 14 days. Cultures were visualised by inverted phase-contrast microscopy and 
images taken at hour 6 (A), 24 (B), 48 (C) and day 4 (D), 9 (E) and 14 (F). x10 
objective. 
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Figure 4.9. Chondrogenic culture staining for proteoglycans. MSC cultures (P4) 
were seeded in chondrogenic differentiation conditions for 14 days. Cultures were 
visualised by inverted light microscopy and imaged prior to staining (A, C and E) and 
following staining with Alcian blue (B, D and F).
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Figure 4.10. Development of adipocytes in a treated AML-MSC culture. 011B 
MSC cultures (passage 4) were seeded in adipogenic differentiation conditions for 
14 days. Cultures were visualised by inverted phase-contrast microscopy and 
images taken on days 0 (A), 2 (B), 7 (C) and 14 (D/E). A–D = x10, E = x20 objective. 
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Figure 4.11. Adipogenic culture staining for lipids. MSC cultures (P4) were 
seeded in adipogenic differentiation conditions for 14 days. Cultures were visualised 
by inverted light microscopy and imaged prior to staining (A, C and E) and following 
staining with Oil Red-O (B, D and F).
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Figure 4.12. Oil Red-O elution of lipids in adipogenic culture. MSC cultures (P4) 
were seeded in adipogenic differentiation conditions for 14 days. Cultures were fixed 
and stained with Oil Red-O, followed by dye elution with 100% isopropanol. Bars 
represent the mean absorbance from duplicate wells, measured at 540 nm and 
adjusted by the blank (isopropanol only). Control represents staining of an empty 
well. n = 1 for three independent patient samples (011B, 016 and 025). * = P < 0.05; 
** = P < 0.01. 
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4.3.4.2  Primary BM-MSC were Confirmed by Immunophenotype 
The immunophenotype of putative MSC isolated from BM cultures was also confirmed 
by multi-colour flow cytometry (see 2.6.3). The surface antigen expression of BM 
derived cells was consistent with that of MSC; all cells highly expressed the MSC 
specific markers CD73, CD105 and CD90, while showing lower expression of 
haematopoietic markers (CD14, CD20, CD34 and CD45); as per international 
guidelines (Dominici et al., 2006) and depicted by example gated scatter plots in 
Figure 4.13. 
Mean CD marker positivity was shown as 99.23%, 97.67% and 65.22% for the MSC 
markers CD73, CD105 and CD90 respectively, while mean MSC – markers showed 
49.97% overall positivity (Figure 4.14.A). Median fluorescence intensity (MFI) was 
also depicted for each marker and grouped based on HM diagnosis and treatment 
status of patients. CD marker MFI was shown to be lowest in previously treated 
patients with a HM, while untreated patients found not to have a HM had the greatest 
MFI for all markers tested (Figure 4.14.B–D). 
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Figure 4.13. Immunophenotyping of example BM cultures by flow cytometry 
for MSC positive and negative CD markers. Patient BM cultures were harvested 
at the end of passage 3 (P4) for co-culture experiments, where they were also 
analysed for immunophenotype to confirm putative MSC. Cells were stained with 
ZNIR live/dead and MSC antibody cocktail or isotype control cocktail. Gates were 
applied to MSC stained cells based on forward scatter (FSC-H) and fluorescence 
intensity scatter plots in isotype control stained cells. A) CD73-APC, B) CD105-PE, 
C) CD90-FITC, D) MSCneg-PerCP (CD14, CD20, CD34 and CD45 pooled 
haematopoietic markers) and to select for cell singlets (B) and live cells (C). Example 
plots for patient ID 010 stained with MSC cocktail (010 M). 
 CHAPTER 4 – MSC IN LEUKAEMIC-STROMAL CO-CULTURE 
134 
  
 
Figure 4.14. Expression of CD markers in BM-MSC cultures. Patient BM cultures 
were analysed for immunophenotype to confirm putative MSC. CD marker positivity 
% for CD73, CD105, CD90 and MSC − (pooled CD14, CD20, CD34 and CD45) (A) 
and median fluorescence intensity (MFI) for CD73 (B), CD105 (C) and CD90 (D) 
were calculated based with subtraction of isotype control positivity/fluorescence. B–
D also show CD marker MFI plotted based on diagnosis of a haematological 
malignancy (HM) and previous treatment status. n = 19 independent patient cultures; 
n = 14 HM untreated, n = 3 HM treated, n = 2 no HM. 
  CHAPTER 4 – MSC IN LEUKAEMIC-STROMAL CO-CULTURE 
   135 
4.3.5   Effects of Co-Culture on Primary MSC and HL-60 Cells 
4.3.5.1  Primary MSC Are Sensitised to Ara-C-Induced Genotoxicity by 
Leukaemic Cells, While Protecting Leukaemic Cells 
Genotoxicity was investigated by measurement of division abnormalities in the 
micronucleus (MN) assay. Treatment with ara-C significantly increased MN incidence 
in HL-60 cells, both cultured alone and in co-culture with patient MSC (P < 0.0001; 
Figure 4.15.A). Co-cultures followed a similar trend, whereby ara-C treatment 
significantly increased MN incidence, but this increase was attenuated by co-culture 
with primary MSC, though without statistical significance (P > 0.05). Co-culture with 
patient MSC significantly reduced MN incidence when considering the % change from 
treated cells cultured alone however (P = 0.0068; Figure 4.15.C), with a mean 
reduction of 0.83%. 
In all patient diagnosis groups, HL-60 had reduced MN incidence, when considering 
the % change between ara-C treated cells cultured alone and in co-culture with 
patient MSC (P > 0.05; Figure 4.16.A). This protective effect was most pronounced 
in co-cultures with MSC from patients who did not have a HM.  
Mean increase in MN incidence was minimal in MSC following ara-C treatment, an 
increase of 1.06%. There continued a slight increase in genotoxicity following co-
culture with HL-60 cells (P > 0.05; Figure 4.15.B). Genotoxicity was less pronounced 
than with HL-60 cells, which had a mean increase of 3.29% MN when ara-C treated 
(Figure 4.15.A). Despite a mean increase in ara-C-mediated MN induction in MSC 
co-cultured with HL-60 as compared to MSC cultured alone (Figure 4.15.C), this trend 
was not statistically significant (P > 0.05). When considering patient MSC by 
diagnosis group, the MN incidence showed little change in MSC following co-culture 
with HL-60 cells (P > 0.05; Figure 4.16.B). 
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Figure 4.15. Genotoxicity in HL-60/primary MSC in co-culture following ara-C 
treatment. HL-60 cells and MSC from patients were cultured alone or in co-culture 
using inserts for 24 h prior to treatment with 25 µM ara-C for 1 h. The MN assay was 
performed on cells after a further 1.5–2 PD (48 h). A) HL-60 MN, B) MSC MN, C) MN 
as % change between treated cells alone and co-culture. Lines represent MN 
incidence as percentage of total scored cells before and after treatment (A/B) or box 
and whisker with 95% confidence of the MN % change (C). A minimum of 2,000 cells 
were scored per treatment group, where possible. n = 22. * = P < 0.05; **** = P < 
0.0001. 
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Figure 4.16. Genotoxicity in HL-60/primary MSC, grouped by diagnosis, in co-
culture following ara-C treatment. HL-60 cells and MSC from patients were cultured 
alone or in co-culture using inserts for 24 h prior to treatment with 25 µM Ara-C for 1 
h. The MN assay was performed on cells after a further 1.5–2 PD (48 h). A) HL-60 
MN, B) MSC MN, as % change between treated cells alone and co-culture depicted 
by box and whisker plot with 95% confidence, and plotted based on diagnosis of a 
haematological malignancy (HM) and previous treatment status. A minimum of 2,000 
cells were scored per treatment group, where possible. n = 22 independent patient 
co-cultures; n = 16 HM untreated, n = 4 HM treated, n = 2 no HM. 
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Genotoxicity was also assessed by the alkaline comet assay in both MSC and HL-60 
cells following ara-C treatment and co-culture (Figure 4.17). Trends suggest a 
decrease in comet tail intensity in HL-60 cells following co-culture. Though this was 
below the significance threshold in treated cells (P > 0.05), tail intensity was 
significantly decreased in untreated HL-60 cells following co-culture with MSC (P = 
0.0012; Figure 4.17.A). This trend can be seen with tail intensity before and after co-
culture in individual patient co-cultures, with high variation between samples (Figure 
4.17.C). Median tail intensity was overall decreased by 0.59% in untreated cells and 
by 0.39% in treated cells following co-culture with MSC, though this trend was again 
not statistically significant due to high inter-experiment variation (P > 0.05; Figure 
4.17.E). 
Genotoxicity by comet assay was also assessed in groups based on patient diagnosis 
(Figure 4.18). The mean % change in comet tail intensity was reduced in HL-60 cells 
co-cultured with MSC from patients with untreated patients with a HM, both without 
and with in vitro ara-C treatment. In those previously treated for a HM, MSC only 
caused a reduction in HL-60 genotoxicity without in vitro ara-C treatment. MSC from 
those found not to have a HM caused a greater reduction in HL-60 tail intensity 
following co-culture (P > 0.05; Figure 4.18.A).  
Conversely, tail intensity was significantly increased in untreated MSC following co-
culture with ara-C (P = 0.0175); a similar yet insignificant trend was also seen for ara-
C treated cells following co-culture (P > 0.05; Figure 4.17.B). High variation can be 
clearly seen between patient co-cultures before and after co-culture (Figure 4.17.D), 
where the increasing trend of genotoxicity following co-culture with HL-60 was not 
statistically significant (P > 0.05). When considering the % change between alone and 
co-culture however, MSC showed significantly increased tail intensity when treated 
with ara-C and co-cultured with HL-60 (P = 0.0159), but not in untreated cultures, with 
mean % change of 0.90% and 0.05% respectively. 
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Figure 4.17. Genotoxicity in HL-60/patient MSC following co-culture and ara-C 
treatment. MSC from patient BM cultures (P4) were cultured for 24 h prior to co-
culture with HL-60 cells in trans-well inserts. Ara-C (25 µM) was added for 1 h at the 
end of 24 h in co-culture conditions. Genotoxicity was determined by comet assay 
and depicted by box and whisker plot with 95% confidence (A; HL-60, B; MSC). 
Median tail intensity before-and-after co-culture in untreated and treated cells is also 
shown for HL-60 (C) and MSC (D), in addition to median % change (HL-60, E; MSC, 
F). A minimum of 200 comets were scored per group, where possible. n = 22 
independent patient co-cultures. * = P < 0.05; ** = P < 0.01. 
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Mean % change tail intensity was increased in MSC from patients with a HM at 
diagnosis when co-cultured with HL-60, both without and with in vitro ara-C treatment 
(Figure 4.18.B). This trend was replicated with MSC from patients previously treated 
with a HM, but only with further in vitro ara-C treatment. MSC from those without 
malignancy had reduced tail intensity when co-cultured with HL-60 and untreated in 
vitro, but a slight increase with ara-C treatment (P > 0.05; Figure 4.18.B). 
In accordance with assay guidelines (OECD, 2014), corresponding ara-C cytotoxicity 
and cell PD was also measured. This is monitored in order to confirm that cells have 
not experienced excessive cytotoxicity to accurately represent genotoxicity, and that 
sufficient cells have undergone cell division to present nuclear abnormalities. Table 
4.4 shows that the percentage of viable cells does not change immediately following 
treatment with ara-C for 1 hour as compared to untreated cells. Following the recovery 
period post-treatment, HL-60 cell viability improves in untreated cells, and is reduced 
in treated cells. MSC viability does not change in cells cultured alone with or without 
ara-C, however a reduction in viability is seen in both treated and untreated MSC 
following co-culture. PD ranged from 1.4 divisions to 4.2 divisions, but the majority of 
groups falling near to the guidelines range of 1.5–2 PD. (Table 4.4). 
 
4.3.5.2  Primary MSC Are Not Sensitised to Ara-C-Induced Cytotoxicity by 
Leukaemic Cells, And Leukaemic Cells Are Not Protected 
Along with effects on genotoxicity, ara-C mediated cytotoxicity was also assessed 
following co-culture of MSC and HL-60 (Figure 4.19). Cells were co-cultured for 24 
hours, followed by treatment with 25 µM ara-C for 1 hour, cultured for a further 48 
hours and viability was assessed. Ara-C significantly reduced the viability of HL-60 
cells cultured alone as compared to untreated HL-60 cells cultured alone (P = 0.0003), 
and untreated cells in co-culture (P = 0.0033). Ara-C induced a reduction in living cells 
of 58.37% (Figure 4.19.A).   
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Figure 4.18. Genotoxicity in patient MSC, grouped by diagnosis, and HL-60 cells 
following co-culture and ara-C treatment. MSC from patient BM cultures (P4) were 
cultured for 24 h prior to co-culture with HL-60 cells in trans-well inserts. Ara-C (25 
µM) was added for 1 h at the end of 24 h in co-culture conditions. Genotoxicity was 
determined by comet assay and % change between alone and co-culture depicted by 
box and whisker plot with 95% confidence (A; HL-60, B; MSC), and plotted based on 
diagnosis of a haematological malignancy (HM) and previous treatment status. A 
minimum of 200 comets were scored per group, where possible. n = 22 independent 
patient co-cultures; n = 16 HM untreated, n = 4 HM treated, n = 2 no HM. 
 CHAPTER 4 – MSC IN LEUKAEMIC-STROMAL CO-CULTURE 
142 
  
GROUP 
ARA-C 
(µM) 
VIABILITY 
1H + 0H % 
(SD) 
VIABILITY 
1H + 1.5-2 
PD 
% (SD) 
PD (SD) N 
MEAN 
SCORED 
FOR MN 
HL-60 
ALONE 
0 87.1 (7.0) 92.8 (4.0) 4.2 (2.3) 22 1,923 
25 85.7 (8.6) 71.1 (11.5) 1.4 (0.6) 22 1,689 
HL-60 CO-
CULTURE 
0 86.3 (7.0) 92.5 (3.3) 3.9 (1.4) 22 – 
25 86.2 (8.4) 84.2 (11.1) 2.3 (2.1) 22 1,608 
MSC 
ALONE 
0 82.0 (10.2) 80.5 (9.7) 1.5 (0.7) 22 1,534 
25 81.7 (8.2) 82.4 (10.3) 1.4 (0.7) 22 1,571 
MSC CO-
CULTURE 
0 80.1 (8.4) 78.4 (10.9) 1.4 (0.4) 22 – 
25 80.3 (10.6) 76.7 (11.6) 1.6 (1.2) 22 1,346 
PD; population doubling, SD; standard deviation. 
Table 4.4. Corresponding mean cytotoxicity of ara-C treatment for genotoxicity 
assays in patient MSC and HL-60 co-cultures. 
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Figure 4.19. Cytotoxicity in HL-60/primary MSC following co-culture and ara-C 
treatment. MSC from patients (P4) and HL-60 cells were cultured alone or in co-
culture using inserts for 24 h prior to treatment with 25 µM ara-C for 1 h. Cells were 
reseeded following treatment, harvested after a further 48 h, and viable HL-60 cells 
(A/C) or MSC (B/D) assessed by manual counting with trypan blue. Bars represent 
mean +/− SD cell viability normalised to untreated cells cultured alone (A/B), or % 
change between alone and co-culture depicted by box and whisker plot with 95% 
confidence. n = 16 untreated, n = 19 treated. 
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HL-60 viability was not significantly altered by co-culture with patient MSC in 
untreated cultures (P > 0.05); a reduction of only 9.43%. HL-60 cells were protected 
by 18.91% in co-culture with MSC post-ara-C. Due to biological variance, this trend 
was not statistically significant (P > 0.05). HL-60 cells which showed protection from 
ara-C following co-culture with MSC were still significantly reduced in viability as 
compared to untreated HL-60 cells alone (P = 0.0249). This is also seen when 
considering HL-60 cell viability as % change between alone and co-culture, with a 
mean % increase of 18.91% in treated co-culture (P > 0.05; Figure 4.19.C). The 
change in % HL-60 viability was significantly increased when cells were treated with 
ara-C (P = 0.0283; Figure 4.19.C). In each patient diagnosis grouping, the % change 
of cell viability between HL-60 alone and in co-culture with MSC increased only with 
in vitro ara-C treatment, but not without (P > 0.05; Figure 4.20.A). 
Patient MSC showed no significant change in viable cells 48 hours post-treatment 
with ara-C (P > 0.05), with a reduction in mean viability of 3.57% in cells cultured 
alone (Figure 4.19.B). Co-culture with HL-60 had little effect on untreated viable cell 
number, with a reduction from 100% to 91.35% (P > 0.05). Equally, treated cells 
showed a slight reduction in viability from 96.48% to 94.52% in cells culture alone and 
in co-culture respectively (P > 0.05). Both MSC ara-C treated and untreated in vitro 
showed a reduction in mean cell viability as % change between alone and co-culture 
with HL-60, though without statistical significance (P > 0.05; Figure 4.19.D). In patient 
diagnosis groups, MSC viability % change was reduced following co-culture with HL-
60 in untreated patients with a HM and those without, but not treated patients with a 
HM (P > 0.05; Figure 4.20.B). Opposite to the trend seen for HL-60 cells (Figure 
4.20.A), % change between alone and co-culture was reduced in ara-C treated MSC 
cells as compared to in vitro untreated cells (P > 0.05; Figure 4.20.B). 
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Figure 4.20. Cytotoxicity in HL-60/primary MSC, grouped by diagnosis, 
following co-culture and ara-C treatment. MSC from patients (P4) and HL-60 cells 
were cultured alone or in co-culture using inserts for 24 h prior to treatment with 25 
µM ara-C for 1 h. Cells were reseeded following treatment, harvested after a further 
48 h, and viable HL-60 cells (A) or MSC (B) assessed by manual counting with trypan 
blue. Bars represent % change in cell viability between alone and co-culture depicted 
by box and whisker plot with 95% confidence, plotted based on diagnosis of a 
haematological malignancy (HM) and previous treatment status. n = 19/16 
independent patient co-cultures (A/B); n = 13/11 HM untreated, n = 4/3 HM treated, n 
= 2 no HM. 
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4.4  DISCUSSION 
The participants enrolled on this study attended the RUH Haematology Department 
for investigations into potential haematological disorders; for diagnosis or monitoring 
of disease. A broad study approach was taken to allow for sufficient samples to be 
collected for the study (31 patients in 12 months). A median age of 68 years (67.5 
years for AML specifically) in this study (see section 4.3.1) is reflective of observed 
median age at diagnosis of 70.6–70.9 years in all HMs (68 years for AML; Short et 
al., 2018) as reported by the HM Research Network (Smith et al., 2011, 2018). There 
was an equal male:female ratio which adds gender balance to the study, with each 
group containing 11 samples in final co-culture experiments (Table 4.1). The cohort 
overall had more male participants (male/female = 1.21), reflecting a predominance 
of male HM diagnoses in the literature (male/female = 1.5; Smith et al., 2018). 
Two thirds of BM aspirates processed were successfully expanded to MSC for co-
culture experiments. The number of MSC per MNC in BM is known to be reduced in 
different disease states (Corradi et al., 2018), therefore, there may not be sufficient 
initiating cells per flask to successfully colonise. This is compounded by the quality of 
BM aspirate. This study used BM material remaining after all clinical needs had been 
met, to render no unnecessary harm to patients beyond clinically indicated 
interventions. The first pull of BM is the most cellular (Fennema et al., 2009) and so 
is used primarily to prepare BM films for morphological assessments, while the next 
pull of aspirate is used for immunophenotyping and cytogenetics (Schey et al., 2013), 
in order to confidently classify disease; the residual sample was then kindly provided 
for this study. MSC number in BM is significantly inversely correlated to increasing 
aspiration (Li et al., 2011) due to unavoidable PB dilution (Fennema et al., 2009; 
Delgado et al., 2017). Furthermore, MSC are known to have impaired functionality, 
senescence and proliferation with increasing patient age (Beane et al., 2014), of note 
as nine of 11 failed cultures originated from patients > 65 years of age (Table 4.3).  
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Cells derived from patients with haematological disorders are known to have varying 
culture requirements (McNiece and Briddell, 2001), for example increased 
concentrations of IL-6 for successful expansion of myeloma cells in vitro (Jourdan et 
al., 2003; Harmer et al., 2019; J. Murray, personal communication, 2020), and may 
be a contributing factor for poor P4 in vitro survival in this study (Figure 4.1.C). All BM 
cultures without in vitro expansion were from patients with diseases of significant BM 
involvement. There may therefore exist a skew for less damaged cultures, as 
healthier cells survived to the co-culture experimental stage. 
Despite insufficient cells for all intended analyses, data was still collected from each 
sample. Study feasibility therefore depends on the cell number requirements, with 
expansion for adequate cell numbers a key limitation of MSC research (Tanavde et 
al., 2015). BM-MNC cultures are not generally ‘pure’ MSC until at least P2 (Pittenger 
et al., 1999; Liu et al., 2016); thus there exists a careful balance between retaining 
MSC properties during long-term cultures and sufficient yield. Moreover, all patient 
cultures were cryopreserved at the end of P1, to allow for the processing of adequate 
samples within the available time, and the synchrony of co-culture experiments at a 
later phase. Though studies have shown no significant impairments for 
immunophenotype, differentiation, proliferation or morphology following 
cryopreservation (Sisakhtnezhad et al., 2017; Bahsoun et al., 2019), for recovery, 
MSC were cultured for longer than they otherwise would have been. Primary cells 
have a finite lifespan in vitro and their expansion capacity is limited, but can retain 
functional and morphological characteristics mimicking in vivo (Kennedy and Barabé, 
2008). MSC stemness is however known to decrease with prolonged culture (Yang 
et al., 2018), with more opportunities for cells to materialise treatment-induced 
damage (Lützkendorf et al., 2017). 
The survival of all BM-MNC cultures was significantly reduced in previously treated 
patients (Figure 4.1.A). Though inferior survival of treated AML patient cells was not 
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statistically significant, treated myeloma cells were significantly depleted, 
unfortunately leaving no cultures available for co-culture experiments by P4 (Figure 
4.1.B/C). Not only is myeloma a disease with significant BM involvement, but 
intensive chemotherapeutics (e.g. melphalan, bortezomib and cyclophosphamide) 
are particularly toxic and known to damage BM-MSC (Li et al., 2004; Kemp et al., 
2011; May et al., 2018). This functional damage is thus a likely factor contributing to 
failed expansion. Somaiah et al. (2018) also showed that ara-C, DNR and vincristine 
significantly reduced MSC viability and proliferation, however cultures from treated 
patients showed increased PD at P4 in this study (Figure 4.1.D). A limitation of this 
data is that there were considerably fewer cultures from previously treated (n = 3–4) 
than untreated patients (n = 22), where one treated patient in particular had high 
overall PD of 14.96 by P4 which skewed the mean.  
MSC proliferation is affected by a number of factors (Beane et al., 2014; 
Oikonomopoulos et al., 2015; Münz et al., 2018). Though MSC from healthy donors, 
MDS and AML patients had similar capacity to support leukaemic cells in vitro, MSC 
from MDS and AML patients had lower proliferative capacity than healthy donor MSC, 
demonstrating aberrant MSC function due to disease (Corradi et al., 2018). Previous 
treatment may have ablated more chemosensitive cells, leaving resistant populations 
of MSC to recover in the BM with increased PD as compared to untreated 
populations. Another factor affecting MSC proliferation is patient age (Beane et al., 
2014), also shown by weak correlations of increased doubling time in this study 
(Figure 4.1.E). Where there were few cells on initial seed (< 1 x107 as of the method), 
MSC may become partially exhausted to reach passage confluency.  
To investigate potential factors affecting MSC yield, viable MNC were correlated 
against patient and sample characteristics (Figure 4.2). BM aspirate volume was 
weakly correlated with MNC number (Figure 4.2.A), and contained fewer MNC/mL 
when from treated patients, as compared to untreated (Figure 4.2.B), which is 
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expected considering the cytotoxic nature of chemotherapeutics. Mean MNC/mL was 
particularly high in untreated AML patients, for example in comparison to untreated 
patients with other diagnoses. This may be explained by patients having vast BM 
blast numbers – characteristic of active disease and a criteria for acute leukaemia 
classification (see 1.1.7). The age of the patient had no effect on viable MNC/mL 
(Figure 4.2.C). 
The BM is a complex mix of cell types which differ depending on factors including 
age, health status and genetics (Li et al., 2011; Pang et al., 2011). In most cases, 
isolated MSC attach to the culture vessel following short incubations, allowing 
suspension haematopoietic cells to be washed away. In one example patient (011), 
shown in Figure 4.3, D7 cultures contained both non-adherent and adherent cells; 
attached cells displayed typical fibroblastic morphology. By D14 and succeeding 
passages, cells had further elongated, become stratified and multi-layered. This 
method of MSC isolation by plastic adherence is particularly crude, but is benefited 
by low cost requirements (Chippendale et al., 2011; Baghaei et al., 2017). 
Additionally, it allows for expansion of MSC numbers, as MSC constitute a very small 
fraction of MNC in BM (< 0.01%; Fennema et al., 2009; Alvarez-Viejo et al., 2013; 
Crippa and Bernardo, 2018). Therefore, isolation methods such as cell sorting are 
limited, compounded by the absence of any one MSC specific cell surface marker 
(Chippendale et al., 2011; Baghaei et al., 2017) and the changeability of such 
expression (Fracchiolla et al., 2017). Heterogeneity exists even within the same 
culture, as MSC occupy distinct flask areas as they expand (Rennerfeldt et al., 2019). 
This is particularly compounded where the disease significantly affects the BM, for 
example bone disease in myeloma, or blast crisis in leukaemia (Fairfield et al., 2016; 
Shafat et al., 2017). This may be a consideration for failed expansion in some 
samples, in that MSC in different disease states may need further support by 
cytokines/growth factors to expand in vitro (Sisakhtnezhad et al., 2017; J. Murray, 
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personal communication, 2020). MSC morphology was vastly heterogeneous 
between patients in this study (Figure 4.4), though evidence in the literature suggests 
that MSC morphology is similar between HMs (Zhao et al., 2007; Azadniv et al., 
2020). Treatment with ara-C, DA and vincristine have been shown to alter MSC 
morphology, however (Somaiah et al., 2018). 
DNA damage was measured in BM cultures which did not expand in vitro, revealing 
that cells from previously treated patients had significantly higher genotoxicity than 
untreated patients (Figure 4.5). This finding is unsurprising, as MSC are known to be 
damaged by a host of chemotherapeutic treatments (Li et al., 2004; Somaiah et al., 
2018), including with functional inhibition (Kemp et al., 2010, 2011; May et al., 2018). 
Though attempts were made to maintain inter-experiment consistency, cells were 
harvested for these comet assay assessments over a large range of days, depending 
on assessments of expansion. Some stayed in culture for much longer to give cells a 
chance to expand, thus should be taken into consideration when interpreting this data. 
Additionally, some cultures had very few cells remaining, and so 200 scored cells, as 
of assay guidelines (OECD, 2016), was not always possible. 
For confirmation of putative MSC in BM cultures, the ability of cells to undergo multi-
lineage differentiation was assessed. Aptitude for osteogenic, chondrogenic and 
adipogenic differentiation was established in all patient cultures tested (see 4.3.4.1). 
This was not realistic to perform on all samples, therefore three cultures were used 
to represent the appropriateness of the MSC isolation method used (Methods 2.1.5), 
and applied to all samples in the same manner. Though all cultures successfully 
differentiated in the conditions tested, one in particular had increased capacity overall 
(Figure 4.7/4.9/4.11); participant 011B, a 36-year-old male following cycle 1 of 
treatment for AML, had greater staining for all differentiation endpoints than untreated 
patients 016 (myeloma; F52) and 025 (AML; M71). 
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One study showed that increasing age reduced the overall cell yield, as well as 
chondrogenic differentiation potential of BM-MSC in a rabbit model (Beane et al., 
2014). However, this study used MSC from rabbits ranging from 4 months to 5 years 
of age, which bears little comparison to humans with a lifespan well into their 80s, for 
example. The chondrocyte nodule was notably larger in 011B than 016 and 025 
(Figure 4.9), which may be explained by this culture showing cell retraction into a 3D 
structure sooner than the other samples (see Figure 4.8 and Appendix). Though MSC 
clones have been shown to progressively lose their adipogenic and chondrogenic 
differentiation potential with increasing PD (Muraglia et al., 2000), the results of this 
modest experiment contradict this notion as 011B also had the highest PD over 016 
and 025 at all passages (data not shown). The number of days in culture were 
however equivocal between the three cultures. BM-MSC from AML patients also 
showed adipogenic differentiation with impact for leukaemic support (Azadniv et al., 
2020). Treatment with ara-C, DA and vincristine however hindered the cells’ capacity 
to undergo osteogenic and adipogenic differentiation (Somaiah et al., 2018). In this 
study, 011B had superior differentiation capacity, over untreated patients, despite 
having received a chemotherapy cycle. 
BM-derived cell surface antigen expression was consistent with that of MSC, at P4 
when co-culture experiments were performed (Figure 4.14). All cells expressed 
markers for MSC; CD73, CD90 and CD105 (Dominici et al., 2006). Additionally, cells 
from all patients used in co-cultures showed lower expression of haematopoietic 
markers; the haematopoietic progenitor marker CD34, CD45 expressed by 
leukocytes, CD14 a known marker for monocytes and macrophages (Baghaei et al., 
2017) and CD20 a pan-B-cell marker (van Lochem et al., 2004). Immunophenotyping 
was successfully undertaken on 19 of 22 co-cultured samples, due to insufficient cell 
numbers for both co-culture experimentation and for flow cytometry; in these cases 
co-culture was prioritised.  
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All MSC highly expressed CD73 and CD105 (> 93%), however CD90 and pooled 
MSC negative expression were suboptimal (Figure 4.14.A). This could be due to 
crossover of fluorescence channels and complexities of compensation with few cells. 
The same procedure to isolate MSC was undertaken for each sample, cultures 
showed plastic adherence and were confirmed for differentiation capacity as well as 
this immunophenotyping, giving some assurance that all samples would have 
contained acceptable MSC purity. The expression of the MSC positive markers was 
shown to be greatest in MSC from patients found not to have a haematological 
malignancy, and least in previously treated HM patients (Figure 4.14.B–D). 
Heterogeneity and aberrant CD marker expression (including CD90 and CD105) by 
MSC has been documented in patients with haematological disorders previously 
(Campioni et al., 2006), which confers with these results. In another study, MSC CD 
marker expression was impaired following ara-C, DNR and vincristine treatment 
(Somaiah et al., 2018). Ara-C and vincristine significantly reduced CD13 and CD49E 
expression, however this was recovered 7 days post-treatment. Significant reduction 
was maintained for CD13, CD29, CD73 and CD90 post-treatment with DNR (Somaiah 
et al., 2018). Additionally, cyclophosphamide and melphalan treatment significantly 
reduced CD44 expression in another study (Kemp et al., 2011). With this in mind, it 
is clear that damage to MSC varies between patients and manifests through 
interconnecting factors, including chemotherapy exposure and disease state, which 
deserve further research.  
This chapter therefore aimed to uncover whether primary MSC are sensitised to 
chemotherapy-induced genotoxicity by leukaemic cells, while leukaemic cells are 
themselves protected by MSC (see 4.2). Primary leukaemic cells/HSC do not survive 
for long in vitro, without the support of a stromal feeder layer (Saleh et al., 2015); 
leukaemic cell lines do not require such support (Katt et al., 2016). For this reason 
and with MSC as the variable of focus, patient MSC were co-cultured with the HL-60 
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cell line using a trans-well model optimised in chapter 3. MSC did significantly protect 
HL-60 leukaemic cells from genotoxicity, as shown by MN incidence % change 
between cells cultured alone and in co-culture (Figure 4.15.C). A trend of increased 
MN incidence was seen in MSC treated with ara-C and co-cultured with HL-60, 
however this trend, nor for HL-60 with MSC, was not significantly significant due to 
high inter-experiment variation (Figure 4.15.A/B). Ara-C had greater effect on HL-60 
genotoxicity, supported by evidence that MSC are more resistant to chemotherapy 
(Bellagamba et al., 2016). These finding support those in chapter 3, whereby HS-5 
protected HL-60 and K562 from ara-C MN incidence, while these leukaemic cells 
increased HS-5 genotoxicity, however with greater significance due to lower 
heterogeneity in cell line co-cultures. 
The protective effect on HL-60 was most pronounced by MSC from patients found 
not to have a HM, followed by untreated HM patients (Figure 4.16.A). In MSC co-
cultured with HL-60, the greatest median % increase from alone to co-culture was in 
MSC from those with a HM at diagnosis (Figure 4.16.B). The ‘no HM’ group however 
contains only two patients in this pilot study, therefore more work in larger cohorts 
would be required to confirm this effect. 
Genotoxicity, measured in the comet assay, was decreased in HL-60 following co-
culture with MSC (Figure 4.17.A), conferring with previously seen trends in cell line 
co-cultures (Figure 3.8). A high level of variation was also seen in these cells. When 
considering % change between cells alone and in co-culture, both when untreated 
and untreated, the median tail intensity decreased following co-culture (Figure 
4.17.E), however, again without statistical significance. Work by Andrews et al., 
(2014) demonstrated the protective effects of BM-MSC on U266 (myeloma cell line) 
to melphalan-induced genotoxicity, however with a bystander effect by previously 
treated MSC on untreated U266. Somaiah et al. (2018) also showed that pre-treated 
MSC prevented efficacy of ara-C, DNR and vincristine in HL-60 cells as compared to 
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previously untreated MSC, further suggesting that damaged MSC communicate in a 
different manner. 
MSC previously co-cultured with HL-60 in this study were found to have increased tail 
intensities following co-culture when untreated (Figure 4.17.B). Interestingly, median 
% change was found to be 0% in untreated MSC between culture conditions, whereas 
co-culture in ara-C treated cells showed a significant increase in comet tail intensity 
in MSC following co-culture with HL-60 cells. This again confirms changes seen in 
cell lines (Figure 3.8.B), where a significant increase in tail intensity was also seen in 
treated HS-5 following co-culture with HL-60 or K562 (Figure 3.8.D). This suggests 
that the leukaemia-mediated survival disadvantage in MSC is induced by treatment, 
also demonstrated by Zhang et al. (2014) when investigating the effects of genotoxic 
agents in ALL. In direct co-cultures of BM-MSC with an ALL cell line, when exposed 
to etoposide and idarubicin, MSC protected ALL cells from apoptosis, increased S-
phase and decreased G2/M-phase ratios, with evidence supporting Erk and Wnt/β-
catenin pathways and down-regulation of p21. This effect was not replicated in 
untreated co-cultures (Zhang et al., 2014). 
Heterogeneity in MSC is again highlighted in this study, both in chemosensitivity of 
cells themselves and in their effect on leukaemic cells. This also brings to light a 
limitation of this data, in that there is also variation in HL-60 genotoxicity for ara-C 
when cultured alone, despite efforts for experimental consistency. HL-60 were used 
at a similar passage number, though this was not always possible due to experiments 
occurring over a number of months. These comet assay results, alongside 
measurements of MN, provide evidence for accepting the hypothesis of this chapter; 
that primary MSC are sensitised to chemotherapy-induced genotoxicity by leukaemic 
cells while leukaemic cells themselves are protected by primary MSC.  
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Previous studies have shown that MSC are functionally damaged by 
chemotherapeutic treatment. One study investigated the functional injury of alkylating 
agents on BM-MSC (Kemp et al., 2011). Their data showed that MSC had reduced 
expansion capacity and aberrant CD44 expression in treated MSC; 
cyclophosphamide treatment reduced CD44 expression in MSC by 30%. Damaged 
MSC were also less equipped to support HSC, both in their growth and migration 
capacity (Kemp et al., 2011). Because MSC in previously treated patients are 
functionally damaged, they may themselves benefit from healthy MSC from 
allogeneic sources to aid their repair (Kemp et al., 2011). 
This thesis shows for the first time that genotoxicity is bidirectionally modulated in co-
culture of leukaemic and BM stromal cells. These findings could provide a basis for 
future research to understand how current or novel therapies can be adapted in such 
a way that reduces the genotoxic damage to the BM. This is a meaningful issue 
clinically, as secondary malignancies are a prominent issue in the haematological 
setting (Shimoni et al., 2013; Ringdén et al., 2014; Delage et al., 2015). Additionally, 
failure of the BM, particularly after SCT, can have catastrophic survival impacts for 
patients with AML (Goulard et al., 2018); a disease with already abysmal survival. 
The protective effect of MSC on malignant cells is recognised in the field (Konopleva 
et al., 2002; Ciciarello et al., 2019; Fathi et al., 2019), with studies in recent years also 
correlating these interactions to patient outcome (Macanas-Pirard et al., 2017a; Diaz 
de la Guardia et al., 2017). Macanas-Pirard et al. (2017) for example showed that 
patients whose BM-MSC CM had a chemoprotective effect on a leukaemic cell line in 
vitro showed reduced overall survival in their own disease. Extending from previous 
work in cell line co-cultures in chapter 3 and genotoxicity assessments in this chapter, 
ara-C cytotoxicity was also investigated in MSC-HL-60 co-cultures. Ara-C induced 
greater cytotoxicity in HL-60 than MSC, both when in alone and co-culture conditions, 
conferring with knowledge in the literature that MSC are more resistant to 
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chemotherapy (Bellagamba et al., 2016). Co-culture with MSC overall improved the 
mean viability of HL-60 cells, however, without statistical significance, and only in ara-
C treated cells. Mean MSC viability was not affected by ara-C or by co-culture with 
HL-60 (Figure 4.19). These findings were confirmed by cell viability experiments 
based on ATP production (see Appendix). Another study also showed MSC 
proliferation from three healthy donors to be minimally affected by co-culture with 18 
primary AML cells in trans-well co-culture (Reikvam et al., 2015), conferring with these 
findings. Co-culture with HS-5 protected HL-60 and K562 cells in the previous chapter 
of this study, in addition to significant reductions in HS-5 viability following exposure 
to the leukaemic cell lines and ara-C treatment (Figure 3.10). The effects on 
chemosensitivity, both genotoxicity and cytotoxicity, were more pronounced in cell 
line experiments, also showing that HS-5 are more chemosensitive to ara-C and HM 
signals than primary MSC. A review by Fathi et al. (2019) also clearly highlights the 
variety of findings from studies of MSC on malignant growth in HMs, presenting 
evidence of MSC both promoting and inhibiting leukaemic cell growth. Taken as a 
whole, these studies contribute to the knowledge that interactions in the tumour 
microenvironment are widely heterogeneous, with a continued need for further 
studies. 
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4.5  CHAPTER SUMMARY 
Research question one (section 4.2) of this chapter aimed to investigate how patient 
characteristics affect the behaviour of BM-MSC. This work shows that MSC from 
previously chemotherapy treated patients have poorer in vitro survival, particularly in 
myeloma, parallel to increased genotoxicity in these non-expanding cultures. BM 
cultures have slower growth with increasing patient age, with additional age effects 
demonstrated by increased differentiation capacity in one young patient. 
Heterogeneity of BM cultures was evident for MSC morphology and growth. MSC 
protected leukaemic HL-60 from ara-C-induced genotoxicity, in contrast to increased 
genotoxicity in MSC with leukaemic influence. The findings of altered genotoxicity are 
not documented elsewhere in the literature, despite the impact of lasting genotoxic 
damage in surviving patients. This altered chemosensitivity was more profound in cell 
lines, however, the heterogeneity of patient experiments reflects the clinical and 
biological heterogeneity which makes the management of HM particularly 
challenging. This work provides a basis for future research to investigate the 
mechanisms of such bidirectional effects.
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Chapter 5 - PROTEIN EXPRESSION MEDIATED BY LEUKAEMIC-
STROMAL INTERACTIONS IN CO-CULTURE AS MECHANISMS OF 
ALTERED CHEMOSENSITIVITY 
5.1  INTRODUCTION 
The findings of the previous chapters showed that leukaemic cells are protected from 
ara-C toxicity, when in communication with BM stromal cells, while stromal cells are 
themselves sensitised to ara-C. This altered chemosensitivity – both cytotoxicity and 
genotoxicity – was seen for both cell line co-cultures (chapter 3), and co-cultures of 
HL-60 with primary patient MSC (chapter 4). It is evident then, that the crosstalk 
between these cells in the co-culture model initiates altered ara-C chemosensitivity. 
The cytotoxic effects of ara-C are reliant on intracellular activation by 
triphosphorylation (Figure 1.3), thus chemoresistance may be initiated by anything 
which reduces intracellular ara-CTP concentration (Galmarini et al., 2002; Levin et 
al., 2019). This includes reduced ara-C influx by hENT1, reduced phosphorylation by 
dCK, dCMPK or NDK, increased degradation enzymes (e.g. 5’-nucleotidase and 
cytidine deaminase), increased DNA polymerase α and reduced topoisomerase I/II 
(Galmarini et al., 2002; Kulsoom et al., 2018). In particular, deficiency of hENT1 – 
responsible for 80% of ara-C uptake (Sundaram et al., 2001) – has been correlated 
to an early relapse (Galmarini et al., 2002) and ara-C resistance (Hubeek et al., 2005; 
Kulsoom et al., 2018). Interestingly, FLT3-ITD (associated with poor prognosis due to 
chemoresistance) induces leukaemic ara-C resistance by suppression of ENT1, 
which is in part due to altered regulation of hypoxia; induction of HIF-1α reduced the 
activity of ENT1 in K562 (Jin et al., 2009). It has also been shown that hENT1 activity 
and expression are reduced in primary AML and leukaemic cell lines following murine 
stromal (Macanas-Pirard et al., 2012) and HS-5 (Macanas-Pirard et al., 2017a) CM 
exposure; with expression at the cell surface disappearing after 2 hours (Macanas-
Pirard et al., 2017a). There remains the question of how bidirectional leukaemia-
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stroma interactions affect hENT1 expression in both cell types, as these studies by 
Macanas-Pirard et al. only investigated the effect of the stromal secretome on 
leukaemic cells unidirectionally. 
The BMM secretome contains a spectrum of factors, including growth factors, 
adhesion molecules and cytokines (Kumar et al., 2019), which together provide the 
ideal environment for haematopoiesis to take place, for example by secretion of 
CXCL12 (Kornblau et al., 2018), and malignant cell survival by facilitation of LSC 
dormancy (Eltoukhy et al., 2018). Cells not in close proximity communicate by 
extracellular secretions, including extracellular vesicles (such as exosomes and 
microvesicles) (Nehrbas et al., 2020), chemokines, cytokines and metabolites 
(Lindoso et al., 2016; Kornblau et al., 2018; Eltoukhy et al., 2018). Despite the known 
important role of MSC extracellular vesicles in the support of HSC (Xie et al., 2016) 
and AML chemoresistance (Huan et al., 2013; Viola et al., 2016), Macanas-Pirard et 
al. (2017a) showed that chemoprotection of leukaemic cells by stromal media is 
mediated by factors in the soluble fraction (e.g. cytokines, growth factors and 
chemokines), and not by microvesicles or exosomes. Cytokines were hence 
investigated in this experimental work. 
Leukaemic cells are known to have aberrant signalling in comparison to healthy 
haematopoietic cells (Bruserud et al., 2007; Islam et al., 2017; Brenner et al., 2017; 
Hoff et al., 2018), with research efforts uncovering a number of cytokines aberrantly 
secreted through interactions in the BMM (Civini et al., 2013; Reikvam et al., 2015; 
Ladikou et al., 2020). A key axis involved CXCR4-CXCL12; CXCR4 is elevated in 
leukaemic cells, leading to increased crosstalk with stromal cells which express 
CXCL12 on their surface (Tabe and Konopleva, 2014). Targeted therapies have been 
developed to interrupt these leukaemia-stromal interactions; plerixafor is an effective 
partial-antagonist of CXCR4-CXCL12, and has had some success in leukaemia 
management (Uy et al., 2015). One study showed that 28 of 151 proteins were 
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differentially expressed by MSC from AML patients as compared to normal MSC, 
which could be grouped by biological properties affecting clinical outcomes and 
attributed to cytogenetic risk (Kornblau et al., 2018). Overexpression of the pro-
inflammatory cytokine IL-8 has been implicated in AML, with one study demonstrating 
that IL-8 is increased in AML cells and further induced by hypoxia, promotes MSC 
migration and is correlated to prognostically unfavourable FLT3-ITD (Kuett et al., 
2015). Abdul-Aziz et al. (2017) further revealed IL-8 to be increased in the media of 
BM-MSC from AML patients directly co-cultured with AML blasts, in addition to fold-
increases in IL-6, leukaemia inhibitory factor and macrophage migration inhibitory 
factor (MIF), among others. Secretion of MIF was linked to PKCβ signalling in MSC 
and the induction of IL-8 secretion for AML benefit (Abdul-Aziz et al., 2017). 
Despite improved understanding of AML signalling and targeted therapy development 
in recent years (Kayser and Levis, 2018), continued poor clinical outcomes highlight 
disease heterogeneity and the need for further research (Ladikou et al., 2020). 
 
5.1.1  Chapter Aims 
Leukaemic and stromal cells are shown to be altered in disease; evidenced in the 
literature and by previous findings in this study. Leukaemic and stromal cells co-
cultured in this study did not come into direct cell-cell contact, and therefore this is 
not required for therapy avoidance. Though research in this area is ever increasing 
and some mechanisms have been identified, still not enough is known about how 
these cells interact, especially because of patient heterogeneity. Additionally, the use 
of multiple models for the leukaemic microenvironment means that findings must be 
acknowledged across these platforms. This chapter therefore aimed to identify some 
of the mechanisms of altered chemosensitivity mediated by leukaemic-stromal 
protein interactions.  
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5.2  RESEARCH QUESTIONS  
The findings from previous chapters and the research scoping in this area have 
founded the following research questions for investigations in this chapter: 
 Is hENT1 differentially expressed by leukaemic and stromal cells following co-
culture and ara-C treatment? 
 Does leukaemic-stromal co-culture in the utilised model result in the 
differential secretion of cytokines? 
 Are differentially expressed cytokines responsible for altered chemosensitivity 
in leukaemic and stromal cells? 
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5.3  RESULTS 
5.3.1  Effects of Co-Culture on hENT1 Expression 
5.3.1.1  Leukaemic-Stromal Co-Culture or Ara-C Treatment Does Not Affect 
Total hENT1 Expression 
As a potential mechanism for altered chemosensitivity following co-culture, as seen 
in previous chapters of this study, the expression of hENT1 protein was investigated 
(Figure 5.1). In HL-60 cells, hENT1 expression was visibly increased following ara-C 
treatment, which then decreased when cells were co-cultured with HS-5, as shown 
by example western blot images (Figure 5.1.A). Densitometry of triplicate blots 
showed a trend of decrease in hENT1 expression in treated HL-60 cells by 9.02% 
following co-culture with HS-5, however, without statistical significance (P > 0.05; 
Figure 5.1.C). In HS-5 cells, hENT1 expression visibly decreased following ara-C 
treatment (Figure 5.1.B), with a further reduction of 57.71% as per densitometry 
following co-culture with HL-60 cells (P > 0.05). In all cells, hENT1 was expressed at 
~ 95 kDa, with some expression also seen below 72 kDa and above 140 kDa in HL-
60 cells.  
 
5.3.1.2  Leukaemic-Stromal Co-Culture or Ara-C Treatment Does Not Affect 
hENT1 Expression in Subcellular Fractions 
Expression of hENT1 was also investigated in ara-C-treated co-cultured cells in 
subcellular fractions to determine changes in expression location (Figure 5.2). hENT1 
was expressed in the cytoplasmic and soluble nuclear fractions in HL-60 cells (Figure 
5.2.A) and cytoplasmic fraction in HS-5 (Figure 5.2.B). Like expression in total lysates 
(section 5.3.1.1), hENT1 was shown to express most strongly above 95 kDa, as well 
as below 72 kDa in both HL-60 and HS-5. No notable changes in hENT1 expression 
were seen when comparing cells cultured alone or in co-culture in each subcellular 
fraction (Figure 5.2). Appropriate controls were also analysed for each subcellular 
fraction, showing some crossover between fractions (see Appendix).  
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Figure 5.1. hENT1 expression in HL-60 and HS-5 cells following co-culture and 
ara-C treatment. HL-60 and HS-5 cells were cultured alone or in co-culture for 24 h 
and untreated or treated with ara-C (25 µM) for 1 h. Total lysates (5 µg) were prepared 
and ran by SDS-PAGE in 12% acrylamide gels. Proteins were transferred to a PVDF 
blotting membrane overnight, prior to incubation in Anti-ENT1 overnight and Goat 
Anti-Rabbit HRP secondary for 1 h. Membranes were stripped and reprobed with Anti-
β-actin overnight and Goat Anti-Mouse HRP secondary for 1 h. Images were obtained 
by chemiluminescent detection (LI-COR), examples of which are shown for HL-60 (A) 
and HS-5 (B) co-cultures. Dashed lines denote where images were stitched for the 
correct group order. Densitometry was performed by Image J software for HL-60 (C) 
and HS-5 (D) co-cultures. Bars represent mean (+ SD) hENT1 expression normalised 
to the control. n = 3 independent co-cultures. 
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Figure 5.2. hENT1 expression in HL-60 and HS-5 cell subcellular fractions in 
ara-C treated co-cultures. HL-60 and HS-5 cells were cultured alone or in co-culture 
for 24 h and treated with ara-C (25 µM) for 1 h. Subcellular Protein Fractionation 
(Thermo-Scientific) was performed and ran by SDS-PAGE in 12% acrylamide gels (4 
µg cytoplasmic/membrane; 1 µg soluble nuclear/chromatin bound (CB)/cytoskeletal). 
Proteins were transferred to a PVDF blotting membrane overnight, prior to incubation 
in Anti-ENT1 overnight and Goat Anti-Rabbit HRP secondary for 1 h. Membranes 
were stripped and reprobed for appropriate fraction controls. Images were obtained 
by chemiluminescent detection (LI-COR), examples of which are shown for HL-60 (A) 
and HS-5 (B) co-cultures. Dashed lines denote where images were stitched for the 
correct group order. Densitometry was performed by Image J software for HL-60 (C) 
and HS-5 (D) co-cultures. n = 1 independent co-culture. 
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5.3.2  Effects of Co-Culture on Differential Cytokine Secretion 
5.3.2.1  Cells Differentially Secrete Cytokines in Leukaemic-Stromal Co-
Cultures 
This work also set out to investigate differential cytokine secretion of leukaemic-
stromal co-cultures, utilising a cytokine array (Methods 2.9.1). Representative array 
membranes following fluorescence imaging can be seen in Appendix, with green 
fluorescence proportional to target analyte binding. The co-culture model used 
throughout this study was modified to maintain media volume between alone and co-
culture wells, as opposed to cells/mL, for direct group comparison. 
Of the 36 cytokines analysed (Appendix), seven significantly differentially expressed 
in media from co-cultured cells comparative to the combined values in media from 
mono-cultured cells (Figure 5.3). For the cytokines CCL2 and GM-CSF (Figure 5.3.A 
and D), co-culture of both HL-60 and K562 with HS-5 produced a significant increase 
in secretion (P = 0.0273; < 0.0001). An increase in co-culture was also found for IL-6 
with HL-60 co-cultures only (P < 0.0001; Figure 5.3.E). Significant decreases were, 
however, noted in both HL-60 and K562 co-cultures with HS-5 for G-CSF (P < 
0.0001), MIF (P < 0.0001) and Serpin E1 (P < 0.0001; Figure 5.3.C/F/G), and in 
CXCL1 for K562 co-cultures only (P < 0.0001; Figure 5.3.B). The function and clinical 
relevance of these differentially expressed cytokines is noted in Table 5.1. Of these 
seven cytokines, expressions for CCL2 and IL-6 were concordant with that found in 
the literature in similar disease states. 
The relative intensity of MIF significantly decreased in co-culture as compared to HS-
5, HL-60 and K562 cells cultured alone (P < 0.0001; Figure 5.3.F). This decrease was 
higher with HL-60 than K562; a reduction of 6.67 and 3.68% respectively. MIF was 
followed up in further experiments as it was significantly differentially expressed, had 
equal involvement of leukaemic/stromal secretion and has been implicated, yet poorly 
studied, in the progression of leukaemia and other malignancies (Table 5.1). 
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Figure 5.3. Differential cytokine secretion by HL-60 or K562 and HS-5 cells 
following co-culture and ara-C treatment. Cells were co-cultured for 24 h prior to 
treatment with ara-C. Media was then collected from cells cultured alone or in co-
culture and analysed by cytokine array. Bars represent mean cytokine secretion, 
relative to positive control spots (+/− SD), as measured by fluorescence imaging. Grey 
bars represent secretion from HS-5 cells cultured alone, stacked with secretion from 
HL-60/K562 cells cultured alone (combined); dark coloured bars represent secretion 
from cells in co-culture. A) CCL2, B) CXCL1, C) G-CSF, D) GM-CSF, E) IL-6, F) MIF 
and G) Serpin E1. n = 2 co-culture/HS-5 alone, n = 1 K562/HL-60 alone. * = P < 0.05; 
**** = P < 0.0001. 
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5.3.2.2  MIF Is Differentially Secreted in Leukaemic-Stromal Cell Line Co-
Cultures 
As confirmation of the cytokine array and quantification of MIF secretion, an ELISA 
was utilised (see Methods 2.9.2). MIF concentration was confirmed to decrease when 
cells were co-cultured compared to the combined levels in the media of cells cultured 
alone (Figure 5.4.A). MIF concentration in HL-60 co-culture was significantly reduced 
(P = 0.0077), while only trends were seen for K562 co-culture (P > 0.05).  
To investigate the effects of ara-C treatment on MIF secretion, supernatant from 
untreated co-cultures was also analysed. MIF concentration also decreased when 
cells were co-cultured as compared to cells cultured alone (Figure 5.4.B). A significant 
decrease was found only with K562 co-culture (P = 0.0157), a decrease of 38.17%; 
the 33.29% decrease in HL-60 co-culture was above the significance threshold (P > 
0.05). MIF concentration was similar from HS-5 cells cultured alone, both with and 
without ara-C treatment. K562 and HL-60 cells alone, however, secreted more MIF 
when untreated than when treated (Figure 5.4). 
To track changes in MIF secretion over time following treatment, HL-60 and HS-5 
cells were returned to culture in fresh media following appropriate co-culture 
conditions and ara-C treatment. MIF concentration was determined at 4, 8, 16 and 24 
hours post-treatment/co-culture (Figure 5.4.C). MIF was below the detectable limit up 
to 8 hours with the exclusion of HS-5 cells alone, which secreted 47.61 pg/mL; 
comparable to that immediately following treatment (Figure 5.4.A). A similar trend was 
seen at the 16- and 24-hour post-treatment timepoints, where MIF secretion was 
significantly decreased (P < 0.0001) when cells were co-cultured rather than cells 
cultured alone, with peak secretion 16 hours post-treatment and co-culture (Figure 
5.4.C). 
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Figure 5.4. MIF secretion by HL-60 or K562 and HS-5 cells following co-culture 
and treatment with ara-C. HL-60 or K562 cells were cultured alone or in co-culture 
with HS-5 cells for 24 h. Cells were treated with ara-C (25 µM) for 1 hour (A) or 
untreated (B), or treated with ara-C and returned to culture in fresh media for the given 
timepoints (C). Media was collected and MIF concentration determined by ELISA. 
Bars represent mean MIF concentration (+/− SD) of three independent experiments 
performed in duplicate (n = 3 in duplicate). * = P < 0.05; ** = P < 0.01; **** = P < 
0.0001. 
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In order to decipher the extent for which each cell was responsible for the decrease 
in MIF secretion in co-culture, cells were separated following co-culture and allowed 
to grow in fresh media for a further 24 hours (Figure 5.5). HL-60 cells showed higher 
MIF secretion following treatment and separation for 24 hours, as compared to media 
collected immediately following treatment (Figure 5.5.A and Figure 5.4.A). HL-60 cells 
previously co-cultured with HS-5 had lower MIF concentrations than HL-60 cells 
treated alone (Figure 5.5.A), yet higher concentrations than co-culture media 
immediately following treatment (Figure 5.4.A). MIF concentration was significantly 
depleted in K562 cells alone following culture for the further 24 hours; 21.63 pg/mL 
as compared with 47.95 pg/mL immediately following 1 hour treatment (Figure 5.4). 
K562 cells that had previously been co-cultured with HS-5 secreted significantly more 
MIF than K562 cells previously cultured alone (P = 0.0005), an increase of 88.96 
pg/mL (Figure 5.5.B). No significant difference was found between HS-5 cells cultured 
alone or following HL-60 or K562 co-culture (P > 0.05). HS-5 alone secretion was, 
however, more than double the original secretion immediately following treatment 
(Figure 5.4.A; 93.21 and 45.26 pg/mL respectively). 
 
5.3.2.3  MIF Is Differentially Secreted in Co-Cultures of Patient MSC and 
Leukaemic Cell Line 
The secretion of MIF was also investigated in media from co-cultures of HL-60 cells 
with patient MSC utilised in chapter 4 (Figure 5.6). Both HL-60 and patient MSC 
showed secretion of MIF in 17 of 22 co-culture experiments (Figure 5.6.A). The MIF 
concentration in media had large variation across all co-cultures, ranging from 386.20 
pg/mL in the combined values of HL-60 cells and MSC from patient 023, to below the 
detection threshold in experiments with patients 004, 012 and 007. All co-cultures 
showed a decrease in MIF concentration following co-culture and treatment with ara-
C, which was shown to be statistically significant in co-cultures with patients 023 (P < 
0.0001), 020 (P < 0.0001), 009 (P = 0.0128) and 016 (P = 0.0018). 
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Figure 5.5. MIF secretion by HL-60 or K562 and HS-5 cells separated post-co-
culture and treatment with ara-C. HL-60 or K562 cells were cultured alone or in co-
culture with HS-5 cells for 24 h. Cells were treated for 1 h with 25 µM ara-C, then 
separated for culture for a further 24 h. Media was then collected and MIF 
concentration determined by ELISA. A) HL-60-HS-5 co-cultures, B) K562-HS-5 co-
cultures. Bars represent mean MIF concentration (+ SD) of three independent 
experiments performed in duplicate. n = 3 in duplicate. * = P < 0.05; *** = P < 0.001. 
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MIF concentration was confirmed as significantly reduced following co-culture across 
all groups (P = 0.0005), with a mean reduction of 95.78 pg/mL from alone to co-culture 
(Figure 5.6.B). To account for such variation, the % decrease in MIF secretion was 
calculated for all co-cultures, and demonstrated a significant decrease in MIF 
secretion (P < 0.0001), with a mean reduction of 52.68% (Figure 5.6.C). Additionally, 
the % decrease in MIF was significantly reduced by co-culture of HL-60 with MSC 
from treated patients with a HM than untreated patients (P = 0.0458; Figure 5.6.D). 
 
5.3.3  Effects of MIF on Chemosensitivity 
5.3.3.1  MIF Treatment or Inhibition Does Not Affect Ara-C Cytotoxicity 
As the differential secretion of MIF was previously confirmed (section 5.3.2), 
experiments were performed in order to identify a potential effect on chemosensitivity. 
Cells were pre-treated with the MIF antagonist, ISO-1, or cultured in recombinant 
human (rh)MIF, followed by treatment with ara-C. Initial experiments to determine the 
baseline effects and rule out any reagent toxicity of MIF spike or inhibition revealed 
no difference between cells treated with rhMIF, ISO-1 or untreated cells at either 24 
(P > 0.05) (data not shown) or 48 hours (P > 0.05) (Appendix). 
Ara-C chemosensitivity was assessed following treatment with rhMIF or ISO-1 in HL-
60, K562 and HS-5 cells (Figure 5.7). In all cells, survival decreased following ara-C 
treatment, however, no significant difference in cell survival was seen following rhMIF 
pre-treatment (P > 0.05; Figure 5.7). Inhibition of MIF by ISO-1 pre-treatment did not 
alter chemosensitivity (Figure 5.7). Ara-C toxicity in HL-60, K562 and HS-5 pre-
treated with ISO-1 was consistent with the vehicle control (P > 0.05; Figure 5.7). 
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Figure 5.6. MIF secretion by HL-60 and patient MSC following co-culture and 
ara-C treatment. HL-60 and patient MSC were cultured alone or in co-culture for 24 
h, treated with ara-C for 1 h (25 µM) and media collected for MIF quantification by 
ELISA. A) Mean MIF concentration (+ SD) of HL-60 and MSC cultured alone (stacked) 
and in co-culture, n = 22. B) Box and whisker plots with 5–95 percentile with outliers, 
the median (line) and mean (cross) for MIF concentration from cells cultured alone 
and co-culture, n = 22. C) Box and whisker plots with 5–95 percentile for percentage 
decrease of MIF secretion in co-culture as compared to alone. D) as of C, separated 
by haematological malignancy (HM) group. n = 19; HM untreated n = 14, HM treated 
n = 3, no HM n = 2. * = P < 0.05; ** = P < 0.01; *** = P < 0.001; **** = P < 0.0001. 
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5.3.3.2  MIF Treatment or Inhibition Does Not Affect Ara-C Genotoxicity 
Genotoxicity was preliminarily investigated (n = 1) in K562 and HS-5 cells following 
treatment with rhMIF or ISO-1 and ara-C. K562 genotoxicity was minimally altered, 
as measured by MN incidence (P > 0.05; Figure 5.8.A) and comet tail intensity (P > 
0.05; Figure 5.8.C). In HS-5 cells, tail intensity was also minimally altered by rhMIF 
or ISO-1 treatment (P > 0.05; Figure 5.8.D). The greatest change was denoted by an 
increase of 3.59% MN incidence in HS-5 treated with rhMIF (P > 0.05; Figure 5.8.B). 
 
5.3.4  MIF Interactions and Clinical Expression 
5.3.4.1  MIF Interacts with Proteins of Clinical Relevance 
To enrich the understanding of how MIF interacts with other proteins, it was searched 
in a protein-protein interactions database. Figure 5.9 shows ten proteins with the 
highest interaction score for MIF. Of these, CD74 had the highest score of 0.986. The 
blue edges connecting the protein nodes show that MIF is known to directly bind to 
CD74, while the green arrow shows that STAT4 has been shown to activate MIF 
(score 0.91). 
 
5.3.4.2  MIF mRNA Expression Is Correlated with Clinical Features 
A freely available mRNA database was utilised to investigate any correlations 
between MIF expression and clinical presentation, i.e. cytogenetic code (Figure 5.10). 
Eight of nine patients who had a gain of MIF mRNA expression had complex/poor 
cytogenetics, while one patient with gain was associated with CBFB-MYH11/good 
cytogenetic risk. Amplification was seen in one patient who had PML-RARA/good 
cytogenetic risk. Patients with a shallow deletion were associated with BCR-ABL1 
and Normal Karyotype codes. The majority of patients were, however, diploid for MIF 
with no mutations.  
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Figure 5.7. ATP production of HL-60, K562 and HS-5 cells following ara-C and 
MIF treatment or inhibition. HL-60 (A), K562 (B) or HS-5 (C) cells were pre-treated 
with ISO-1 (10 µM) for 5 minutes or incubated in rhMIF protein (100 ng/mL), as well 
as treated with 25 µM ara-C for 48 h. Cells were analysed alongside appropriate 
controls. ATP production (cell viability) was assessed by the CellTiter-Glo assay. Bars 
represent mean (+ SD) ATP production normalised to the untreated control. (n = 3 in 
triplicate). ***P < 0.0005; ****P < 0.0001. 
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Figure 5.8. Genotoxic effects in K562 and HS-5 cells following ara-C and MIF 
treatment or inhibition. K562 (A/C) or HS-5 (B/D) cells were pre-treated with ISO-1 
(10 µM) for 5 minutes or incubated in rhMIF protein (100 ng/mL), as well as treated 
with 25 µM ara-C for 48 h. Cells were analysed alongside appropriate controls for 
micronucleus incidence (A/B) and comet tail intensity (C/D). Micronucleus assay bars 
represent mean nuclear abnormalities as a percentage of total scored cells. n = 1, 
with > 2,000 cells scored per group. Comet assay bars represent the 5–95 percentile 
with outliers, the median (line) and mean (cross). n = 1, with > 200 comets scored per 
group. 
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Figure 5.9. Known protein interactions of MIF. MIF was searched in the STRING 
protein-protein interactions database (STRING 11.0; https://string-db.org). Nodes 
represent proteins with their known or predicted 3D structure within. Edges represent 
protein-protein associations (grey and blue lines). Blue edges are known to have 
binding action, for example, MIF is known to bind to the cell surface protein CD74. 
Green arrow represents activation, for example, STAT4 activates MIF. Parentheses 
denote interaction score to MIF. 
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Figure 5.10. MIF mRNA expression with cytogenetic code in an AML cohort. MIF 
mRNA expression was correlated against the cytogenetic code. The cBioPortal 
database (http://www.cbioportal.org) was utilised, n = 173 AML patients. Circle 
symbols represent z-score for MIF mRNA expression for each patient and their 
defined cytogenetic group, while colours represent MIF status. 
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5.4  DISCUSSION 
The previous chapters in this thesis showed ara-C chemosensitivity to be altered in 
leukaemic-stromal co-cultures; confirmed both in cell lines and with primary patient 
MSC (chapter 3 and 4). These investigated interactions showed effects to occur both 
uni and bidirectionally with indirect contact, indicating communications result from 
secretion of signalling rather than adhesion mechanisms. There is a plethora of 
evidence regarding the release of soluble factors for cell communication in leukaemia 
(Civini et al., 2013; Reikvam et al, 2015; Kornblau et al., 2018; Eltoukhy et al., 2018; 
Nehrbas et al., 2020), however, there is still much to be understood about how some 
patient’s cells evade the toxic effects of chemotherapeutics, especially as ara-C 
remains the primary agent in AML treatment regimens; despite poor efficacy and the 
advent of novel therapies. 
An identified mechanism of chemoresistance in some patients is reduced expression 
of hENT1 (Kulsoom et al., 2018), primarily responsible for intracellular nucleoside 
transport and consequently the nucleoside analogue ara-C (Sundaram et al., 2001). 
One group further investigated the involvement of the BMM on leukaemic cell ENT1-
associated chemoresistance (Macanas-Pirard et al., 2012, 2017a). Stromal CM 
reduced ENT1 activity in APML cells by 50% in a murine model (Macanas-Pirard et 
al., 2012), which was confirmed in human cells with HS-5 CM on THP1/AML blasts 
(Macanas-Pirard et al., 2017a). There was significant hENT1 removal from THP1 cell 
surface within 2 hours of HS-5 CM exposure, but not mRNA/total protein expression 
(Macanas-Pirard et al., 2017a), suggesting post-translational control of ENT1 activity 
at the cell surface. As these studies only investigated ENT1 in the leukaemic 
microenvironment unidirectionally, and in untreated cells, this thesis undertook 
preliminary experiments to determine differential hENT1 expression by both 
leukaemic and stromal cells following co-culture and ara-C treatment (section 5.2). 
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Co-culture reduced hENT1 expression in treated HL-60 and HS-5 cells, with greater 
effects seen in HS-5, as shown by representative western blots (Figure 5.1.A/B; see 
Appendix for all blots). These trends were, however, not statistically significant (P > 
0.05) due to high biological variation in triplicate experiments (Figure 5.1.C). A 
decrease in hENT1 expression may suggest that less ara-C can enter cells to induce 
toxicity, therefore the trend of reduced mean hENT1 in co-cultured HS-5 (P > 0.05) is 
not consistent with previous findings of leukaemic-mediated stromal 
chemosensitisation in Chapter 3 and 4. On the other hand, hENTs are bidirectional 
(Zhang et al., 2007) and so reduced expression may infer reduced ara-C efflux 
capacity. Moreover, inhibition of hENT1 by NBMPR caused ara-C chemoprotection 
in leukaemic cells in one study; confirmed by inhibition of 40–50% hENT1 activity in 
stromal CM (Macanas-Pirard et al., 2017a). hENT1 therefore may be expressed, but 
inhibited, and consequently western blot analyses in this study may not reflect 
biological activity. 
hENT1 was shown to band similarly to the 95 kDa ladder, as well as with low intensity 
~ 140 kDa and < 72 kDa. The predicted hENT1 MW of 50.2 kDa (Huang et al., 2017) 
is thus not consistent with bands seen in this work, however, many studies cite hENT1 
to express at varying weights due to oligomerisation, glycosylation or degradation 
(Jarvis et al., 1980; Cravetchi, 2016; Huang et al., 2017). Efforts to optimise the 
western blotting method (Methods 2.8) consistently expressed hENT1 ~ 100 kDa 
(perhaps reflecting dimers) including use of the reducing agent DTT in place of β-
mercaptoethanol, a range of denaturing temperatures/urea and the detergent Triton 
X-100 for cell lysis (data not shown). However, antibody specificity was confirmed by 
a reduction in hENT1 expression when the anti-ENT1 antibody was blocked by pre-
incubation with pure ENT1 protein (Appendix). 
Furthermore, total hENT1 expression may not reflect functional levels at cellular 
membranes, therefore preliminary work aimed to investigate the effect of co-culture 
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and ara-C treatment on hENT1 expression in subcellular fractions. No visible 
difference was seen between hENT1 bands in HL-60 (Figure 5.2.A) or HS-5 (Figure 
5.2.B) when in co-culture. Interestingly these bands were present with highest 
intensity in the cytoplasmic and soluble-nuclear fractions (Figure 5.2), despite hENT1 
being a characterised cellular membrane protein (Sundaram et al., 2001; Zhang et 
al., 2007), however, with known localisation in mitochondria, nuclear envelopes and 
the endoplasmic reticulum (Zhang et al., 2007). Subcellular fraction controls 
(Appendix) showed greatest contamination of NaKATPase (membrane), which may 
account for lack of membrane hENT1 expression in this experiment. Additionally, AIF 
(soluble nuclear) was only shown in HL-60, with contamination in membrane 
fractions, while vimentin (cytoskeletal) was shown only in HS-5, with contamination in 
all but chromatin-bound nuclear fractions (Appendix). Future work is required to 
determine the effects of co-culture on hENT1 expression, particularly using patient 
cells. Due to limited availability of primary material and low MSC numbers for co-
culture experiments, it was not possible to obtain reliable results for western blot 
analyses of hENT1 expression. As other experiments were prioritised in this work, 
further research using patient MSC in co-cultures with leukaemic cells could be 
possible with hENT1 expression as the main research focus. 
Another research question addressed whether leukaemic-stromal co-cultures in the 
utilised model result in the differential secretion of cytokines. To do so, a cytokine 
array was utilised and later confirmed by ELISA. Of 36 proteins detected by the array, 
seven were significantly differentially secreted by cells in co-culture, as compared 
with the combined secretion of each cell type cultured alone (Figure 5.3). A significant 
decrease in expression with co-culture was seen for CXCL1, G-CSF, MIF and Serpin 
E1. Increased expression with co-culture was, however, seen for CCL2, GM-CSF and 
IL-6. Interestingly, G-CSF can inhibit CXCR4 signalling (Sheng et al., 2016), therefore 
a reduction could increase leukaemic chemoprotection by mobilisation away from the 
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BMM. Other associated literature is summarised in Table 5.1, with CCL2 and IL-6 
secretion consistent with that documented for the AML BMM. Many studies have been 
conducted on the leukaemia secretome, with the findings of this study contributing to 
understanding how the BMM is altered in leukaemia. Research in this area is 
challenged by vast heterogeneity, as highlighted throughout this thesis. AML cells are 
heterogeneous for their responsiveness to cytokine signals and release of such 
signals, with increased proliferation by IL-3, GM-CSF and SCF in some subsets of 
patients but not others (Bruserud et al., 2007), for example. 
While the relative expression of proteins was primarily attributed to stromal cells, MIF 
was the only cytokine which showed equivalent secretion by leukaemic cells as by 
stromal cells (Figure 5.3). MIF is a multifunctional cytokine, first classified as an 
inhibitor of random macrophage migration (Bloom and Shevach, 1975). MIF is 
overexpressed in a number of cancer types, including colorectal (Wilson et al., 2005), 
breast (Bando et al., 2002), prostate (Meyer-Siegler et al., 2006) and more recently 
MDS/AML (Falantes et al., 2015), with overexpression implicated in poor response 
(Pei et al., 2014; Falantes et al., 2015; Wang et al., 2018). Conversely, low MIF levels 
have also been correlated with poor prognosis in other cancers (del Vecchio et al., 
2000; Suzuki et al., 2005). Despite evident controversy regarding role, a monoclonal 
MIF inhibitor imalumab is currently in early-phase clinical trials for solid tumours 
(Mahalingam et al., 2020). 
One group investigated the involvement of MIF in AML specifically, showing MIF to 
be highly expressed in AML blasts by cytokine array (Abdul-Aziz et al., 2017, 2018). 
IL-8, but not MIF, was shown to be consistently elevated in direct contact co-cultures 
of AML cells with BM-MSC from AML patients using ELISA (Abdul-Aziz et al., 2017). 
Treatment of cells with rhMIF increased the expression of IL-8 in MSC, which was 
shown to be mediated through CD74 (Abdul-Aziz et al., 2017); a known MIF activation 
receptor (Bernhagen et al., 2007; Jankauskas et al., 2019; Figure 5.9). MIF binds to 
 CHAPTER 5 – PROTEIN MECHANISMS OF ALTERED CHEMOSENSITIVITY 
184 
the extracellular domain of CD74, forming a complex with CXCR2/4 which recruits 
CD44 for signalling (Bernhagen et al., 2007). Interestingly, MIF recruits CXCR4-
expressing leukocytes (Bernhagen et al., 2007), thus may also be implicated in 
homing of HSC/leukaemic cells – also expressing CXCR4 (Burger and Bürkle, 2007). 
Additionally, chemotherapy treatment has been shown to reduce adhesion-critical 
CD44 expression in MSC (Kemp et al., 2010). Another study demonstrated 
upregulation of IL-8 and IL-6 in a co-culture model of the ALL microenvironment 
(Vernot et al., 2017). They also used a cytokine array to identify changes in cytokine 
secretion in their model, which interestingly aimed to replicate the leukaemic niche by 
pre-incubation of BM-MSC with primary paediatric ALL cells or the REH (ALL) cell 
line, followed by functional analysis of HSPC added to co-culture (Vernot et al., 2017). 
This model style could be adapted in future work to characterise the supportive 
capacity for MSC following influence of leukaemic cells.  
The cytokine array combines the membrane imaging technology of western blot with 
the sandwich antibody procedure of ELISA, making it a sensitive, rapid and cost-
effective method for measuring multiple cytokines in a single experiment. It, however, 
identifies relative analyte levels, therefore ELISA was performed to both confirm and 
quantify array results. MIF concentration was confirmed as significantly decreased in 
HL-60-HS-5 co-cultures following ara-C treatment (Figure 5.4.A), as in K562-HS-5 
co-cultures when untreated (Figure 5.4.B). Though there was a minimal change in 
HS-5 secretion with ara-C treatment, HL-60 and K562 appeared to secrete less MIF 
when treated (Figure 5.4), demonstrating an ara-C effect, which was not investigated 
by the Abdul-Aziz group.  
Supernatant analyses provide a ‘snapshot’ of cell secretomes, therefore MIF 
secretion was investigated in co-cultures at four timepoints post-treatment (Figure 
5.4.C). HS-5 and HL-60 peaked at 16 hours, and with a significant decrease in MIF 
following co-culture at both 16 and 24 hours, consistent with trends seen immediately 
 CHAPTER 5 – PROTEIN MECHANISMS OF ALTERED CHEMOSENSITIVITY 
 
   185 
post-co-culture and ara-C (Figure 5.4). At 8 hours post-treatment, only HS-5 cells 
alone showed detectable levels of MIF (ELISA detection limit 8.23 pg/mL), suggesting 
that HS-5 secrete MIF before HL-60 cells. 
These findings do not support those reported in the above mentioned study (Abdul-
Aziz et al., 2017), however, they used primary cell co-cultures. MIF secretion was 
also investigated in co-cultures using patient MSC with HL-60 in this study (Figure 
5.6), confirming a significant reduction in MIF secretion following co-culture. The 
decrease in MIF secretion following co-culture was significantly greater in co-cultures 
with MSC from untreated patients with a HM (Figure 5.6.D). This suggests that HS-5 
are a suitable cell type to model the effects of MIF secretion, however, further 
investigations would need to be carried out to compare more secreted cytokines in 
both HS-5 and patient MSC, particularly as heterogeneity was evident in this study 
(Figure 5.6.A). The same research group further showed MIF to be pro-survival in 
myeloma, in addition to myeloma cell-derived MIF inducing IL-6 and IL-8 expression 
in BM-MSC through c-Myc (Piddock et al., 2018). Another group showed MIF to 
increase myeloma cell plasticity (Joseph et al., 2018); highlighting the role of MIF in 
other HMs. 
In order to determine which cell type was responsible for the decrease in MIF 
secretion in co-culture – a limitation of testing pooled media – cells were separated 
following co-culture and treatment, then cultured alone for a further 24 hours before 
analysis. MIF concentration was higher in all samples, bar K562 alone, than 
immediately following treatment (Figure 5.5). HS-5 MIF secretion was unaffected by 
co-culture with either leukaemic cell line at this timepoint. Secretion by HL-60 cells 
was significantly lower in previously co-cultured cells as compared to alone, however, 
a drastic increase was seen in K562 cells that were co-cultured with HS-5. As HS-5 
were mainly unaffected by co-culture it could suggest that leukaemic cells are the 
origin of differential MIF secretion, while vast changes in leukaemic cell secretion in 
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co-culture shows that stromal cells are important in the phenotypic alteration of 
leukaemic cell in the BM. More research will be required to confirm this, perhaps using 
mRNA expression, although not directly translatable to secreted protein, to determine 
the individual role of leukaemia/stroma in MIF production. To investigate correlations 
between MIF expression and clinical presentation, an mRNA database was utilised. 
Complex/poor risk cytogenetics were associated with a gain of MIF mRNA expression 
(Figure 5.10), however, this evidence is limited due to relatively low patient numbers 
in the database. One challenge in cytokine research is that their action is rapidly 
changing, often short-lived and with a limited half-life (Berraondo et al., 2019), with 
MIF half-life shown to increase from 9–33 hours in prostate cancer (Meyer-Siegler, 
2000). 
The reported evidence for MIF in leukaemia has also shown induction of IL-8 to 
involve downstream PI3K/Akt for the improved survival of leukaemic cells (Abdul-Aziz 
et al., 2017). Another study also found a significant negative correlation between MIF 
and TNF-related apoptosis-inducing ligand in AML, with increased MIF hypothesised 
to promote survival of leukaemic blasts by PI3K/Akt-mediated apoptosis attenuation 
(Islam et al., 2017). The Abdul-Aziz et al., (2017) study did not directly link MIF with 
cell survival, and much focus was placed on the AML cells themselves. This is an 
evident gap throughout the literature that has focussed on leukaemic cells 
themselves, in precedence to the effects on the supportive BM. However, one study 
did find MIF to be positively correlated to rat BM-MSC survival (Xia et al., 2015b).  
MIF was differentially secreted in leukaemia-stroma co-cultures in this chapter, and 
MIF has not yet been associated with survival in the BMM, therefore this work further 
aimed to address whether MIF is correlated with altered chemosensitivity (see section 
5.2). No significant difference in chemosensitivity was found between leukaemic or 
stromal cells cultured and treated in the presence of rhMIF, or the MIF antagonist 
ISO-1, as compared to cells cultured and treated without rhMIF/ISO-1; neither for 
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cytotoxicity (Figure 5.7) nor genotoxicity (Figure 5.8). Interestingly, some studies have 
linked MIF with DNA damage checkpoints, for example MIF has been shown to 
promote the effectors downstream of ATR for the DNA damage response (Fingerle-
Rowson and Petrenko, 2007; Nemajerova et al., 2007); potentially relevant to ara-C 
chemoresistance as ATR is the activated DDR pathway (see 1.1.11), and its inhibition 
has been linked to improved chemotherapy efficacy (Ma et al., 2017). Further work 
would be required to investigate any correlation with MIF activity and genotoxicity. 
MIF is therefore differentially secreted in the leukaemic microenvironment, however, 
MIF alone is not responsible for altered chemosensitivity previously seen in chapters 
3 and 4. 
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5.5  CHAPTER SUMMARY 
This chapter shows that leukaemic and BM stromal cell lines do not differentially 
express hENT1, but do differentially secrete a number of cytokines by interactions in 
co-culture, as compared to cells cultured in isolation. MIF is down-regulated in co-
culture of HL-60 and K562 with HS-5 cells and following treatment with ara-C, as 
confirmed by co-culture of HL-60 with primary BM-MSC. Though MIF secretion is 
overall reduced following treatment with ara-C, as compared with untreated cells, the 
same trend of reduced MIF in shared co-culture media persists. Separation of cells 
following co-culture revealed that the leukaemia cells are likely the source of this 
differential secretion, since HS-5 cell MIF secretion was unchanged post-treatment. 
This, to the best of my knowledge, has not been documented elsewhere. When MIF 
was investigated as a regulator of chemosensitivity, no significant changes occurred. 
Therefore, it can be concluded that MIF is differentially secreted in the leukaemic 
microenvironment, however, MIF alone is not responsible for altered 
chemosensitivity. That being said, MIF may lead to significant changes in other 
parameters which were not investigated in this study
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Chapter 6 - FINAL DISCUSSION 
The main aim of this research was to elucidate the mechanisms by which the BM 
stroma interacts with leukaemia cells, leading to changes in chemosensitivity and 
poor survival outcomes in leukaemia. This was in response to the issue of 
chemoresistance; development of which is a common cause of treatment failure, 
patient morbidity and mortality (Lamba et al., 2011). The nucleoside analogue ara-C 
continues to be the mainstay agent in chemotherapy regimens for AML, despite poor 
response in many patients. Ara-C-based regimens such as “7 + 3” are often effective 
at inducing first complete remission, however, this initial chemosensitivity is short-
lived due to drug resistance development (Lamba et al., 2011; Anderson et al., 2014; 
Zhang et al., 2019). Despite leaps in understanding of AML pathogenesis, there is 
still much that is unknown, particularly as AML encompasses many genetically distinct 
disorders, which are further complicated by patient heterogeneity. It is now widely 
accepted that leukaemic cells are protected in the BMM, however the fact that these 
mechanisms are not yet fully understood warranted further research. 
The unidirectional effects of stroma on leukaemic cells have been implicated 
elsewhere (Zhou et al., 2016; Macanas-Pirard et al., 2017). Preliminary work in 
chapter 3 conferred with previously reported findings of ara-C chemoprotection of 
leukaemic cell lines by HS-5 CM. The greatest effect on leukaemic cell protection was 
produced by HS-5 CM constituting 25% of the culture media, however, other studies 
utilised CM at much higher dilutions, eliciting significant effects even up to 1:1,000 
(Macanas-Pirard et al., 2017a). Hence further work could benefit from investigating 
conditioning-dose effects, potentially by proteomic means to determine the key 
players of the secretome. Additionally, the effects of leukaemic CM on stromal cells 
could also be investigated. The approach of this thesis, however, was to move 
towards a co-culture model for bidirectional investigations of co-culture on ara-C 
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chemosensitivity, for greater physiological relevance. A major consideration from the 
outset of this study was the optimisation of an appropriate co-culture model, tailored 
to the requirements and scope of the project as a whole. Concordance of results from 
other published studies, both by CM and co-culture cytotoxicity findings, hence 
validated the use of selected model parameters outlined in chapter 3.  
One of the main areas of focus for this thesis was the genotoxic effects of ara-C in 
leukaemic-stromal co-cultures. Allogeneic SCT is the only long-term curative option 
for some AML patients, however, graft failure remains a catastrophic issue (Crippa 
and Bernardo, 2018). Functional genotoxic damage to supportive BM-MSC has been 
documented post-chemotherapy (Kemp et al., 2011; May et al., 2018), which may 
correlate with this BM failure and increased incidences of secondary malignancies in 
surviving patients (Delage et al., 2015). The involvement of the BMM in the 
chemosensitivity of leukaemic cells to genotoxic events is understudied, with no 
studies to my knowledge investigating the effects of genotoxicity in leukaemic-stromal 
co-cultures. With this in mind, the data presented in chapter 3 and 4 show for the first 
time that leukaemic cells are protected from ara-C genotoxicity by MSC, while MSC 
are themselves sensitised to such effects; where initial findings in cell line co-cultures 
were confirmed by co-culture of a leukaemic cell line with primary MSC. The potential 
clinical impact of these findings relates to the reduction of adverse treatment-related 
effects. This work provides a basis for further investigations into the key mechanisms 
of increased genotoxicity in MSC, perhaps in the down-stream mediators of DNA 
damage response signalling. Future targeting of the interactions between leukaemic 
and stromal cells in the BM could reduce the damage to vital MSC which persist in 
the BM post-SCT (Rieger et al., 2005). 
The cytotoxic effects of chemotherapeutic agents have undoubtedly benefited 
patients with a haematological malignancy, and it is unsurprising that research has 
focussed on the cytotoxic effects of such treatments which reduce disease burden so 
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acutely. This work therefore aimed to further assess altered cytotoxicity in leukaemia-
stroma co-cultures. Leukaemic cells were also found to exhibit reduced 
chemosensitivity with influence from stromal cells, shown by increased viability and 
decreased ara-CTP production. This was mirrored by an increase in stromal 
chemosensitivity mediated by leukaemic cells. Investigations in similar yet distinct 
models in other studies (Garrido et al., 2001; Konopleva et al., 2002; Moshaver et al., 
2008; Civini et al., 2013; Sheng et al., 2016) are confirmed by the work documented 
in this thesis. Altered chemosensitivity was more profound in cell lines due to 
heterogeneity in patient experiments, which reflects the heterogeneity seen both 
clinically and biologically in leukaemia patients. Work with patient MSC exhibited 
wildly varying culture characteristics, including doubling capacity, morphology and co-
culture effects (chapter 4), as well as MIF secretion (chapter 5). Conclusions of poorer 
ex vivo survival and increased genotoxicity in non-expanding BM-MNC cultures 
further support the notion that lasting genotoxicity is in part responsible for long-term 
complications in previously chemotherapy-treated patients. Additionally, 
discrepancies between the findings of studies in the area may reflect the complexity 
of mechanisms involved in progression of the leukaemic microenvironment, which 
warrant its ongoing investigation towards interventions with clinical impact. 
A number of chemoresistance mechanisms have already been identified, including 
processes which result in reduced intracellular levels of ara-C. Depleted expression 
of the membrane transporter hENT1 has been linked to ara-C resistance (Hubeek et 
al., 2005; Kulsoom et al., 2018) and early relapse (Galmarini et al., 2002). This thesis 
aimed to investigate whether hENT1 is differentially expressed by leukaemic and 
stromal cells following co-culture and ara-C exposure, as a means to explain the 
altered chemosensitivity in chapter 5, further rationalised by findings of reduced ENT1 
expression in leukaemic cells exposed to stromal CM (Macanas-Pirard et al., 2012, 
2017a). No significant changes in hENT1 expression were seen in total or subcellular 
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fractions when HL-60 and HS-5 cells were ara-C treated or co-cultured, however, 
further work would be required with increased cell numbers. This would be particularly 
interesting to investigate in patient MSC co-cultures, which was not possible in this 
study due to a shortage of cells for all analyses. 
The direction of this work then turned towards analysis of culture media containing 
soluble factors released by cells in response to co-culture. A cytokine array of ara-C 
treated leukaemic-stromal cell line co-cultures revealed seven differentially secreted 
cytokines compared with cells cultured alone. In co-culture, there was a significant 
increase in CCL2, GM-CSF and IL-6 and decrease of CXCL1, G-CSF, Serpin E1 and 
MIF. Though these cytokines have all been investigated in AML in previous studies, 
the findings of their secretion in the co-culture model with ara-C is unique to this study.  
Further investigation into each of these cytokines individually is warranted, however, 
due to the scope of the study, one cytokine was selected for further analyses. 
Confirmation of MIF secretion by ELISA supported the conclusion that leukaemic-
stromal co-culture does result in the differential secretion of cytokines.  
MIF has been implicated in the progression of both solid tumours and haematological 
malignancies and was the only cytokine which showed equivalent secretion by both 
leukaemic and stromal cells. Further studies by ELISA showed that the leukaemic cell 
lines secrete more MIF when untreated, however, following ara-C treatment the trend 
of reduced MIF concentration in co-culture was more pronounced than immediately 
post-treatment. This suggests that the interaction between leukaemic and stromal 
cells induces the differential secretion of MIF, which is lasting up to 24 hours post-
treatment. Separation of cells following co-culture and treatment showed HS-5 to be 
stable in MIF secretion between cells cultured alone and previously co-cultured with 
leukaemic cell lines, however, MIF secretion significantly differed following co-culture 
in leukaemic cells. This could suggest leukaemic cells are the source of differential 
MIF secretion in co-culture, however, further work would be required to confirm these 
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effects, for example tracking separated cells over more timepoints and by mRNA 
analysis.  
The expression of MIF is clearly complex, with reports of both decreased and 
increased MIF in malignancies (del Vecchio et al., 2000; Suzuki et al., 2005; Falantes 
et al., 2015; Wang et al., 2018), however, with much greater evidence for the latter. 
One study in particular showed MIF secretion to be elevated in AML blasts, however, 
co-culture of AML cells with BM-MSC from AML patients did not significantly alter MIF 
secretion between alone and co-cultured cells. IL-8 was, however, differentially 
secreted by co-culture, in addition to being induced by MIF, CD74 and PKCβ 
signalling (Abdul-Aziz et al., 2017). Increased IL-8 and IL-6 in leukaemia-stroma co-
culture, within this study, were also shown to be altered in another study investigating 
the ALL microenvironment (Vernot et al., 2017). 
These studies did not, however, investigate MIF effects on chemosensitivity, hence 
this thesis preliminarily investigated the impact of MIF on leukaemic and stromal 
chemosensitivity to ara-C. Exposure to rhMIF protein, or MIF inhibition by ISO-1, did 
not alter leukaemic or stromal ara-C chemosensitivity, either by genotoxicity or 
cytotoxicity measurements. Further work would be required to confirm these effects 
in cell lines and in primary MSC, including with additional treatment times and doses.  
A weakness of this study as a whole is the treatment protocol used. Ara-C was 
selected as it is the mainstay of regimens for AML despite continuing to show poor 
efficacy and high toxicity in patients. The dose was selected based on standard dose 
for the average adult (Methods 2.2.3.2), with the treatment time of 1 hour, used 
primarily through the study, chosen based on appropriate toxicity in cells in vitro. This 
is an important limitation as patients are typically treated with continuous infusions of 
ara-C for up to 24 hours (Momparler, 2013). In vitro treatment also lacks the 
metabolism of the drug in the same way as in vivo. Due to poor response in a number 
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of chemotherapy agents alone for AML, most therapies are combination regimens 
(Döhner et al., 2017). Though combination of ara-C with DNR was investigated early 
in this study, the toxicities of combined treatment were too high for accurate results, 
therefore ara-C was taken forward for investigations alone. DNR undergoes 
substantial liver metabolism in vivo, so equivalent in vitro doses are highly cytotoxic 
(Skarka et al., 2011). Beyond the scope of this project, including fewer time 
constraints, ara-C would be investigated at a range of doses, treatment times and 
combinations for greater physiological relevance. Within the means of the project, the 
methodology chosen allowed for the investigation of 36 cytokines in a cytokine array 
and for just one of these cytokines to be followed up in further experiments. Future 
work would benefit from full secretome analyses, for example using mass 
spectrometry-based proteomics, both to determine the composition of CM and of co-
culture media. This would be particularly useful in studies with patient MSC from 
different haematological malignancies and treatment backgrounds, in an effort to 
further elucidate which factors are implicated in the dysfunction of the BMM. Research 
in chapter 4 was a pilot study investigating the involvement of MSC in health and 
haematological disease, from which it can be concluded that MSC studies of this 
small scale are feasible; a total of 31 patients were recruited and provided 33 BM 
aspirate samples in a 12-month period. 
Another potential avenue for future work could be metabolic analyses of co-cultured 
leukaemic-stromal cells, perhaps utilising a Seahorse analyser for glycolysis and 
mitochondrial respiration measurements. One study showed chemoresistant AML 
clones were able to adapt energy metabolism towards a mitochondrial oxidative 
phosphorylation profile in response to ara-C treatment (Farge, 2017). Another key 
area for further work would be to extend investigations of leukaemic-stromal 
interactions into hypoxic conditions, as regions of the BMM are known to be hypoxic 
(Nombela-Arrieta and Silberstein, 2014; Méndez-Ferrer et al., 2020). Pro-malignancy 
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chemokine signalling in leukaemic has been correlated to hypoxia and HIF1a (Abdul-
Aziz et al., 2018), however, the study of both leukaemic and stromal cells in hypoxic 
BM conditions remains to be delineated fully. Despite the endosteal niche primarily 
maintaining HSC quiescence in hypoxic conditions, oxygen is more readily available 
for proliferating cells in the vascular niche (Suda et al., 2011), therefore demonstrating 
the validity of models in normoxia – as was the focus of this study. 
Overall, this study has demonstrated that the interaction between leukaemic and BM 
stromal cells causes phenotypic and behavioural changes which prove preferential to 
the leukaemic microenvironment. The BM is also remodelled in haematological 
malignancies, evidenced by altered cytokine secretion and chemotherapy drug 
handling; in support of the main hypotheses of this thesis. The key contributions of 
this study to the understanding of leukaemic-stromal interactions are summarised in 
Figure 6.1. This data has added evidence to the current understanding of altered 
chemosensitivity in leukaemic/stromal cells, as well as providing sound justification 
for additional research efforts in this area. More research is vital, for improving drug 
efficacy, reducing unnecessary toxicity, and ultimately producing superior clinical 
outcomes for patients with leukaemia and haematological malignancies more widely. 
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Figure 6.1. Contributions of this thesis to leukaemia-stroma interactions. The 
work in this thesis added to the current knowledge of leukaemia-stroma interactions, 
with this diagram building on interactions presented in Figure 1.4. Crosstalk by soluble 
factors altered chemosensitivity – genotoxicity and cytotoxicity – in both leukaemia 
and stromal cell co-cultures (in cell lines in chapter 3 and leukaemic cell line with 
primary MSC in chapter 4). Cytokines were differentially secreted in leukaemia-
stromal co-cultures (chapter 5), including down-regulation of G-CSF, MIF, Serpin E1 
and CXCL1 and up-regulation of CCL2, GM-CSF and IL-6. MIF did not alter ara-C 
chemosensitivity in either leukaemia or stromal cells, however further work is needed. 
Additionally, co-culture of leukaemic and stromal cells did not alter hENT1 expression, 
again requiring further work. 
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Supplementary Figure 1. Alamar blue optimisation of cell density/incubation 
time. HL-60 (A), K562 (B) and HS-5 (C) cells were serially diluted in complete RPMI 
media, incubated with alamar blue and fluorescence measured at 535nm(ex)/590nm(em) 
hourly 1–6 hours and at 24 hours post-addition. Data represents mean % alamar blue 
reduction +/− SD, calculated based on 100% reduced control. 
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ID 
NO. 
M/F AGE DIAGNOSIS 
TX 
(Y/N) 
REGIMEN 
001 F 73 
Essential 
thrombocythaemia 
N – 
002 F 67 Plasma cell myeloma N – 
003 M 74 
MDS-ring sideroblasts, 
single lineage dysplasia 
N – 
004 F 68 Ph+ CML N – 
005 F 78 
Infective endocarditis 
(non-malignant) 
N – 
006 F 80 Asymptomatic myeloma N – 
007 M 79 Myelofibrosis N – 
010 M 69 AML N – 
011* M 36 
AML, myelodysplasia 
related changes 
N – 
012 M 59 Plasma cell myeloma N – 
014 F 73 Plasma cell myeloma N – 
015 F 74 Plasma cell myeloma N – 
016 F 52 Plasma cell myeloma N – 
018 F 70 Plasma cell myeloma N – 
019 F 73 
Leukaemic mantle cell 
lymphoma 
N – 
020 M 56 
Essential 
thrombocythaemia 
N – 
021 M 64 
Primary myelofibrosis 
accelerated phase 
(JAK2+) 
N – 
022 F 66 JAK2+ myelofibrosis N – 
023 M 90 
Refractory anaemia, ring 
sideroblasts, unilineage 
dysplasia 
N – 
025 M 71 AML N – 
027 M 68 
AML – FLT3 & NPM1 wild 
type 
N – 
030 M 77 
MDS transforming to AML 
(complex karyotype 
including del 5q, del17) 
N – 
031 F 57 
Immune 
thrombocytopenic purpura 
N – 
 
Supplementary Table 1. Patient characteristics for provided BM samples. 
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Supplementary Table 1. Continued. 
ID 
NO. 
M/F AGE DIAGNOSIS 
TX 
(Y/N) 
REGIMEN 
008 F 68 
APML in remission, MRD 
neg, breast cancer history 
Y 
C1- AIDA, Con1- AIDA, Con2- ATRA + 
Mitox, Con4- IDA. Anastrozole 
009 F 62 
Small lymphocytic 
lymphoma 
Y 
Radiotherapy left neck (4 Gy; 41 
months prior), right parotid (4 Gy; 40 
and 12 months prior)  
011B* M 36 
AML, myelodysplasia 
related changes 
Y Ind- AML19 Trial 
011C* M 36 
AML, myelodysplasia 
related changes 
Y AML19 Trial 
013 M 77 IgG ĸ myeloma relapsing Y VCD (35 months previously) 
017 M 56 AML 2° to ALL Y 
ALL- Ind1-2- DNR + vincristine + Dex + 
PEG-ASP + methotrexate, Intens, 
Con1-4, Maint, 3-monthly vincristine, 
methotrexate (11 months previously) 
(UKALL14 trial) 
AML- C1 FLAG-IDA 
024 M 73 
Follicular lymphoma 
(stage IV), MDS/MPN/ 
chronic anaemic BM 
Y 
C1-6- R-CVP (15 months previously), 
Maint- rituximab 
026 M 39 AML (FLT3-ITD mut.) Y C1-2- ara-C + DNR + midastaurin 
028 M 67 APML Y 
ATRA + ATO (molecular complete 
remission) 
029 M 67 Myeloma (IgG Kappa) Y 
CCD, cyclophosphamide primed stem 
cell collection, HD melphalan and stem 
cell return, Maint- carfilzomib 
(CARDAMON trail) 
AIDA; ATRA + IDA, C; cycle, CML; chronic myeloid leukaemia, Con; consolidation, CCD; 
carfilzomib + cyclophosphamide + Dex, FLAG; fludarabine + ara-C + G-CSF, IDA; idarubicin, 
Ind; induction, Maint; maintenance, Mitox; mitoxantrone, R-CVP; rituximab + 
cyclophosphamide + vincristine + prednisolone, TX; treated. * = Matched sample (B and C 
refer to the same patient, sampled post-chemotherapy cycles). 
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Supplementary Figure 2. Gating strategy for multi-colour compensation. Patient 
BM cultures were harvested at the end of passage 3 (P4) for co-culture experiments, 
where they were also analysed for immunophenotype to confirm MSC purity. For 
compensation, cells were individually stained with FITC, PE, APC, Per-CP and APC-
Cy7. Events were gated to exclude debris (A). Gates were applied to select for 
positive (green) and negative (blue) staining for each dye (B), and compensation 
applied to account for spillover of fluorochromes in each channel. The example shown 
is for cells single-stained with APC-Cy7 for Zombie ZNIR live/dead, mixing untreated 
and heat treated cells for live/dead discrimination. 
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Supplementary Figure 3. Osteocyte development in untreated myeloma-MSC 
culture. 016 MSC cultures (P4) were seeded in osteogenic differentiation conditions 
for 10 days. Cultures were visualised by inverted phase-contrast microscopy and 
images taken at hours 0 (A) and 48 (B) and days 7 (C) and 10 (D/E). A–D = x10, E = 
x20 objective. 
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Supplementary Figure 4. Osteocyte development in untreated AML-MSC 
culture. 025 MSC cultures (P4) were seeded in osteogenic differentiation conditions 
for 10 days. Cultures were visualised by inverted phase-contrast microscopy and 
images taken at hours 0 (A) and 48 (B) and days 7 (C) and 10 (D/E). A–D = x10, E = 
x20 objective.
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Supplementary Figure 5. Chondrocyte development in treated AML-MSC 
culture. 011B MSC cultures (P4) were seeded in chondrogenic differentiation 
conditions for 14 days. Cultures were visualised by inverted phase-contrast 
microscopy and images taken at hour 6 (A), 24 (B) and 48 (C) and day 4 (D), 9 (E) 
and 14 (F). x10 objective. 
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Supplementary Figure 6. Chondrocyte development in untreated AML-MSC 
culture. 025 MSC cultures (P4) were seeded in chondrogenic differentiation 
conditions for 14 days. Cultures were visualised by inverted phase-contrast 
microscopy and images taken at hour 6 (A), 24 (B), 48 (C) and day 4 (D), 9 (E) and 
14 (F). x10 objective. 
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Supplementary Figure 7. Adipocyte development in untreated myeloma-MSC 
culture. 016 MSC cultures (P4) were seeded in adipogenic differentiation conditions 
for 14 days. Cultures were visualised by inverted phase-contrast microscopy and 
images taken on days 0 (A), 2 (B), 7 (C) and 14 (D/E). A–D = x10, E = x20 objective. 
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Supplementary Figure 8. Adipocyte development in untreated AML-MSC 
culture. 025 MSC cultures (P4) were seeded in adipogenic differentiation conditions 
for 14 days. Cultures were visualised by inverted phase-contrast microscopy and 
images taken on days 0 (A), 2 (B), 7 (C) and 14 (D/E). A–D = x10, E = x20 objective. 
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Supplementary Figure 9. ENT1 antibody sensitivity testing. rENT1 protein (30 ng) 
or HL-60 total lysate (5 µg) were ran by SDS-PAGE in a 12% acrylamide gel for 
western blotting analysis. Proteins were transferred to a PVDF blotting membrane 
overnight, prior to incubation in appropriate antibodies: Anti-ENT1 + secondary; 
blocked Anti-ENT1 + secondary; or secondary only. Blocked Anti-ENT1 was prepared 
by pre-incubation of the ENT1 antibody with rENT1 protein (0.25:1.25 µg/mL in 
blocking buffer; 5X weight excess). Images were obtained by chemiluminescent 
detection (LI-COR). n = 1. 
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Supplementary Figure 13. Representative images of cytokine array membranes. 
Membranes were imaged using the Li-Cor Odyssey Fc analyser using the 700 (red) 
and 800 (green) channels, following staining with IRDye CW800-Streptavidin. Green 
fluorescence intensity is proportional to binding of target cytokine to capture/detection 
antibodies on the array. The white box encloses the membrane spots for the cytokine 
MIF. 
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CYTOKINE GENE ID CYTOKINE GENE ID 
CCL1 6346 IL-4 3565 
CCL2 6347 IL-5 3567 
MIP1α/β 6348/6351 IL-6 3569 
CCL5 6352 IL-8 3576 
CD40L 959 IL-10 3586 
C5 727 IL-12 p70 3592/3593 
CXCL1 2919 IL-13 3596 
CXCL10 3627 IL-16 3603 
CXCL11 6373 IL-17A 3605 
CXCL12 6387 IL-17E 64806 
G-CSF 1440 IL-18 3606 
GM-CSF 1437 IL-21 29067 
ICAM-1 3383 IL-27 246778 
IFN-γ 3458 IL-32a 9235 
IL-1α 3552 MIF 4282 
IL-1β 3553 Serpin E1 5054 
IL-1ra 3557 TNF-α 7124 
IL-2 3558 TREM-1 54210 
Supplementary Table 2. Cytokines tested in the cytokine array. 
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Supplementary Figure 14. Baseline metabolism following MIF 
treatment/inhibition. HL-60, K562 or HS-5 cells were incubated in rhMIF protein at 
0–400 ng/mL (A) for 48 h or pre-treated with ISO-1 at 0–80 µM for 5 minutes and 
incubated for 48 h (B). Metabolism was determined by AB reduction. Bars represent 
mean (+ SD) AB reduction normalised to the untreated control (n = 3 in triplicate). 
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